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Summary
The work in this thesis aimed to characterise the regulation of phospholipase D 
(PLD) activity by receptor occupancy in Swiss 3T3 fibroblasts.
Bombesin-stimulated PLD activity had previously been found to be partially 
dependent on protein kinase C (PKC) suggesting that activation of PLD was to some 
extent down stream of the G-protein coupled receptor activated phosphatidylinositol 4,5, 
bis phosphate (PtdIns(4,5)P2) hydrolysis (Cook et al., 1992). Using a permeabilised cell 
system to introduce non-hydrolysable analogues of guanine-nucleotides, bombesin- 
stimulated PLD activity was found to be indirectly regulated by a G-protein.
The phosphorylation of proteins on tyrosine was determined using 
immunoblotting with a monoclonal anti-phosphotyrosine antibody. The elevation of 
tyrosine phosphorylation using pervanadate, an inhibitor of tyrosine phosphatases, was 
found to activate PLD activity. PLD activity was found to be reduced by pretreatment 
with the tyrosine kinase inhibitor Genistein. Pretreatment with both Genistein and the 
selective PKC inhibitor Ro-31-8220 reduced bombesin-stimulated PLD activity to basal.
Elevation of Ca2+ from intracellular pools using thapsigargin, an inhibitor of the 
Ca2+-ATPase on the intracellular stores was found to be insufficient to activate PLD alone 
nor did it affect bombesin-stimulated PLD activity. Elevation of cyclic AMP using 
forskolin and dibutyrylcyclicAMP did not affect bombesin-stimulated PLD activity nor did 
it alone affect the enzyme.
A common event in cells exposed to agonist is a loss of responsiveness to the 
stimulant, referred to as desensitisation. Bombesin-stimulated PLD activity was found to 
desensitise rapidly with a complete loss in the response after a 40 second agonist 
exposure. Desensitisation was reversible and occurred within 4.5 minutes of agonist 
removal, however was never complete. In the continuous presence of agonist resensitisation 
of PLD activity occurred. The resensitised rate was reduced from that generated in 
response to the initial stimulus but activity continued over a period of an hour. The
XX
recovery of bombesin-stimulated total inositol phosphate generation commenced later than 
that of bombesin-stimulated PLD activation and reached completion within 11.5 minutes 
after removal of the desensitising stimulus.
Radio-receptor binding studies showed that there was a transient loss of binding 
sites from the cell surface which was due to internalisation and recycling of the receptor. 
Although the rate of receptor loss and recovery paralleled that of the desensitisation and 
resensitisation of PLD activity, differences were observed in the extent of the two 
processes. Readdition of bombesin was essential for a stimulation of PLD activity to be 
observed on resensitisation of the enzyme. Hence degradation of the ligand was occurring 
before the receptor was recycled.
Desensitisation and resensitisation was independent of PKC activation and a 
desensitising pretreatment with bombesin did not affect the PMA- stimulated PLD activity. 
A23187-stimulated PLD activity also underwent homologous desensitisation and could 
not stimulate enzyme activity after prior desensitisation by bombesin pretreatment. Thus 
desensitisation was not due to a decrease in intracellular Ca2+ levels.
Bombesin also induced heterologous desensitisation. Pretreatment with bombesin 
or vasopressin reduced a subsequent stimulation with the other agonist by approximately 
70%. A desensitising pretreatment with either agonist attenuated the GTPyS-stimulated 
PLD activity in permeabilised cells by approximately 50%. It was thus proposed that 
desensitisation not only affected the cell surface receptors but also occurred at or distal to 
the receptor-coupled G-protein.
These findings support a role for PLD-derived PtdOH in mitogenic signalling, in view 
of the resensitisation and subsequent maintenance of PLD activity in an early mitogenic 
situation when the agonist is continually present. The kinetics of the agonist-stimulated 
PLD activity are discussed with relation to the regulatory pathways of PLD activation and 
mitogenic signalling.
1Chapter 1 
Introduction
[
i
2Introduction
The binding of hormones and growth factors to specific receptors on the 
plasma membrane of cells initiates a cascade of signalling pathways which are 
involved in a wide variety of physiological and pathological responses including the 
propagation of the signal into the nucleus. The tight control of the cell cycle is 
crucial for the regulation of growth and proliferation. Loss of coordination of the 
cell cycle gives rise to uncontrolled cell proliferation and cancer. Research has 
focussed on early events in signalling since initiation of DNA synthesis generally 
occurs 10-15 hours after exposure to mitogens. The identification of second 
messengers pathways, their regulation and interaction, is thus paramount for full 
understanding of cell biology.
Several signalling transduction processes exist in cells involving: receptor- 
linked cyclic AMP generation; tyrosine phosphorylation; ion-channel modification 
and phospholipid hydrolysis. These systems may regulate each other through their 
interaction in a process known as 'cross-talk'.
The work in this thesis has focussed on receptors coupled to the 
phospholipase-catalysed hydrolysis of phospholipids. Phospholipase C-stimulated 
breakdown of phosphoinositides is known to be required for a variety of cellular 
functions including cell proliferation, secretion, smooth muscle contraction and 
neuronal activity. However, it is now clear that the stimulation of phospholipase D 
catalysed hydrolysis of phosphatidylcholine (PtdCho) is commonly observed in 
response to a wide range of growth factors and may thus be of significant relevance 
to cellular physiology.
31.1 Phosphoinositide specific -phospholipase C.
1.1.1 Agonist-stimulated phosphoinositide metabolism.
Phosphoinositides constitute approximately 10% of the total eukaryotic 
membrane phospholipids (Michell 1975). The majority of the inositol containing 
phospholipids are in the form of phosphatidylinositol (Ptdlns), phosphatidylinositol 
4-monophosphate (PtdIns(4)P) and phosphatidyl 4,5-bisphosphate (PtdIns(4,5)P2). 
The first evidence of agonist-stimulated inositol phospholipid metabolism arose 
from the finding that acetylcholine stimulated the incorporation of 32p into the 
phospholipids of pancreatic slices (Hokin and Hokin, 1953). The incorporation of 
radiolabel into phosphoinositides was later found to be a common response to 
agonist-stimulation and was proposed to be due to a phospholipase C-catalysed 
hydrolysis of Ptdlns, generating diacylglycerol and the inositol phosphate head 
group (Michell, 1975; Downes, 1982: Hokin, 1985). However, it was subsequently 
realised that PtdIns(4,5)P2 was actually the initial substrate for phospholipase C 
(PLC) (Michell and Kirk, 1981; Kirk et a l,  1981; Creba et a l,  1983).
Recently a series of 3-phosphorylated phospholipids were found to be 
generated in response to growth factors such as PDGF in Balb/C3T3 fibroblasts and 
NGF in PC 12 cells (Carter and Downes, 1992) suggesting a role for these molecules 
in mitogenesis and neuronal development (reviewed Downes and Carter 1991). The 
reaction was found to be catalysed by a Ptdlns-3-kinase which has been isolated 
from a number of sources including bovine brain (Otsu et a l , 1991). The in vivo 
substrate for PtdIns-3-kinase has been shown to be PtdIns(4,5)P2 which is 
phosphorylated to PtdIns(3,4,5)P3 (Traynor-Kaplan et al., 1988; Stephens et al., 
1991; Irvine, 1992). PtdIns(3,4,5)P3 is thought to be subsequently metabolised to 
produce PtdIns(3,4)P2 and PtdIns3P.
PtdIns-3-kinase contains the src homology domains SH2 and SH3 (Skolnik 
et al., 1991). Src homology regions resemble the conserved, non-catalytic regions 
in cytoplasmic tyrosine kinases such as the src gene product and are found in many
4proteins involved in signalling pathways (reviewed Pawson and Gish, 1992). 
Phosphotyrosine contained within a specific amino acid sequence is recognised by 
SH2 domains (Cantley et al., 1991), whilst SH3 regions have been proposed to 
target molecules to cytoskeletal components. Although the function of the PtdIns-3- 
kinase pathway is unclear the presence of such domains in PtdIns-3-kinase suggests 
that the enzyme may be involved in second-messenger generation through the 
activation of tyrosine kinases.
1.1.2 Identification of phosphoinositide specific- phospholipase C.
Allan and Michell (1974) identified a neutral phospholipase C which 
catalysed the hydrolysis of Ptdlns (Ptdlns-PLC) producing cyclic and non-cyclic 
phosphates. The enzyme was reported to be cytosolic, requiring micromolar Ca2+ 
for maximal activity. This was followed by the discovery of a neutral membrane 
associated Ptdlns-PLC activity in rat brain (Oran et al., 1975). However, the first 
identification of heterogeneity in Ptdlns-PLC arose from the purification of two 
immunologically and functionally distinct enzymes from sheep seminal vesicles 
(Hofmann and Majerus, 1982). Despite the use of Ptdlns to analyse purification 
products most Ptdlns-PLCs were subsequently found to preferentially hydrolyse 
polyphosphoinositides at physiological Ca2+ concentrations, such as the isoform 
purified from bovine brain (Katan and Parker, 1987) and that from turkey 
erythrocytes (Morris et al., 1990a,b). This was consistent with the discovery of 
receptor-mediated PtdIns(4,5)P2 breakdown
1.1.3 Structure and classification of Ptdlns-PLC isoforms.
A total of 16 distinct Ptdlns-PLCs have been identified, consisting of 14 
mammalian and 2 Drosophila enzymes (reviewed Rhee and Choi, 1992). The 
Ptdlns-PLC family have been divided into three sub-families based on amino acid 
similarity, PLC-p, PLC-y and PLC-5, with more variants within each family. 
Although PLC5 has been purified and cloned, its regulation is unknown.
5There are two regions of sequence common to all three enzyme families 
which are designated the X and Y regions. These domains have been proposed to 
constitute the catalytic region of the molecule. PLCpl and 81 contain a short region 
of 50-70 highly charged amino acids between the X and Y domains which may 
interact with other proteins. In PLCyl this intervening region comprises of 400 
amino acids which contain SH2 and SH3 domains, implying a role in tyrosine 
kinase-induced signalling pathways.
The Ptdlns-PLC isoforms are regulated to varying extents by Ca2+ which is 
thought to interact with residues in the C-terminal domain of the Y-region. The 
different isoenzymes all hydrolyse Ptdlns, PtdIns(4)P and PtdIns(4,5)P2, but display 
distinct substrate specificities in vitro , with selectivity for the preferred substrate 
PtdIns(4,5)P2 decreasing in the order PLC-pl > PLC-81 > PLC-yl (Ryu et al., 
1987).
1.1.4 G-protein coupled regulation of receptor activated PLCp.
Evidence for the regulation of signal transduction pathways by guanine 
nucleotides was first presented for the glucagon-sensitive adenylyl cyclase system in 
the plasma membrane of the rat liver (Rodbell et al., 197la,b). Guanyl nucleotides 
were found to be obligatory for the activation of adenylyl cyclase, they decreased the 
affinity of glucagon binding sites and inhibited the fluoride-stimulated enzyme 
response. GTP binding proteins (| G-proteins) are now known to control a variety 
signal transduction processes including receptor-coupled PLCP activation and the 
regulation of ion channels (reviewed Simon et al., 1991; Saverese and Fraser, 1992).
(i) G-protein coupled receptors
The secondary and tertiary structure of G-protein coupled receptors was 
modelled predominantly on that of the bacteriorhodopsin protein which consists of 
seven transmembrane helices (Henderson et al., 1990). Studies on the structure of 
the p2 -adrenergic receptor (P2 -AR) used site-directed anti-peptide antibodies to
6define its topography (Wang et al., 1989). Immunofluorescence of intact and 
permeabilised CHO cells transfected with the cDNA for the P2 -AR supported the 
existence of a seven transmembrane structure, with an extracellular amino-terminus 
and cytoplasmic C-terminal tail. The transmembrane domains show significant 
homology between most receptor types.
(ii) Receptor-coupled G-protein activation.
The activated, ligand bound receptor, binds to the G-protein and elicits a 
conformational change promoting GDP/GTP exchange (reviewed Conklin and 
Bourne, 1992). The activated receptor has a high affinity for the heterotrimeric G- 
protein in a conformation where GDP is absent and the guanine nucleotide binding 
site on the a-subunit is open (Chabre et al., 1988) Subsequent association of GTP 
with the a-subunit promotes dissociation of the heterotrimer from the receptor with 
release of the activated a  and the Py subunits. Hydrolysis of GTP to GDP by the 
intrinsic GTPase of the a-subunit (Godchaux and Zimmerman, 1979) increase its 
affinity for py and allows reassociation of the py subunits and termination of the 
signal.
Mutagenesis studies have attempted to determine the structure-function 
relationship between G-protein coupled receptors (reviewed Savarese and Fraser,
1992). The N and C-terminal regions of the third intracellular loop were found to be 
the major interaction sites with G-proteins, though the C-terminal regions of the tail 
and second intracellular loop were also possibly involved (Conklin and Bourne,
1993).
(iii) Classification of Ga subunits.
G-protein sub-classes are defined by the amino acid sequence similarity of 
their a-subunits. Structural division resulted in four classes Gs, Gi/G0, Gq and G 12. 
Within each class, there are sub-classes which are highly conserved in amino acid
7sequence. The use of bacterial toxins has enabled further functional assignment to 
G-proteins in cells.
Pertussis toxin catalyses the ADP-ribosylation of the Gi/G0 class of a  
subunits on a C-terminal cysteine, thereby uncoupling the receptor/G-protein 
interaction and inhibiting signal transduction. The Gi family consists of Goto, Goti, 
G a  z and G at and several variants arising from differential splicing. Whereas Gi 
lowers cyclic AMP levels, both Gi and G0 have been found to modulate ion channels 
(Brown and Bimbaumer, 1990; Yatani et al., 1990) and Gt functions to activate 
cyclic GMP phosphodiesterase in the visual transduction system (reviewed Hamm et 
al., 1990). The functions of GOz and that of the G 12 remain undefined.
Cholera toxin catalyses the ADP ribosylation of an N-terminal arginine in 
the Gs group of G-proteins leading to constitutive activation of Gs-effector signals. 
The Gs class of G-proteins activate adenylyl cyclase to increase intracellular cyclic 
AMP levels and also regulate Ca2+ channels (Yatani et al., 1988).
The Gq and G 12 class of G-proteins lack the C-terminal cysteine and are 
hence insensitive to pertussis toxin. Partial purification and reconstitution studies 
(Taylor et al., 1991, Smrcka et al., 1991) showed that the pertussis toxin insensitive 
G-protein that activated PLCpl was similar in amino acid sequence to purified Gaq 
(Pang and Stemweiss, 1990). Other members of the Gq class, G a i4 > G a i5 and G ai6 
may also interact with PLC enzymes (reviewed Majerus, 1992). In support of this 
proposal, membrane extracts from Sf9 insect cells expressing G i6a were found to 
activate PL C pl, PLCp2 and PLCp3 in the presence of GTPyS with similar 
effectiveness to Gqa  (Kozasa et al., 1993). In view of the differences between Gqa  
and G i6a in sequence and distribution it was suggested that the two G a subunits 
may interact with different receptors or effector systems.
iv) Regulation of Ptdlns-PLCpi by Gaq subunits.
In 1983, Gomperts proposed that G-proteins were involved in the activation 
of Ptdlns-PLC, from the observation that guanine nucleotides promoted histamine
8secretion in mast cells on addition of Ca2+. Many agonists have been shown to 
activate Ptdlns-PLC through a pertussis-toxin insensitive G-protein including 
vasopressin in vascular smooth muscle cells (Socorro et al., 1990) and bombesin in 
Swiss 3T3 fibroblasts (Plevin et al., 1990). Bombesin is a tetradecapeptide 
originally isolated from frog skin (Anastasi et al., 1971). More than twenty peptides 
structurally related to bombesin have been reported but there are only three related 
mammalian peptides, gastrin-releasing peptide (GRP) and neuromedins B and C. 
Bombesin-like peptides have a variety of pharmacological and physiological effects 
in mammals such as secretion of gut hormones, the regulation of smooth muscle 
contraction and the regulation of homeostasis. However the finding of a mammalian 
bombesin in human lung small-cell carcinoma (SCCL) and in SCCL cell lines 
(Erisman et al., 1982; Moody et al., 1981) suggested that it may act as an autocrine 
growth factor. Furthermore bombesin has been reported to exert mitogenic effects 
when added to SCCL cell lines (Cuttita et al., 1985), human breast cancer cells 
(Nelson, et al., 1991) and Swiss 3T3 fibroblasts (Rozengurt and Sinnett-Smith, 
1983). Bombesin-binds to high affinity receptors on Swiss 3T3 cells (Zachary and 
Rozengurt, 1985) which have been purified and cloned (Feldman et al., 1990; 
Spindel et al., 1990; Battey.er al., 1991) and found to contain seven transmembrane 
helices, characteristic of G-protein coupled receptors.
However, it was not until the development of exogenous substrate systems 
that the relationship between inositol phospholipid breakdown and G-proteins could 
be fully characterised. In 1991 Taylor et al. purified a G-protein belonging to the Gq 
family of G-proteins from bovine liver membranes. The G-protein was found to 
activate partially purified PLCpl but not the yl or 51 isozymes. A similar 
conclusion was reached by Smrcka et al. (1991) who used an in vitro assay to 
demonstrate that a purified Gq preparation reconstituted a partially purified PLCpl 
activity. In support of these findings, agonist-stimulated PtdIns(4,5)P2 hydrolysis in 
several cell lines was attenuated by an antibody raised to the common carboxyl 
terminal of the a  subunits of Gq and G\ \ (Gutowski et al., 1991). Furthermore,
9transient transfection of the cDNA to Gocq and G a ll together with PLCpl was found 
to increase the generation of inositol phosphates in the presence of GTPyS, whilst 
other G a  subunits were without effect (Wu et al., 1992).
Activation of PLCpi by agonist-stimulated muscarinic receptors, was recently 
reported to act as a GTPase-activating protein (GAP) specifically for G a q/ i i  
(Berstein et al., 1992). This implied that PLCpl accelerated the termination of its 
own activation and thus enhanced the control of G-protein linked signalling.
Both cytosolic and membrane associated forms of PLCp have been reported 
to be regulated by guanine nucleotides. Taylor et al. (1991) showed that PLCpl 
purified from bovine brain cytosol stimulated PtdIns(4,5)P2 hydrolysis when 
reconstituted with a purified activated G a  subunit from bovine liver membranes. 
However in turkey erythrocytes where the majority of PLC is cytosolic, the 
remaining Ptdlns-PLC present after preparation of ghosts was found to be associated 
with the cytoskeleton and was sufficient to account for all the receptor/G -protein 
coupled activity (Vaziri and Downes, 1992). It has been proposed therefore that 
membrane association of PLCp may be important in growth-factor stimulated 
PtdIns(4,5)P2 hydrolysis.
(v) The regulation of PLCp isoforms by Py subunits.
Not all receptor coupled Ptdlns-PLC activity is pertussis-toxin insensitive. 
For example, stimulation of PtdIns(4,5)P2 hydrolysis in HL 60 cells by the 
chemotactic peptide formylmethionine-leucine-phenylalanine (fMLP) was inhibited 
by the toxin (Paris and Pouyssegur, 1987) implying that G0 or Gi may interact with 
Ptdlns-PLC. Though direct evidence for this is lacking, it has been shown that 
purified Go and Gi could reconsitute the generation of inositol phosphates in 
membranes from differentiated HL60 cells (Kikuchi et al., 1986).
Camps et al. (1992) reported that pyt subunits purified from bovine retinal
\
transducin activated one of the two unidentified Ptdlns-PLC enzymes present in 
soluble fractions from HL-60 granulocytes. Pyr stimulation of PtdIns(4,5)P2
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hydrolysis was additive to that activated by GTPyS and was proposed to occur by 
interaction of the Py subunits with the enzyme itself or a regulatory component apart 
from G-protein a-subunits. Further studies on co-transfected COS-7 cells showed 
that py-subunits stimulated PLCp2 activity but not the p i isoform (Katz et al.,
1992), whereas PLCp3 and PLCp2 catalysed PtdIns(4,5)P2 hydrolysis was activated 
on the addition of py subunits to reconstituted lipid vesicles (Park et a l ., 1993). 
Moreover, cotransfection of the M2 muscarinic receptor with PLCp2 in COS-7 cells 
elicited the generation of inositol phosphates in response to carbachol which could 
be inhibited by pertussis toxin (Katz et al., 1992). These reports led to suggestions 
that py subunits released from Gi/G0 may account for pertussis-toxin sensitive 
Ptdlns-PLC activity.
The py complex have been found to modulate various other components of 
the signal transduction system in their own right (reviewed Clapham and Neer,
1993) including adenylyl cyclase (Tang and Gilman, 1992), phospholipase A2 
(Jelsema and Axelrod, 1987), ion channels (Logothetis et al., 1988) and the 1 p- 
adrenergic receptor kinase, which is involved in phosphorylation and desensitisation 
of the P-adrenergic receptor (Kim et al., 1993).
(vi) The regulation of PLCp-catalysed PtdIns(4,5)P2 hydrolysis by PKC.
Pretreatment of many cells with PMA attenuates agonist-stimulated 
PtdIns(4,5)P2 hydrolysis (Brown et al., 1987; Lo and Hughes, 1988; Bishop et al., 
1990) though the mechanism of uncoupling is unclear. PMA treatment of PC12 and 
NIH 3T3 cells was reported to stimulate the phosphorylation on serine residues of 
PLCP (Ryu et al., 1990). However, proteolytically activated rat brain PKCP 
catalysed the phosphorylation of bovine brain PLCp in vitro but did not alter its 
activity, suggesting that such a modification may alter the interaction of PLCP with 
the G-protein. The PKC-catalysed phosphorylation of PLCpl was therefore 
suggested to explain the PMA-induced attenuation of agonist-stimulated generation 
of inositol phosphates in some cells. A similar mechanism was proposed to account
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for the observation that overexpression of PKCpi attenuated the GTPyS-stimulated 
hydrolysis of PtdIns(4,5)P2 in permeabilised Rat-1 fibroblasts (Pachter et al., 1992). 
However, this proposed mechanism for PMA-mediated inhibition of receptor- 
activated PLCp does not hold for cells such as Swiss 3T3 fibroblasts in which PKCa 
is the predominant isoform and PKCP is absent (Olivier and Parker, 1992). PMA- 
induced inhibition of agonist-stimulated Ins(l,4,5)P3 production in Swiss 3T3 cells 
appears to occur at the level of the receptor/G-protein interaction (Plevin et al.,
1990).
1.1.5 Regulation of PLCy
(i) Regulation by receptors possessing tyrosine kinase activity.
Receptors possessing tyrosine kinase activity stimulate the hydrolysis of 
PtdIns(4,5)P2 through activation of PLCy. PDGF and EGF were found to increase 
the phosphorylation of PLCy on tyrosine residues and serine residues whereas the 
PLCpi and PLC8 forms were unaffected (Meisenhelder et al., 1989). Furthermore, 
the tyrosine phosphorylation of PLC-y has been shown to coincide temporally with 
turnover of inositol phosphates (Todderud et al., 1990). Mutant receptors that 
lacked intrinsic tyrosine kinase activity were defective in stimulating PtdIns(4,5)P2 
hydrolysis suggesting that activation of PLCy was dependent on the enzyme activity 
of the receptor (Margolis et al., 1990).
Purified EGF and PDGF receptors phosphorylated PLCy in vitro on 
tyrosine residues 771, 783, 1254, the same sites that are modified in cells 
(Meisenhelder et al., 1989; Kim et al., 1990; Wahl et al., 1990). Stimulation of 
PtdIns(4,5)P2 hydrolysis by the EGF receptor tyrosine kinase in vitro or in A-431 
cells suggested that tyrosine phosphorylation increased the catalytic activity of PLCy 
(Nishibe et al., 1991). Moreover, treatment of EGF-activated PLCy with a tyrosine 
phosphatase decreased the catalytic activity of the enzyme. Tyrosine 
phosphorylation of PLCy is thus considered to be the mechanism by which receptors
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such as that of PDGF and EGF (such as in A431 cells) (Meisenhelder et al., 1989), 
stimulate PtdIns(4,5)P2 hydrolysis. Furthermore, both receptors have been reported 
to physically associate with PLCy such that they were co-precipitated with an 
antibody to PLCy or receptor (Wahl e ta l., 1988; Nishibe etal., 1990).
The role of tyrosine phosphorylation in the PDGF stimulation of PLCy 
activity was investigated by over expression of NIH 3T3 cells with mutant enzyme, 
in which phenylalanine was exchanged for tyrosine at each of the phosphorylation 
sites (Kim et al., 1991). Mutation at tyrosine 783 abolished the PDGF-stimulated 
PLC y activ ity , whereas the enzyme activity was inhibited by 40% when 
phenylalanine was present at Tyr 1254 and enhanced by 50% when Tyr 771 was 
mutated. This report indicated that phosphorylation at Tyr 783 was essential to 
activation of PDGF-stimulated PLCy activity and that the enzyme was that 
responsible for PDGF-mediated PtdIns(4,5)P2 hydrolysis.
In unstimulated cells most of the PLC-y is present in the cytosol. Upon 
EGF receptor activation several residues in the C-terminal domain of the receptor 
become phosphorylated upon tyrosine (Carpenter and Cohen, 1990) and PLCy 
translocates to the membrane (Todderud et al., 1990). This presumably occurs 
through the recognition of the tyrosine phosphorylated proteins on the carboxyl 
terminus of the receptor by SH2 domains of PLCy. Such an event would generate 
the immunoprecipitable complex reported by Nishibe et al. (1990) and lead to 
phosphorylation of PLCy tyrosine residues. This proposal is supported by the 
finding that proteins containing SH2 domains, bound in a tyrosine phosphorylation 
dependent manner to a truncated C-terminal region of the EGF receptor containing 
all known tyrosine autophosphorylation sites (Margolis et al., 1990). Following 
tyrosine phosphorylation of PLC-y the enzyme is thought to be released from the 
receptor. A model has been suggested whereby an intramolecular reaction allowing 
the SH2 domains to bind to the tyrosine phosphorylated residues in PLCy elicits a 
conformational change permitting a SH3/cytoskeleton interaction (Rhee, 1991). 
Hence, the catalytic sites of the enzyme would be exposed to its substrate
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PtdIns(4,5)P2. Although there is no evidence for such an intramolecular reaction, 
this proposal is partially supported by the reports that the SH3 domain of proteins 
are responsible for their targetting to the cytoskeleton (Bar-Sagi et al.y 1993).
(ii) Activation of PLC-y by nonreceptor tyrosine kinases.
Activation and tyrosine phosphorylation of PLC-y also occurs through 
receptors which regulate cytosolic tyrosine kinases, for example in CD3 activated T 
cells (Park et al., 1991) and anti-IgG activated B lymphocytes (reviewed Cushley 
and Harnett, 1993). The sites of tyrosine phosphorylation in PLCy in activated T- 
cells are identical to those phosphorylated in PDGF or EGF-treated cells. Recent 
reports have shown that stimulation of several G-protein-coupled receptors which 
activate cytosolic tyrosine kinases can also stimulate PLC-y activity. Thrombin 
-stimulated phosphoinositide metabolism in human platelets was inhibited by 
tyrphostins suggesting regulation of PtdIns(4,5)P2 breakdown by PLCy activation 
(Guinebault et al., 1993). Furthermore, immunoprecipitation of carbachol- 
stimulation of CHO cells transfected with muscarinic receptors showed that PLCy 
was phosphorylated upon tyrosine in a Ca2+ dependent manner (Gusovsky et al.,
1993). Carbachol-stimulated Ins(l,4,5)P3 generation was partially inhibited by a 
tyrosine kinase inhibitor or removal of extracellular Ca2+. This suggested that 
muscarinic-stimulated tyrosine phosphorylation of PLCy was involved in 
PtdIns(4,5)P2 hydrolysis and was due to activation of Ca2+-sensitive tyrosine 
kinases.
Although the mechanism of PLC-y activation by cytosolic tyrosine kinases 
is unclear, regulation may involve the src family of protein tyrosine kinases. This 
proposal is supported by the finding that immunoprecipitated src related kinases 
were found to phosphorylate both PLC-yl and PLC-y2 (Liao et al., 1993).
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1.2 Phosphatidylcholine specific phospholipase D.
Phosphatidylcholine (PtdCho) is the major phospholipid in mammalian 
tissues, accounting for approximately 50% of the total phospholipid. The hydrolysis 
of PtdCho occurs predominantly through the action of three phospholipases 
(Fig. 1.1): phospholipase A2  (PLA2 ), generating a fatty acid (generally arachidonic 
acid) and lysophosphatidyl choline; phospholipase C, to form DAG and 
phosphatidylcholine; phospholipase D, which generates phosphatidic acid (PtdOH) 
and choline.
1.2.1 Identification of phospholipase D
Phospholipase D catalyses a reaction where water acts as a nucleophilic 
acceptor for a putative enzyme/substrate intermediate (Fig 1.2):
phosphatidyl base A + H2O <-> phosphatidic acid+ base A
Using the generation of PtdOH from exogenenous PtdCho to monitor the hydrolytic 
activity of PLD, the enzyme was originally identified in plants (Hanahan and 
Chaikoff, 1947) and later in fungi and bacteria (reviewed Heller, 1978). A partially 
pure PLD from cabbage was characterised by incubation with egg PtdCho 
dispersions (Dawson and Hemington, 1967). The PLD-catalysed production of 
PtdOH was optimal at pH 5.4 and was stimulated by Ca2+ and ether. However, 
inhibition by p-chloromercuribenzoate, suggested the presence of an essential 
sulphydryl group. A later purification of cabbage PLD demonstrated that the 
enzyme activity was inhibited at high ionic strength and the pH optimum of PtOH 
generation from exogenous PtdCho depended on the concentration of Ca2+ (Allgyer 
and Wells, 1979). At 0.5mM Ca2+ the pH optimum was 7.25 but at 50mM Ca2+ it 
was 6.
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F ig u re  1.1 Sites of action  of phospholipases A 2 , C and D on 
phosphatidylcholine.
The figure shows the phosphatidylcholine molecule with the ester-linked 
fatty acid groups in the sn- 1 and sn- 2 position represented by R1 and R2 
respectively.
Phospholipase A2 catalyses the hydrolysis of the ester bond at the sn-2 position of 
the molecule to generate a free fatty acid, typically arachidonic acid and l-acyl-2- 
lyso-PtdCho.
Phospholipase C catalyses the cleavage of the phospho-ester linkage between the 
DAG moiety and phosphocholine (PCho) group thereby producing sn -1,2-DAG and 
PCho.
Phospholipase D catalyses the hydrolysis of the phosphoester bond between the 
choline head group and the PtdOH moiety to generate PtdOH and choline.
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Figure 1.2 The hydrolytic and transphosphatidylation  activities of 
phospholipase D
The schematic diagram shown opposite represents a proposed mechanism 
for PLD-catalysed PtdCho hydrolysis. Activation of the enzyme results in rebase of 
the head group and the formation of a phosphatidyl-PLD intermediate. In the 
presence of water as a nucleophilic acceptor for the phosphatidyl moiety (left-hand 
side of diagram) the hydrolytic activity of PLD generates PtdOH which may then be 
metabolised to DAG by phosphatidate phosphohydrolase (PAP). However, in the 
presence of short chain primary alcohols such as butanol which act as a stronger 
nucleophilic acceptor than water (right-hand side of diagram), the intrinsic
i
transphosphatidylation activity of PLD generates a phosphatidylalcohol at the 
expense of PtdOH.
The transphosphatidylation activity of PLD forms the basis of an assay for 
the enzyme activity in whole cells. As phosphatidylalcohol can not be metabolised 
by the cells it accumulates and can be quantified. Furthermore, as
i
phosphatidylalcohol is a poor substrate for PAP the relative contribution of the 
stimulated PLD pathway to the generation of DAG can be assessed.
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PLD also catalyses a transphosphatidylation reaction where in the presence of a 
preferential nucleophilic acceptor such as a short chain alcohol a phosphatidylation 
of the alcohol occurs at the expense of PtdOH (Fig. 1.2).
phosphatidylbase A + alcohol <-> phophatidylalcohol+ base A
The transphosphatidylation activity of PLD was first demonstrated using the 
cabbage enzyme. In the presence of exogenous PtdCho and glycerol or ethanol, the 
enzyme generated Ptdglycerol or Ptdethanol (PtdEtOH) and PtdOH (Hemington and 
Dawson, 1967; Yang et al., 1967). The PLD-catalysed transphosphatidylation 
occurred simultaneously with the hydrolytic activity and was similarly activated by 
Ca2+.
It was not until 1975 that Saito and Kanfer reported a mammalian PLD 
activity in a detergent solubilised preparation from particulate rat brain fraction. 
Using the generation of radiolabelled PtdOH and choline from a [U-14C]PtdCho 
microdispersion as an assay for enzyme activity, the Km was 8.3 x 10-4 M. The pH 
optimum for PtdCho hydrolysis was reported to be 6 and that for 
transphosphatidylation was 7.2. Ca2+ was not essential but maximum stimulation 
was achieved at a concentration of 5mM and Mg2+ could replace Ca2+, whereas 
blockage of -SH groups was inhibitory. Partially purified rat brain PLD catalysed 
the hydrolysis of exogenous PtdCho with a Km of 0.75mM and an optimum pH of 6 
(Taki and Kanfer, 1979). The calculated molecular weight was 200 kDa, similar to 
that estimated for peanut seed PLD (Heller et al., 1974). In an early study by Kater 
e ta l. (1976) PLD isolated from human eosinophils had an apparent molecular 
weight of 60,000Da and generated choline from exogenously added PtdCho at a pH 
optimum of 4.5-6. A later study on rat brain microsomal PLD activity showed that 
the production of [3H]choline from exogenous [3H]PtdCho and the production of 
[3H]Ptdglycerol monitored by introduction of [3H]glycerol into the microsomal 
membrane, was highly dependent on bile acids such as deoxycholate and free
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unsaturated fatty acids (Chalifour and Kanfer, 1982). Oleate was reported to be the 
best in vitro activator. The concentration of oleate required for maximal enzyme 
activity present in a rat brain synaptosomal enriched preparation was found to vary 
with the concentration of exogenous PtdCho as assessed by the accumulation of 
[14C]PtdEtOH ( Kobayashi and Kanfer, 1987).
Martin (1988), identified a neutral PLD activity in endothelial cells which 
exhibited strict specificity for PtdCho. The production of [3H]choline and 
[3H]PtdOH from exogenous l-oleoyl-2-[3H]oleoyl-PtdCho and Ptd[3H]choline 
catalysed by the enzyme was dependent on the presence of Triton-X-100 and was 
inhibited by Mg2+ and Ca2+. Chalifa et al.y 1990 also partially characterised a 
neutral PLD activity from rat brain synaptic plasma membranes. Oleate was found 
to be essential for the production of [3H] PtdOH and [3H]PtdEtOH from [3H]PtdCho 
in the presence or absence of ethanol and Mg2+ also strongly stimulated PLD 
activity. Triton -X-100 stimulated the PLD activity but with a much lower specific 
activity than that for oleate. Ca2+ up to 0.25mM activated the enzyme but was 
inhibitory at 2mM. The authors proposed that the failure of earlier studies to 
observe a neutral PLD activity in rat brain microsomes was due to the use of a buffer 
system that was inhibitory to the neutral enzyme.
The existence of a cytosolic PLD activity that constituted the majority of the 
PLD activity in bovine tissues was reported by Wang et al. (1991). Using 
exogenous [14C]PtdCho as a substrate in the presence or absence of ethanol to detect 
both the hydrolytic and transphosphatidylation activities of PLD, the cytosolic PLD 
activity was only detected in the presence of 160|iM PtdCho. This was a 
concentration 10-fold greater than that needed to detect membrane bound activity. 
The Km for cytosolic PLD activity was 1.45mM whereas the membrane bound 
activity could only be detected at substrate concentrations of less than 32pM. 
Furthermore, whereas the membrane-bound enzyme was specific for PtdCho, the 
cytosolic PLD was more active against PtdEtn than PtdCho. Ca2+ was not
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essential for either enzyme activity but maximal stimulation was observed at lOmM, 
whereas Mg2+ inhibited the membrane bound but not the cytosolic enzyme activity.
Further characterisation of the rat brain microsomal enzyme was achieved 
using the generation of [3H]PtdBut from enzyme incubated in the presence of 
[3H]butanol and exogenously added PtdCho (Horwitz and Davis, 1993). As this 
method obviated the need for a labelled substrate the phospholipid specificity of the 
enzyme was investigated. Although a small activity was detected against PtdEtn and 
PtdSer as substrates, the enzyme preparation hydrolysed PtdCho most efficiently 
with an EC50  of 0.4mM. Furthermore the substrate specificity was independent of 
fatty acid composition. Full characterisation of mammalian PLD activity awaits 
complete purification.
1.2.2 PLD and base-exchange activites.
It is possible that the formation of phosphatidylalcohol is derived from a 
base exchange reaction between the choline head group and alcohol. Base-exchange 
reactions exchange the bases on phospholipids with free bases such as serine, 
ethanolamine and choline as follows:
phosphatidyl base A + base B phosphatidylbase B + base A
The base exchange reactions were found to closely resemble transphosphatidylation 
activity in plant PLD (Yang et al., 1967). However later investigations compared 
the phosphohydrolase and base exchange activity of a cabbage PLD preparation 
(Saito et al., 1974). Base-exchange activities, detected by incorporation of labeled 
ethanolamine and choline into phospholipids were found to have a pH optimum of 9 
whereas that for the formation of PtdOH was 5.6. The two activites could also be 
distinguished by their Ca2+ requirements, the base exchange reaction was optimal at 
a concentration of 4mM Ca2+, whereas the phosphohydrolase activity required 
concentrations of Ca2+ greater than 28mM for optimal activity. However, though
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the activities could be clearly differentiated the study could not resolve whether 
separate proteins were responsible.
Such reactions have also been shown to occur in several tissues such as 
brain (Porcellati et al., 1971). The partial purification of the rat brain enzyme 
suggested that the base exchange enzymes were distinct from PLD (Taki and 
Kanfer, 1979). In support of this, a partially purified phospholipid serine base- 
exchange enzyme from rat brain did not exhibit any PLD activity (Taki and Kanfer, 
1978). Furthermore the properties of this enzyme were distinct from that of the 
partially pure rat brain PLD (Taki and Kanfer, 1979) as L-serine incorporation into 
the most effective acceptor, ethanolamine phospholipid, had a Km of 0.4mM and an 
optimum pH of 8. Furthermore, maximal activity was observed at lOmM Ca2+. 
However, in bovine-retinal microsomes, PLD-like activity was suggested to play a 
role in Ca2+-dependent base incorporation as the characteristics of both base 
incorporation and PtdOH generation were similar (Mori et al., 1989). The pH 
optimum for both the amount of base incorporated and the formation of PtdOH was 
8-8.5 whereas the optimum concentration of Ca2+ was 3mM for both activities. 
Hence it appears the relationship between PLD and base exchange may be tissue or 
species specific and a contribution of base exchange to phosphatidylalcohol 
formation can not entirely be eliminated.
1.2.3 The identification of cellular PtdCho-specific PLD activity.
Evidence for the cellular breakdown of PtdCho arose from a study in 1981 
in which phorbol esters were found to stimulate the release of [^HJcholine and 
[^HJphosphocholine from cells prelabelled with [^HJcholine (Mufson et al.t 1981). 
The first report of an agonist-stimulated turnover of PtdCho came from experiments 
with muscarinic agonists in perfused hearts in vitro and in vivo in rat cortex 
(Corradetti et al., 1982; Corradetti et al., 1983). Further evidence for agonist- 
stimulated PtdCho hydrolysis has arisen from studies in intact cells using fatty acids 
such as [3H]myristate in rat embryo fibroblast cells (Cabot et al., 1988) or labelled
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phospholipids such as [3H]lysophosphatidylcholine in neutrophils (Domino et al., 
1989; Billah et al., 1989) to selectively label PtdCho. Stimulation of labelled cells 
resulted in sustained [3H]DAG or [3H] PtdOH, supporting the theory of growth 
factor stimulated phospholipase-catalysed PtdCho hydrolysis.
However, the differentiation between PLD and PLC-catalysed hydrolysis of 
PtdCho has necessitated the use of several techniques. Double-labelling of cells, 
with [32P] and [3H] in the acyl chain enabled the relative contribution of PLD and 
PLC to PtdCho hydrolysis to be determined in fMLP-stimulated neutrophils (Billah 
et al., 1989). [3H]PtdOH would be generated both by the PLD and PLC pathway 
(from metabolism of [3H]DAG by DAG kinase), whereas [32P]PtdOH would be 
formed from the PLD pathway only. The relationship between the DAG kinase 
pathway and PLD-catalysed PtdCho hydrolysis to PtdOH generation could therefore 
be assessed by comparing the 3H/32P ratios of PtdCho and PtdOH. It was found that 
in neutrophils at early time points, the ratio was identical to that of PtdCho 
suggesting that PtdOH was primarily generated through PLD-catalysed PtdCho 
hydrolysis. At later time points the 3H/32P ratio was higher than that of PtdOH, 
suggesting a PLC-catalysed hydrolysis of PtdCho and subsequent conversion of 
DAG to PtdOH.
Cells have also been labelled with lyso[32P]PtdCho such that there was no 
labelling of the cellular ATP pool. Any [32P]PtdOH generated upon agonist- 
stimulation thus unequivocally demonstrated PLD-catalysed hydrolysis of PtdCho. 
Such strategies were used to define fMLP, phorbol ester and Ca2+-ionophore 
stimulated PLD activity in neutrophils (Billah etal., 1989).
Activation of PLD by agonists has definitively been assessed utilising the 
transphosphatidylation property of the enzyme to accumulate phosphatidylalcohols 
following cell stimulation in the presence of short chain alcohols such as ethanol or 
butanol (Fig. 1.2). As phosphatidylalcohols are poor substrates for phosphatidate 
phosphohydrolase (PAP) (Metz and Dunlop, 1991), they accumulate in the cell at 
the expense of PtdOH formation and can thus be quantified. The accumulation of
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[3H]Ptdbutanol ([3H]PtdBut) was detected in unlabelled neutrophils stimulated with 
fMLP in the presence of [3H]butanol (Randall et al., 1990). Alternatively 
stimulation of cells labelled in PtdCho with fatty acids such as [3H]palmitate, in the 
presence of unlabelled butanol has also been used to determine activation of PLD by 
quantification of the [3H]PtdBut generated . The latter technique has been used to 
definitively assess the stimulation of PLD activity in many cell types including EGF, 
PDGF, bombesin and vasopressin stimulated Swiss 3T3 cells (Cook, 1991; Cook et 
al., 1992; Cook and Wakelam, 1992), a-thrombin-, ATP- and bradykinin stimulated- 
endothelial cells (Martin and Michaelis, 1989) and vasopressin-stimulated A 10 
vascular smooth muscle cells (Plevin et al., 1992).
1.2.4 The regulation of cellular PLD activity.
Many agonists that activate PLD activity also promote PtdIns(4,5)P2 
hydrolysis such as observed for bombesin-stimulated Swiss 3T3 cells (Cook et al.,
1992) and fMLP-stimulated HL60 cells (Geny and Cockcroft, 1992) implying a 
possible interaction between the two pathways. The modulatory effect of the 
second-messengers arising from inositol phospholipid hydrolysis appears to vary 
between cell type, perhaps reflecting different isoforms of PLD.
As agonist-stimulated Ptdlns-PLC-catalysed PtdIns(4,5)P2 hydrolysis is 
regulated through a G-protein, the possible regulation of PLD activity by such a 
pathway has also been investigated. The addition of non-hydrolysable GTP to 
permeabilised cells (Xie and Dubyak, 1991; Geny and Cockcroft, 1992) and cell 
membranes (Hurst etal., 1990; Van der Meulen and Haslam, 1990) have shown that 
receptors can regulate PLD activity through the activation of G-proteins. The use of 
cell-free systems from neutrophils and granulocytes (Olson et al., 1991; Anthes et 
al., 1991) established that stimulation of PLD activity with GTPyS required protein 
factors in both the plasma membrane and the cytosol. Although G-protein regulated 
PLD activity has been reported in a variety of cell types, whether this requirement 
for protein factors is a general phenomenon has yet to be fully investigated.
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It appears that the sub-type of G-protein involved in the regulation of PLD 
activity can vary which may relate to activation of PLD as an event downstream of 
receptor-stimulated Ptd(4.5)P2 hydrolysis. This is exemplified by the reports that 
fMLP-stimulated PLD activity in granulocytes was found to be pertussis toxin 
sensitive (Agwu et al., 1989), whereas that in prostaglandin treated erytroleukemia 
cells (Wu et al., 1992), vasopressin-stimulated rat hepatocytes (Bocckino et al., 
1987), and A 10 aortic smooth muscle (Grillone et al., 1988) was insensitive.
The nature of G-protein coupled PLD activity is still unclear. In HL60 
cells coupling was proposed to be partly direct, rather than completely downstream 
of G-protein coupled Ptdlns-PLC or kinase activation. This was based on the 
finding that GTPyS-stimulated PLD activity could be partially dissociated from 
PtdIns(4,5)P2 hydrolysis when cellular ATP was depleted (Geny and Cockcroft,
1993). Regulation of stimulated PLD activity in neutrophils was therefore suggested 
to be under the control of two G-proteins. One G-protein is thought to be coupled to 
PtdIns(4,5)P2 hydrolysis and hence regulates PLD activity indirectly, in a Ca2+- 
dependent manner. The other G-protein is proposed to couple directly to PLD and is 
thought to regulate Ca2+-independent secretion (Cockcroft, 1992).
Ca2+ appears to play an important regulatory role in the stimulation of PLD 
activity in most cells types irrespective on their requirement for PKC. Depletion of 
extracellular Ca2+ in Swiss 3T3 cells reduced bombesin-stimulated PLD activity by 
approximately 50% (Cook et al., 1992), though in neutrophils fMLP-stimulated PLD 
activity was completely attenuated (Billah et al., 1989; Pai et al., 1988). Ca2+ was 
also obligatory for fMLP- and GTPyS-stimulated PLD activity in neutrophil 
homogenates and permeabilised cells (Olson et al., 1991; Geny and Cockcroft, 
1992). However, in rabbit platelet membranes GTPyS-stimulated PLD activity was 
Ca2+ independent, although the presence of Ca2+ greatly augmented the response 
(Van der Meulen and Haslam. 1990). Common to many cell types, the Ca2+ 
ionophore A23187 stimulated PLD activity in Swiss 3T3 fibroblasts (Cook et al., 
1992). However, the exact mechanism of this is unclear as the response was only
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50% inhibited in the presence of EGTA and the protein kinase C inhibitor Ro-31- 
8220..
The hydrolysis of PtdIns(4,5)P2 is however not obligatory for activation of 
PLD. PMA-stimulated PLD activity is observed in a wide variety of cell types 
(reviewed Billah and Anthes, 1990), suggesting the potential for regulation of the 
enzyme activity by PKC. PKC plays a major role in the bombesin-stimulated PLD 
activity, since the selective PKC inhibitor Ro-31-8220 attenuated the response by 
50-70%. Similarly involvement of PKC in the regulation of stimulated PLD activity 
has been reported for many cell types for example in a-throm bin stimulated
endothelial cells (Garcia et al., 1992) and vasopressin-stimulated Rat-1 fibroblasts 
(Plevin et al., 1992). Overexpression PKC|3l in rat fibroblasts was found to 
upregulate stimulated PLD activity, although PtdIns(4,5)P2 hydrolysis was 
attenuated (Pachter et al., 1992). However, in Swiss 3T3 cells overexpressing 
PK Ca , PLD activity was also upregulated, though the fold change in activity upon 
stimulation remained unaltered (Eldar et al., 1993). This was proposed to be due to 
an increase in PLD expression leading to a higher level of cellular activity. The 
authors proposed that the PKC isozyme that regulated PLD activation in Swiss 3T3 
cells did not appear to be PKCa but may involve another sub-type.
Whether PKC activates PLD by a direct phosphorylation is unknown, 
however Conricorde et a l  (1992) have suggested that PMA-stimulated activation of 
PLD occurs via a phosphorylation independent mechanism in fibroblast membranes. 
PMA-stimulated choline release and accumulation of [14C]phosphatidylpropanol 
from membranes labelled with [14C]myristate was observed in the in absence of 
exogenous ATP. Furthermore, addition of an ATPase did not affect PMA- 
stimulated PLD activity although autophosphorylation of PKC was abolished. It 
was therefore proposed that PKC may bind directly to PLD or alternatively may 
bind to another membrane protein responsible for activating PLD.
However, agonist-stimulation of PLD activity is not dependent on PKC in 
all cells. Although PMA can stimulated PLD activity in neutrophils, kinase
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inhibitors do not attenuate fMLP-stimulated PLD activity (Geny and Cockcroft,
1992). Furthermore, agonists which do not stimulate the hydrolysis of PtdIns(4,5)P2 
such as EGF in Swiss 3T3 cells (Cook et al., 1992), have been shown to stimulate 
PLD activity, suggesting that mechanisms other than PKC activation and inositol 
phospholipid turnover are required.
Recent evidence has emerged showing that receptor tyrosine kinases and 
receptor-stimulated cytosolic tyrosine kinases may also regulate PLD activity. EGF- 
stimulated PLD acivity was found to be completely inhibited by incubation with a 
tyrphostin, whereas inhibition of PKC activity had no effect (Cook and Wakelam,
1992). The use of tyrosine kinase inhibitors such as Genistein, Erbstatin, Lavendstin 
and ST271 showed that fMLP-stimulated PLD activity was regulated through a 
tyrosine kinase in neutrophils (Uings et al., 1992) and also in endothelin-stimulated 
A10 vascular smooth muscle cells (Wilkes et al., 1993). Furthermore, activation of 
PLD was found to correlate with tyrosine phosphorylation in cells stimulated with 
pervanadate (Bourgoin and Grinstein, 1992; Dubyak et al., 1993). This treatment 
artificially elevates the levels of tyrosine phosphorylation by inhibition of tyrosine 
phosphatases (Fantus etal., 1989).
Bombesin is among several peptide agonists known to induce the rapid 
tyrosine phosphorylation of a number of proteins in Swiss 3T3 cells (Zachary et al.,
1991). The identity of the kinases, or mechanisms involved remains to be clarified. 
However, several of the proteins phosphorylated by bombesin in Swiss 3T3 
fibroblasts may be substrates for src or releated kinases such as the 125kDa focal 
adhesion protein tyrosine kinase pl25fak (Schaller et al., 1992) which was found to 
be activated and localised to focal adhesions in v-src transfomed fibroblasts 
(Zachary and Rozengurt, 1992).
Regulation by the adenylyl-cyclase signalling pathway has been suggested 
in certain cells. The elevation of cyclic AMP has been reported to inhibit fMLP- 
stimulated PLD activation in neutrophils, possibly mediating its effect at the G- 
protein or enzyme itself (Tyagi et al., 1991). However in thrombin-stimulated
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endothelial cells PLD activity was augmented by elevation of cyclic AMP (Garcia et 
a l, 1992).
Interplay between the various modulatory pathways has also been shown to 
occur. In permeabilised HL60 cells GTPyS-stimulated PLD activity was found to be 
synergistic with that stimulated by PMA or through the tyrosine kinase based 
pathway (Geny and Cockcroft, 1992; Dubyak et al., 1993). Thus the regulation of 
PLD activity involves the coordination of separate stimulatory pathways.
1.2.5 Functions of cellular PLD activation.
Inferences on the function of stimulated PLD activity are based on 
correlation between PtdOH production and other cellular events. The 
characterisation of fMLP-stimulated PLD activity in the neutrophils has suggested a 
role for the enzyme in the inflammatory response. Several reports have suggested 
that PtdOH-derived from PLD-catalysed PtdCho hydrolysis is the important 
mediator in the respiratory burst, critical for the killing of bacteria in neutrophils. 
The respiratory burst is characterised by the production of reduced oxygen species 
such as superoxide and hydrogen peroxide, catalysed by a multi-component 
electron-transfer complex termed NADPH oxidase. Several studies have shown that 
stimulated superoxide production is inhibited in the presence of a primary alcohol 
(Bauldry et al., 1991). Using a permeabilised cell system, Bauldry et al. (1992) 
showed that under conditions where DAG formation was not observed, PtdOH 
production occurred before or concurrently with NADPH oxidase activity. However 
at high concentrations of Ca2+, PtdOH formation occurred in the absence of 
superoxide production. Furthermore, stimulation of cells with GTPyS and Ca2+ in 
the presence of ethanol inhibited PtdOH production but has no effect on oxidase 
activity. This suggested that superoxide production did not correlate with DAG 
production and that PtdOH was not the only second-messenger involved in the 
response.
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PLD activation has also been proposed to play a regulatory role in secretion. 
Agonist-stimulated secretion has been shown to correlate temporally with PLD 
activation and to be inhibited in the presence of primary alcohols in various cells 
including: platelets (Benistant and Rubin, 1990), mast cells (Lin et al., 1991) and 
differentiated HL 60 cells (Stutchfield and Cockcroft, 1993). As previously 
described (section 1.2.4) a G-protein other than that coupled to receptor activated 
Ptdlns-PLC is thought to control Ca2+-independent secretion by the activation of 
PLD (Stutchfield and Cockcroft, 1993; Cockcroft, 1992). Evidence for such a 
mechanism has emerged from studies in various cells including mast cells 
(Cockcroft et al., 1987) and platelets (Wheeler-Jones, 1992; Coorssen and Haslam,
1993). However PtdOH formation was not an absolute requirement for secretion in 
HL60 cells, though could provide an initiating signal (Stutchfield and Cockcroft,
1993). As the NADPH oxidase system is partly under the control of small molecular 
weight G-proteins rac and rho (Abo et al., 1991), the regulation of secretion by 
PLD activity was suggested to also involve non- heterotrimeric G-proteins (see 
section 5.1.2).
The activation of PLD activity by mitogenic agonists has also implied a role 
for PLD in the control of growth and proliferation. Huang and Cabot (1992) 
reported that PLD activity in non-transformed fibroblasts was activatable to a lesser 
extent than in transformed fibroblasts. However, when the cell-free PLD activity of 
the normal and transformed cells was investigated using an exogenous PtdCho 
substrate in the presence of ethanol the accumulation of PtdEtOH generated was 
very similar in both cell types. Furthermore, when the assay was repeated using 
endogenous membrane-bound substrates the formation of [3H]PtdEtOH in 
transformed cell homogenates was 4-fold lower than that accumulated from normal 
cells. It was thus conluded that PLD activity was dependent on the source of the 
PtdCho substrate rather than the enzyme. As many factors may be involved in 
comparisons between transformed and non-transformed systems including 
isoenzyme expression and receptor number a further insight into PLD and
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mitogenesis has arisen through the relationship between its product, PtdOH and cell 
signalling (section 1.4.3 (ii)).
1.3 Phospholipase-catalysed phosphatidylcholine hydrolysis and the source of 
sustained DAG.
1.3.1 The source of sustained DAG generation.
Agonists known to stimulate the hydrolysis PtdIns(4,5)P2 were found to 
generate a biphasic DAG profile with the first transient phase corresponding to the 
production of Ins(l,4,5)P3, and a second more sustained phase (Cook et al., 1990). 
The source of the sustained DAG was initially thought to originate from Ptdlns 
(Griendling et al., 1986). However Bocckino et al. (1985), suggested that stimulated 
DAG generation may arise from other phospholipid sources. This was supported by 
the reports that growth factors and agonists that did not hydrolyse PtdIns(4,5)P2, 
generated DAG in a single sustained phase (Wright eta l.t 1990).
The suggestion that PtdCho could potentially be the source of DAG arose 
from early studies with PMA-stimulated myoblasts (Grove and Schimmel, 1982) 
and in neutrophils stimulated with the chemotactic peptide fMLP (Cockcroft, 1984), 
in which the fatty acid composition of DAG was found to resemble that of PtdCho. 
Definitive evidence for PtdCho as the source of the late-phase DAG was achieved 
through the separation of derivatised DAG from a-thrombin stimulated IIC9 
fibroblasts (Pessin and Raben, 1989) and mitogen-stimulated fibroblasts (Pessin et 
al., 1990) by gas-liquid chromatography on the basis of their fatty acyl composition. 
Subsequent analysis of the molecular species by mass spectrometry showed that the 
DAG profile of the initial phase was comparable to that attained from PLC-catalysed 
inositol phospholipid hydrolysis. At later time points the DAG was found to be 
derived from PtdCho. The profile of EGF- and PDGF-stimulated generation of 
DAG was similar though not identical to that of PtdCho (Pessin et al., 1990). This 
led to the proposal that there could be distinct pools of PtdCho sensitive to hormones
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which may differ in their fatty acid composition or DAG metabolism. This work 
was further supported by the observation that nine species of polyunsaturated DAG 
were found to be elevated in a time-dependent manner in bombesin-stimulated Swiss 
3T3 cells (Pettit and Wakelam, 1993). Comparison of the species with the acyl 
chain structure of phospholipids showed that the elevation of DAG at early 
stimulation points could have arisen from the inositol lipids whereas PtdCho could 
have been the source of DAG at all time points.
1.3.2 The generation of DAG by phospholipase D-catalysed PtdCho hydrolysis.
Growth-factor stimulated DAG generation may be produced from 
phosphatidate phosphohydrolase (PAP) catalysed dephosphorylation of PtdOH 
produced from PLD-catalysed PtdCho hydrolysis. Two distinct forms of PAP have 
been identified in rat liver (Jamal et al., 1991). PAP-1 is a Mg2+-dependent 
cytosolic enzyme that can reversibly associate with the endoplasmic reticulum and is 
inhibited by sulphydryl reagents such as NEM (Brindley, 1984). PAP-1 is thought 
to be involved in glycerolipid synthesis and is activated by translocation to the 
endoplasmic reticulum (Brindley, 1984; Martin et al., 1986). PAP-2 is an integral 
plasma membrane protein and therefore proposed to be involved in signal 
transduction. It can be distinguished from PAP-1 by virtue of its Mg2 + 
independency and lack of inhibition by sulphydryl reagents.
However, evidence is accumulating to show that PLD-catalysed hydrolysis 
of PtdCho is not primarily responsible for DAG generation in response to agonist in 
several cell types. For example, in Swiss 3T3 cells the inclusion of butanol inhibited 
bombesin-stimulated DAG generation by only 30% whereas that formed in response 
to PMA was diminished by up to 70% (Cook et al., 1992).
1.3.3 The generation of DAG by PtdCho-specific phospholipase C.
Several reports have suggested that PLC-catalysed PtdCho hydrolysis may 
be responsible for the sustained phase of DAG. Huang and Cabot (1991)
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investigated the pathways of PtdCho derived DAG generation in response to PMA 
in three cell lines of diverse origin. PMA-stimulated PLD activity in all cell types 
examined. The relationship between a PLC and PLD-mediated production of DAG 
was determined by comparing the production of [3H]PtdOH and [3H]DAG in the 
presence or absence of ethanol, in cells labelled with [3H]myristate. In a rat smooth 
muscle cell line ethanol had no effect on PMA-stimulated [3H]DAG generation 
although in cells prelabelled with [3H]choline PMA generated both [3H]choline and 
[3H]PCho. This suggested that both PLC and PLD-catalysed PtdCho hydrolysis was 
responsible for DAG formation. A similar pathway for DAG generation was 
reported in PMA-stimulated bovine artery endothelial cells. However in Madine 
Derby Canine Kidney (MDCK) cells ethanol inhibited PMA-stimulated [3H]DAG 
suggesting that activation of PLD-stimulated PtdCho hydrolysis indirectly generated 
DAG. This suggested that PMA-stimulated DAG formation may be produced either 
by PLC- or PLD-catalysed PtdCho hydrolysis, the relative contribution of each 
pathway appearing to be cell specific.
However, the existence of PtdCho-specific PLC activity remains a matter 
for debate. Partial purification of PtdCho hydrolysing PLC activity from dog heart 
cytosol (Wolf and Gross, 1985), bull seminal plasma (Sheikhnejad, 1986) and 
promonocytic U937 cells (Clark et al., 1986) has been reported. PLC activity was 
optimal at neutral pH and was inhibited by Ca2+ chelation.
Detection of PLC-catalysed PtdCho hydrolysis has relied upon the 
production of PCho which is subject to metabolism as the first comitted step in the 
biosynthesis of PtdCho (section 1.4.4) and could also be produced from choline- 
kinase catalysed phosphorylation of choline produced by PLD-catalysed PtdCho 
hydrolysis. PCho production was observed in bombesin and PMA-stimulated Swiss 
3T3 cells but always subsequent to activation of PLD (Cook et al., 1989). Ha-ras 
transformed cells displayed an increased level of PCho and DAG suggesting 
activation of PtdCho-PLC (Lacal etal., 1987;Teegarden et al., 1990). However, this 
could be explained by increases in activity of choline kinase and CTP
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phosphocholine cytidyltransferase, both enzymes involved in resynthesis of PtdCho 
(section 1.4.4) or by elevation of de novo DAG synthesis (Chiarugi et al., 1989). 
Exogenous addition of PtdCho-PLC purified from B. cereus was reported to be 
mitogenic for Swiss 3T3 cells (Larrodera, 1990). Although the downregulation of 
PKC by prolonged phorbol ester treatment had no effect on the PtdCho-PLC 
induced mitogenesis, the finding that PKC£ was not degraded by the phorbol ester 
treatment led to difficulties in interpreting the PKC dependency of the effect. The 
physiological relevence of exogenously added PtdCho-PLC is however debatable.
1.3.4 Alternative sources of DAG.
An alternative possibility for the generation of DAG in response to growth 
factors is synthesis de novo, thought to occur at the endoplasmic reticulum 
(revie ed Bishop and Bell, 1988). PtdOH and DAG generation de novo from 
glycerol in insulin-stimulated BC3H-1 myocytes (Farese et al., 1987) has been 
reported and from glucose in human neutrophils subsequent to phagocytosis of p- 
glucan particles (Rossi et al., 1991). However in 3T3-L1 cells insulin was without 
effect upon DAG mass levels (Merrall etal., 1993).
De novo synthesis occurs predominantly through phosphorylation of 
glycerol to produce glycerol-3-phosphate which can then be acylated to PtdOH (Fig.
1.3). However in some cell types such as adipose with low levels of glycerokinase, 
lysoPtdOH is formed by acylation of dihydroxyacetone phosphate (DHAP), an 
intermediate in the glycolytic pathway. LysoPtdOH is then further acylated to 
produce PtdOH. PtdOH formed de novo is dephosphorylated to DAG by PAP-1.
It is also conceivable that the continued hydrolysis of inositol phospholipids 
observed over at least 30 minutes both in bombesin-stimulated Swiss 3T3 cells 
(Cook et al., 1991) and vasopressin-stimulated A10 vascular smooth muscle cells 
(Plevin and Wakelam, 1992) could contribute t j  the sustained generation of DAG 
observed in these cells.
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Figure 1.3 Summary of phosphatidylcholine metabolising pathways involved 
the production of PtdOH and DAG.
The numbered enzymes are:
1. 5 /1 - glycerol-3-phosphate acyltransferase.
2. dihydroxyacetonephosphate (DHAP) acyltransferase.
3. acyl (alkyl) DHAP oxidoreductase.
4. lysophosphatidic acid (lysoPtdOH) acyltransferase.
5. phosphatidate (PtdOH) phosphohydrolase-2 (PAP-2).
6. PtdOH.cytidyl transferase.
7. phospholipase D (PLD).
8. phosphoinositide specific phospholipase C (Ptdlns-PLC).
9. choline kinase.
10. choline phosphate (PCho) cytidyl transferase.
11. diacylglycerol (DAG) choline phosphotransferase.
12 DAG kinase (cytosolic).
13. phosphatidylinositol (Ptdlns) synthase.
14. phosphatidylinositol-4-kinase.
15. phosphatidylinositol-4-phosphate (PtdIns(4)P) kinase.
16. phosphatidylinositol specific phospholipase C (Ptdlns-PLC).
17. DAG kinase (membrane).
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1.4 The function and metabolism of products derived from phospholipase- 
catalysed phospholipid breakdown.
1.4.1 Ins(l,4,5)P3 and elevation of intracellular Ca2+.
(i) The Ins(l,4,5)P3 receptor and mobilisation of Ca2+ from intracellular stores.
A relationship between agonist-stimulated inositol phospholipid hydrolysis 
and the elicited rise in intracellular Ca2+ was first proposed by Michell (1975). In 
1983 Streb et al. found that in permeabilised rat pancreatic acinar cell, Ins(l,4 ,5 )P3 
could mobilise Ca2+ from non-mitochondrial stores. Further evidence that 
Ins(l,4 ,5 )P3 was a second messenger emerged from studies by Berridge and Irvine 
(1984), who demonstrated that Ins( 1,4,5 )P3 production coincided temporally with 
Ca2+ dependent processes in liver and GH3 cells. This led to the suggestion that 
Ins(l,4 ,5 )P3 may bind to an intracellular membrane site to release Ca2+.The purified 
Ins(l,4 ,5 )P3 receptor from rat cerebellar membranes (Supattapone et al., 1988) has 
been shown to be a protein of molecular weight of 260kDa on SDS-PAGE. 
However the native molecular weight of the receptor was lOOOkDa implying that the 
protein is a homotetramer. Incorporation of the purified protein into phospholipid 
vesicles (Ferris et al., 1989) and bilayers (Maeda et al., 1991), showed that the same 
protein contained the Ins(l,4 ,5 )P3 binding site and the Ca2+ release mechanism and 
thus was both a receptor and Ca2+ channel. The receptor has been shown to be a 
substrate for PKA, PKC and Ca2+-calmodulin-dependent kinase (Suppatapone etal., 
1989; Ferris et al., 1991). Hence phosphorylation of the Ins( 1 ,4,5 )P3 receptor is 
thought to regulate the release of Ca2+ (reviewed Ferris and Snyder, 1992).
There are now known to be at least four members of the Ins(l,4 ,5 )P3 
receptor family, arising from products of different genes with splice site variants 
(Sudhof et al., 1991; Ross et al., 1992). Analysis of the cloned sequence of the 
In s(l,4 ,5 )P3 receptor (Mignary' eta l., 1990) has predicted membrane spanning 
regions localised to the C-terminal end of the molecule, with the N-terminus free in
34
the cytoplasm. Comparison with the ryanodine receptor, responsible for mobilising 
stored Ca2+ primarily from skeletal-muscle (Takeshima et al., 1989; reviewed 
Sorrentino and Volpe, 1993), has indicated that the four membrane spanning 
domains constitute the Ca2+ channel. Studies of Ins(l,4,5)P3 binding to truncated 
receptors showed that the ligand binding site was located at the N-terminus 
(Mignery and Sudhof, 1990). Binding of Ins(l,4,5)P3 to the receptor produced a 
decrease in apparent molecular weight determined by gel filtration experiments 
(Mignery and Sudhof, 1990). This suggested that a large conformational change 
occurred on the interaction of Ins(l,4,5)P3 with the receptor, consistent with the idea 
that the binding to the receptor must transmit a signal to the relatively distant Ca2+ 
channel.
Evidence that the Ins(l,4,5)P3 receptor was localised to the endoplasmic 
reticulum has arisen from several studies. Subcellular fractionation of pancreatic 
acinar cells showed that the characteristics of ATP-dependent Ca2+ uptake into 
permeabilised cells and isolated endoplasmic reticulum were similar (Beyerdorffer 
et al., 1984). Later studies using electron microscopic immunocytochemistry 
showed that Ins(l,4,5)P3 receptors in cerebellar Purkinje cells were localised to the 
endoplasmic reticulum (Ross et al., 1989).
(ii) Metabolism of Ins(l,4,5)P3 and calcium influx.
In mammalian cells Ins(l,4,5)P3 is metabolised via a 5-phosphatase to 
Ins(l,4)P2 and a 3-kinase to Ins(l,3,4,5)P4. Ins(l,3,4,5)P4 is also a substrate for the 
5-phosphatase that catalyses the dephosphorylation of Ins(l,4,5)P3, producing 
Ins(l,3,4)P3 (reviewed Erneux and Takazawa, 1991). Since Ins(l,3,4,5)P4 is made 
from Ins(l,4,5)P3 at the expense of ATP it has been proposed that Ins(l,3,4,5)P4 
may itself be a second messenger involved in the control of intracellular Ca2+. 
However the respective roles of Ins(l,3,4,5)P4 and Ins(l,4,5)P3 and the mechanism 
behind Ca2+entry remains a matter of controversy (reviewed Irvine, 1991; Berridge, 
1993).
35
1.4.2 DAG and activation of PKC
(i) The protein kinase C family; classification and structure.
In 1977 Inoue et a l  isolated a histone protein kinase from brain which was 
activated by limited proteolysis. Further investigations found that it was also 
activated by Ca2+ or phorbol esters in the presence of phospholipids (Takai, et a l , 
1979; Castagna, 1982). Subsequently these enzymes have been termed "PKC". 
Molecular cloning has revealed ten members of the PKC family all of which are 
dependent on phosphatidylserine and diacylglycerol for activation apart from PKC£ 
(reviewed; Bell and Burns, 1991; Hug and Sarre, 1993). The Ca2+-dependent PKC 
forms include the a, p i, (32 and y enzymes. The presence of DAG lowers the Ca2+ 
requirement of these enzymes to the pM range which is consistent with the role of 
DAG as a second messenger (Lee and Bell, 1991). The Ca2+ independent or nPKC 
isoforms include the 8, e, £, 0, X and T| enzymes.
The cDNA sequence for each PKC enzyme is composed of four conserved 
domains interspersed with five variable domains (Coussens et a l,  1986). The C- 
terminal region contains the catalytic domain along with the protein substrate and 
ATP binding sites. The regulatory domain, in the N-terminal region of the molecule 
(V1-C2 ), contains a cysteine-rich sequence which is thought to form two Zn-finger 
motifs, commonly found in DNA-binding proteins (Freedman et al., 1988). The 
generation of deletion mutants enabled the function of the cysteine rich domains to 
be assigned to the binding of phorbol esters and DAG (Burns and Bell, 1991; 
Muramatsu et al., 1989). PKC£ only contains one Zn finger and does not bind DAG 
or phorbol ester (Ono et a l, 1989). The flexible hinge region consists of the domain 
between the regulatory and catalytic domains and is sensitive to proteolysis by the 
Ca2+-dependent calpain proteases even in the Ca2+-independent PKC isoform, 
PKCe (Schaap et a l, 1990).
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The regulatory domain also contains a pseudosubstrate domain, a region 
homologous to that of the consensus phosphorylation site observed in the substrates 
of PKC (xRxxS/Tx), except that the serine and threonine residues are changed to 
non-phosphorylatable alanine residues. This region was proposed to serve as an 
autoregulatory domain by binding to the catalytic domain of the molecule (House 
and Kemp, 1987). The lipid activators of PKC, phosphatidylserine (PtdSer) and 
DAG were found to induce a reversible conformational change in this region of 
PKCpII thus exposing the pseudosubstrate domain which was subsequently cleaved 
(Orr et al., 1992). Whether this mechanism of activation holds for the Ca2+- 
independent isoforms or for activation of the enzyme by other molecules such as 
fatty acids has yet to be determined.
Binding of Ca2+ to the C2 region present in the a,P and y  enzymes induces 
translocation of PKC to the membrane and hence activation through interaction with 
PtdSer present in the membrane and DAG. However the mechanism of activation 
for the nPKC enzymes is unclear.
The role of PKC in cell signalling may thus depend on the cell-specific 
distribution of the isozymes. Swiss 3T3 fibroblasts contain predominantly PKCa 
though PKC 5, PKCe and PKC£ are also present (Olivier and Parker, 1992).
(ii) PKC substrates.
Physiological substrates for PKC have mainly been assessed using in vitro 
assays or stimulation in vivo with phorbol esters, and appear to fall into three 
categories. Those substrates involved in signal transduction include the 80 kDa 
myristoylated alanine-rich C kinase substrate (MARCKS) protein which was 
reported to be phosphorylated in response to phorbol esters both in brain 
synaptosomes (Wu et al., 1982) and Swiss 3T3 fibroblasts (Rozengurt et al., 1983). 
The ubiquitous distribution of the MARCKS protein has led to its frequent use as in 
assays for PKC activity. PKC activation also mediates negative feedback regulation 
in second-messenger pathways. Phosphorylation of the EGF receptor in response to
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PMA was found to decrease its ligand-induced tyrosine kinase activity and reduce 
its binding capacity, eventually leading to receptor downregulation (Schlessinger, 
1986; Countaway et al., 1990). Furthermore, PKC-catalysed phosphorylation 
regulates the production of metabolites leading to its activation. This is observed in 
the PMA-induced inhibition of receptor-mediated hydrolysis of inositol 
phospholipids, for example in Swiss 3T3 cells (Plevin et al., 1990) (see section 
1.1.4(vi)) and the PMA-stimulation of DAG kinase activity (Kanoh et al., 1990) 
(section 1.4.3(ii)).
PKC substrates also include membrane transport proteins and ion channels. 
PKC may regulate the [Ca2+]i of cells by activating the Ca2+-ATPase (Chen et al., 
1986) and control intracellular pH by catalysing the phosphorylation of the Na+/H+ 
exchange protein (Moolenaar et al., 1984). PKC also plays an important role in the 
modulation of neuronal ion-channels, regulating the release of nerotransmitters, thus 
indicating the importance of the enzyme in behavioural control. In this respect 
activation of PKC has been reported to have both positive and negative effects on 
voltage-gated Ca2+ channels. For example, in the bag cell neurons of Aplysia, PKC- 
catalysed phosphorylation was found to enhance the Ca2+ influx through voltage- 
gated Ca2+ channels during action potentials (Kaczmarek, 1986), whereas 
attenuation was observed in Helix neurons (Hammond etal., 1987).
The control of nuclear events such as the regulation of transcription factors 
is also under the influence of PKC-catalysed phosphorylation (reviewed by Meek 
and Street, 1992). Phorbol esters stimulate the induction of a number of 
transcription factors, including c-jun and c-fos (reviewed Bomer and Fabbro,
1992), predominantly through interaction with a DNA-motif termed the TPA- 
responsive element (TRE), present in many TPA-inducible genes.(Boyle et al.,
1991). Evidence for a nuclear PKC is increasing and experiments have indicated 
that PKC-catalyses the phosphorylation and activation of DNA topoisomerase 1, an 
enyme crucial for efficient gene transcription (Pommier et al., 1990) and also lamin 
B, involved in disruption of the nuclear envelope during mitosis (Peter et al., 1990).
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It is thus clear from the diversity of PKC substrates that enzyme activation 
plays a pivotol role not only in controlling cellular homeostasis, growth and 
proliferation but also in neuronal activity.
(iii) Activation of PKC during the sustained phase of DAG generation.
In vitro experiments have shown that most forms of unsaturated DAG 
species can activate PKC (Go et al., 1987). However other reports in vivo have 
suggested that the second phase of growth factor-stimulated DAG generation in 
several cell lines does not activate a, P or y  isoforms PKC even in the presence of 
Ca2+ (Martin et al., 1990; Leach et al., 1991). Martin et al. (1990) suggested that 
the loss of activity may have been due to compartmentalisation of the DAG species. 
However, Ha and Exton (1993) showed that the transient translocation of PKCa and 
P enzymes in thrombin-stimulated IIC9 fibroblasts was due to the failure of PC 
hydrolysis to elevate Ca2+. Bombesin-stimulated Swiss 3T3 cells generated time- 
dependent increase in nine different polyunsaturated DAG species (Pettit and 
Wakelam, 1993). This suggested that activation of different isoforms of PKC may 
change over the period of agonist stimulation.
The loss in membrane association of PKC could be attributable to a number 
of effects. Autophosphorylation is a general phenomenon for all PKC enzymes, 
usually occurring concomitantly with activation. Autophosphorylation in other 
protein kinases often modulates activity (Galabru and Hovanessian, 1987), but 
whether it is important in PKC activation or degradation remains to be clarified 
(Hug and Sarre, 1993).
Proteolytic cleavage by the calpain enzymes follows enzyme activation 
(Kishimoto et al., 1983; Saido et al., 1992) and results in a protein containing the 
regulatory domain and a constitutively active fragment. Whether proteolytic 
degradation terminates the kinase activity or serves to release the active fragment 
into the cytosol and other intracellular compartments remains unclear. In support of 
the latter argument, bombesin stimulation of Swiss 3T3 cells was reported to
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translocate native and truncated protein containing the catalytic region of PKC to the 
nucleus, following turnover of nuclear phosphoinositides (Martelli et al., 1991). 
However the down regulation of PKC by phorbol ester treatment, reported to be due 
to an increased rate of degradation (Young et al., 1987), suggests that proteolysis 
inactivates the kinase activity.
(iv) Activation by fatty acids.
PKC has been reported to be activated in vitro by cis -unsaturated fatty 
acids such as arachidonic and oleic acids, both potential products of phospholipase 
A 2 -catalysed phospholipid hydrolysis. Fatty acids have been reported to 
preferentially activate soluble forms of PKC a  and P in the absence of phospholipids 
(Murakami and Routtenberg, 1986; Khan et al., 1992), although reports vary as to 
the Ca2+ dependency of the fatty acid activation possibly due to the PKC species 
used and the assay conditions. For example, arachidonic acid-stimulated PKCy has 
been reported to be predominantly independent of Ca2+ (Sekiguchi et al., 1987) 
whilst El Touny et al. (1990) showed that the presence of Ca2+ was essential for the 
activation of PKC a  and p. Furthermore, fatty acids were unable to inhibit phorbol 
ester binding suggesting that the mechanism by which oleate and arachidonate 
stimulated PKC activity was distinct from that of PtdSer/DAG (Sharkey and 
Blumberg, 1985; El Touny et al., 1990). This proposal was supported by reports of 
synergy between cis -unsaturated fatty acids and DAG in the stimulation of PKCa 
activity (Chen and Murakami, 1992).
Investigations in vivo have led to suggestions as to the physiological role of 
the fatty acids with respect to PKC activation. Whilst oleate induced a translocation 
of PKC a  and p from the cytosol to the membrane in isolated hepatocytes, it was 
proposed that activation of PKC also involved the increase in [Ca2+]i elicited by 
oleate and the DAG synthesised from the fatty acid (Diaz-Guerraetal., 1991) 
Furthermore Yoshida et al., 1992 reported that in platelets fatty acids acted as 
enhancers of PKC activity, as phosphorylation of an endogenous PKC substrate was
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absolutely dependent on the additional presence of DAG. Although the fatty acids 
themselves did not increase [Ca2+]i they were reported to increase the sensitivity of 
PKC to Ca2+ (Yoshida et al., 1992). These findings therefore implicated that the 
initial activation of PKC arose from PtdIns(4,5)P2 hydrolysis but activity could 
remain sustained, despite the decrease in intracellular Ca2+, provided that the levels 
of DAG and cis -unsaturated fatty acids remained elevated.
(v) Activation by other phospholipids.
Other lipid regulators of PKC have been reported including PtdIns(4,5)P2 
(Huang and Huang, 1991; Kochs, 1993), sphingosine / lysosphingolipids (Merrill 
and Stevens, 1989), phosphatidylcholine (Kaibuchi, et al., 1981; Chen et al., 1992) 
and lysophosphatidylcholine (Oishi etal., 1988).
(vi) Phorbol-esters and PKC.
Phorbol esters have been shown to provoke a variety of biological effects in 
cells including tumour promotion (Blumberg, 1980), platelet activation (Zucker et 
al., 1974), cellular proliferation (Dicker and Rozengurt, 1980) and prostaglandin 
production (Edwards et al., 1985). These effects are presumed to be mediated by the 
activation of PKC. PMA activates PKC by interacting with the DAG binding site 
and dramatically lowering the Ca2+ requirement of the enzyme (Castagna et al., 
1982).
As previously described prolonged exposure to PMA down-regulates PKC 
isoforms. However, PMA has a differential effect on PKC isozymes in vitro 
(Huang et al., 1989) and in vivo (Olivier and Parker, 1992). In Swiss 3T3 cells 
PMA causes translocation of PKCa, PKC5, PKCe, but not PKC £ (Olivier and 
Parker, 1992).
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1.4 Function and metabolism of phospholipase-derived PtdOH.
The growth factor-stimulated elevation of PtdOH may be derived not only 
from PLD-catalysed PtdCho hydrolysis, but also from de novo synthesis (section
1.3.4) and from metabolism of DAG by DAG kinase.
(i) The production of PtdOH from DAG.
DAG kinase is thought to phosphorylate DAG produced from growth factor 
activation of Ptdlns-PLC hence initiating the resynthesis of phosphatidylinositols 
(reviewed Bishop and Bell, 1988) and regulating the activation of PKC (reviewed 
Kanoh et al.y 1990). The reaction is thought to be catalysed by a membrane form of 
DAG kinase specific for arachidonyl containing DAG species which has been 
identified in several tissues including porcine testis (Hodgkin et al., 1993) and in 
Swiss 3T3 cells (Macdonald et al., 1988b). However, a cytosolic form of the 
enzyme was identified in Swiss 3T3 cells (Macdonald et al., 1988a) and 
subsequently an 80kDa soluble DAG kinase was purified and cloned from porcine 
thymus (Sakane et al., 1990) which did not display substrate specificity. The 
enzyme activity was found to be enhanced by pM Ca2+ and the protein contained 
two Zn fingers as found in PKC. Translocation of the 80kDa enzyme from the 
cytosol to the paticulate fraction of porcine thymus cytosol was detected using 
antibodies to the enzyme (Sakane et al., 1990). However the effect of translocation 
on the catalytic activity of DAG kinase is unclear.
DAG kinase was also found to be phosphorylated by PKC and cyclic AMP 
dependent protein kinase in vitro. Although the phosphorylation did not alter the 
catalytic enzyme activity it did increase the binding to PtdSer vesicles. A recent 
report showed that DAG kinase was a substrate for PKC a  and e when both were 
transfected into COS 7 cells (Schaap et al., 1993). Furthermore, stimulation of a 
transfected EGF receptor resulted in tyrosine phosphorylation of DAG kinase. The 
80kDa form of DAG kinase has therefore been proposed to translocate to the
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membrane in response to elevation of Ca2+ and phosphorylation by PKC to 
metabolise DAG formed from PtdCho hydrolysis (Sakane et al., 1990).
(ii) PtdOH and lysoPtdOH.
PtdOH is at the crux of de novo glycerolipid synthesis as it can be 
converted to CMP-PtdOH for biosynthesis of phosphatidylinositol,
phosphatidylglycerol and cardiolipin ordephosphorylated by PAP-1 to DAG (section
1.3.4). DAG can then be used to synthesise PtdCho, PtdEtn, PtdSer and 
triacylglycerol.
Alternatively PtdOH could be degraded by a PLA2  to generate lysoPtdOH 
and a free fatty acid. Evidence for the interconversion of PtdOH and lysoPtdOH is 
scarce but both PtdOH and lysoPtdOH were reported to accumulate in PDGF- 
stimulated Balb/c3T3 cells (Fukami and Takenawa, 1992).
Both lysoPtdOH and PtdOH added exogenously to cells have been shown to 
have second messenger functions. Although a previous report of the Ca2+ 
mobilising effect of PtdOH (Moolenaar et al., 1986) was found to be due to 
contaminating lysoPtdOH (Jalink et al., 1990) both phospholipids were found to be 
equally mitogenic for fibroblasts (Van Corven etal., 1992).
LysoPtdOH added exogenously to Rat-1 fibroblasts was found to stimulate 
Ptdlns-PLC activity (Van Corven et al., 1991; Plevin et al., 1992). Addition of 
GTPyS enhanced the lysoPtdOH response by decreasing the EC5 0  for the agonist 
suggesting that lysoPtdOH acted through a G-protein coupled receptor (Plevin et al.,
1992). The identification of a putative receptor for lysoPtdOH of molecular weight 
38-40kDa suggested that the phospholipid mediated its effects extracellularly (Van 
der bend et al., 1992a). This may be physiologically significant as lysoPtdOH was 
recently reported to be released from thrombin stimulated platelets (Eichholtz et al.,
1993). Although lysoPtdOH-stimulated PtdIns(4,5)P2 hydrolysis (Murayama and 
Ui, 1987) and PLD activity (Van der bend et al., 1992b) were reported to be 
insensitive to pertussis-toxin the putative receptor may also be coupled to a
43
pertussis-toxin sensitive G-protein. This is supported by the finding that in 
fibroblasts the lysoPtdOH-stimulated increase in the GTP content of ras , 
mitogenesis and inhibition of adenylyl cyclase were attenuated by the toxin (Van 
corven et al., 1993; Murayama and Ui, 1987). Furthermore, Van Corven et al. 
(1993) showed that the incease in the GTP content of ras by lysoPtdOH was 
inhibited by Genistein and that activation of Ptdlns-PLC was neither required nor 
sufficient for DNA synthesis. It was therefore proposed that a member of the Gj 
subfamily of G-proteins may couple the lysoPtdOH receptor to the regulation of ras 
via a tyrosine kinase.
Although PtdOH was shown not to activate Ptdlns-PLC (Jalink et al., 1990 
nor increase the GTP content of ras (Van Corven et al., 1993) in vivo , it has been 
found to inhibit adenylyl cyclase (Murayami and Ui, 1987) and stimulate 
arachidonic acid release (Van Corven et al., 1992) as reported for lysoPtdOH. 
However PtdOH has also been reported in vitro to inhibit ras GTPase activating 
protein (GAP) (Tsai et al., 1989a) and activate ras GTPase-inhibitory protein (GIP) 
(Tsai et al., 1989b). Both PtdOH and lysoPtdOH have been shown to activate 
various kinases including PKC (Epand and Stafford, 1990), phosphatidyl-4- 
phosphate kinase purified from bovine brain (Moritz et al., 1992) and a 
phosphatidate dependent kinase in soluble extracts from rat liver, brain, lung and 
testis (Bocckinoetal., 1991).
1.4.4 The role of choline.
There is no evidence for a role of choline in signalling. However a 
relationship between choline produced from the stimulation of PLD activity and 
acetylcholine synthesis has been suggested. Incubation of the PLD from a 
synaptosomal rat brain preparation in the presence of oleate and acetyl-coenzyme A 
was reported to form acetylcholine (Hattori and Kanfer, 1985). Furthermore the 
generation of choline in muscarinic-stimulated rat cortex was reported to be used in 
the resynthesis of the acetylcholine pool (Corradetti, 1983).
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However, choline is generally assumed to be used in the resynthesis of 
PtdCho (reviewed Bishop and Bell, 1988; Pelech and Vance, 1984) with 
phosphorylation to PCho by choline kinase being the first committed step (Fig. 1.3). 
Evidence for the regulatory role of choline kinase in PtdCho biosynthesis arises 
from reports of increased activity in ras -transformed cells (Macara et al., 1989; 
Wakelam et al., 1989) and serum-stimulated Swiss 3T3 fibroblasts (Warden and 
Friedkin, 1985). The rate limiting step in PtdCho synthesis is catalysed by 
CTPrphosphocholine cytidyl transferase and generates CDP choline (Pelech and 
Vance, 1984). Stimulation of PtdCho biosynthesis such as in PMA and thyrotropin- 
releasing hormone treated GH3 cells (Kolesnick, 1987) or by treatment of cells with 
Ptdlns- PLC (Terce et al., 1988; Wright et al., 1985) elicits translocation of the 
inactive cytosolic enzyme to the membrane where it is active . Regulation of the 
enzyme may involve PKC as it is activated by PMA and DAG. The final step in the 
synthesis of PtdCho involves the transfer of choline onto DAG with the release of 
CMP and is catalysed by an intrinsic microsomal protein choline 
phosphotransferase.
Aims of Thesis
The project aims were to study the stimulation of PLD activity in Swiss 3T3 
fibroblasts in response to bombesin. Primarily investigations were directed to the 
determination of the PKC-independent arm of the regulatory pathway and the 
relationship between PLD activation, receptor occupancy and PtdIns(4,5)P2 
hydrolysis. With regard to the regulation of stimulated PLD activity in other cell 
types involvement of several components of the signal transduction machinery were 
investigated as follows;.
1 . The regulation by G-proteins
2. Regulation through increases in cytosolic Ca2+
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3. Regulation through interaction with the adenylate cyclase signal transduction 
system i.e. through 'cross-talk'
4. Regulation through protein tyrosine phosphorylation.
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Chapter 2 
Materials and Methods
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2.1 Cell lines and materials
2.1.1 Cell lines
Swiss mouse 3T3 fibroblasts were obtained from the European collection of 
animal cell cultures.
2.1.2 Materials
Affiniti Research Products Ltd. Nottingham. England.
Mouse monoclonal antibody to phosphotyrosine PY54.
Aldrich Chemical Company Ltd. Gillingham. England.
2,2,4-trimethylpentane (iso-octane).
Amersham International pic. Amersham. Buckinehamshire. England.
[methyl -3H] Choline chloride (specific activity 75-85 Ci.mmoH).
(4_[125i]iodotyrosyl) Gastrin Releasing Peptide 
(specific activity 2000 Ci.mmol-1).
[2-3H]myo-Inositol (specific activity 10-20 Ci.mmoH).
[9,10(n)-3H]Palmitic acid (specific activity 40-60 Ci.mmoH). 
Phosphoryl[met/zy/-14C]choline, ammonium salt 
(specific activity 50-60 mCi.mmoH).
[5;8-3H]Adenosine 3'5' cyclic phosphate.
Glycerophospho[N-mef/ry/-3H]choline (GroPCho) had previously been prepared 
from [3H]PtdCho by N-O transacylation with monoethylamine according to the 
method of Clarke and Dawson (1981).
Enhanced chemiluminescence (ECL) reagent kit.
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BDH Chemical Company. Poole. England.
Ammonium formate, butan-l-ol, ethanol, glycerol, potassium di-hydrogen 
phosphate, perchloric acid, sodium hydroxide, sodium carbonate, sodium 
dodecylsulphate, trichloroacetic acid, universal indicator and urea.
Boehringer (UK') Ltd. Lewes. England.
ATP and EGTA.
Cambridge Research Biomedicals. Cambridge. England.
Bombesin and [Arg8] vasopressin.
Calbiochem (Novabiochem (U.K.) Ltd). Nottingham. England.
Dithiothreitol.
Canberra Packard. Pangboume. England.
Ultima-Flo A.F. scintillation fluid.
Costar. Cambridge. M.A.. U.S.A.
Nitrocellulose
Dupont (U.K.) Ltd.. New England Nuclear research products. Stevenage. England. 
[phenylalanyl] 3,4,5-3H(N)]vasopressin (specific activity 40-87Ci.mmol'1) 
[p-M ercapto-p-p-cyclopenta-m ethylenepropionyl1, 0-Et-Tyr2, Val4, Arg8]- 
vasopressin (specific activity 40-87Ci.mmol'1), (Via antagonist).
Fisons Scientific Apparatus.
Acetic acid (glacial), chloroform, ethyl acetate, methanol, magnesium chloride, 
potassium chloride, glycine, hepes and calcium chloride.
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Formachem (Research InternationaLplc. Strathaven. Scotland.
D-glucose and sodium hydrogen carbonate.
Genetic Research Instrumentation Ltd.. Felsted. Essex. England.
Fuji film.
Gibco. Paisley. Scotland.
Dulbeccos' modified Eagles' medium (DMEM, lOx), glutamine (lOOx), 
penicillin/streptomycin (lOOx), sodium bicarbonate (7.5%) and Tris.
Hopkin and Williams.Essex. England 
Potassium iodide.
Koch-Light Ltd. Suffolk. England.
Dimethyl sulphoxide and magnesium sulphate.
Mav and Baker. Dagenham. England.
Formic acid, hydrochloric acid and sodium tetraborate.
Murex. Dartford. England 
Streptolysin-O.
Pierce and Warriner. Chester. England.
Micro BCA protein assay reagent kit.
Roche (UK)Ltd. Welwvn Garden citv. England.
The provision of the drug Ro-31-8220, a PKC inhibitor, by Drs. G. Lawton and T. 
Hallam is gratefully acknowledged.
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Sapu. Lanarkshire. Scotland.
Sheep serum.
Upstate Biotechnology. Inc. (U.B.I.). Buckingham. England.
Anti-phosphotyrosine monoclonal antibody IgG2bK.
Whatman Ltd. Maidstone. England.
LK5DF thin layer chromatography plates.
The gift of [8-Arginine][P/ie--3,4,5-3H(n)]vasopressin ([3H]AVP) and [3H]-labelled 
vasopressin (Via) antagonist, [p-Mercapto-P-p-cyclopenta-methylenepropionyl1, 0- 
Et-Tyr2, Val4, Arg8]-vasopressin ([3H]AVP antagonist), by Dr. M. Wheatley 
Department of Biochemistry, University of Birmingham, Birmingham B15 2TT 
U.K., is gratefully acknowledged.
All other chemicals including ion-exchange resins and phorbol esters were obtained 
from the Sigma Chemical Company, Poole, England.
2.2 Culture and preservation of Swiss mouse 3T3 fibroblast cells.
Swiss 3T3 cells were maintained in DMEM containing 10% (v/v) newborn 
calf serum, 27mg glutamine/ml and penicillin/streptomycin (250 units/ml and 
250mg/ml respectively) at 37°C, in a humidified atmosphere of air/CC>2 (19:1). 
Medium was changed every 2-3 days. Cells were routinely grown in 75cm2 tissue 
culture flasks and passaged when approximately 70% confluent.
After each passage a single flask of cells was allowed to reach confluency, 
to ensure that the cells were contact inhibiting. Cells were discarded at passage 
number 15 or when cells exhibited aberrant or transformed morphology.
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2.2.1 Cell passage
Sterile trypsin for cell pasage
0.1% (w/v) Trypsin, 0.025% (w/v) EDTA, lOmM glucose was prepared in PBS pH 
7.4. Aliquots were filtered and stored at -20°C.
Cells were routinely passaged when approximately 70% confluent, at a ratio 
of 1 to 5. Counting of cells was performed using a haemocytometer.
2.2.2 Cryogenic preservation of cell lines
Cells were removed from the flask surface by trypsinisation. The cells were 
then resuspended in medium containing 20% (v/v) calf serum and 8% (v/v) DMSO 
in DMEM and 1ml aliquots containing approximately 106 cells were placed into 
freezing vials. The vials were frozen at -80°C overnight before being placed into 
liquid nitrogen.
Cells brought up from storage in liquid nitrogen were thawed rapidly at 
37°C and the contents of one vial added to 4ml of complete medium in a 25cm2 
flask. The cells were then cultured overnight, the medium containing dead cells was 
then replaced with fresh medium. When the cells were sub-confluent they were 
passaged into a 75cm2 flask, then grown and passaged as described.
2.3 Measurement of second-messengers in Swiss 3T3 cells
Unless otherwise indicated, cells were washed and stimulated in hepes 
buffered Hanks buffered saline with glucose and BSA (HHBG) pH 7.4, prepared as 
below and supplemented with lOmM glucose and 1% (w/v)BSA (fraction V).
Hanks buffered saline (Hanksl.
1.26mM calcium chloride, 0.5mM magnesium chloride, 0.4mM magnesium 
sulphate, 5.37mM potassium chloride, 137mM sodium chloride, 4.2mM sodium 
hydrogen carbonate, 0.35mM sodium di-hydrogen phosphate, pH 7.4.
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2.3.1 Assays for phospholipase D activity
(a) Measurement of phospholipase D transferase activities in [3H]palmitate 
labelled Swiss 3T3 cells
(i) Incorporation of [3H]palmitic acid into the major phospholipids in Swiss 
3T3 cells
Equilibrium labelling of lipids with 2pCiml_1 [3H]palmitate (Cook, 1991) in 
DMEM +1%  calf serum, has been shown to be complete after 24 hours, though 
[3H]palmitate labelling of cells for 48 hours was routinely used. After 48 hours the 
majority of [3H]palmitate was found to be incorporated into PtdCho with only minor 
incorporation into Ptdlns. However, after 48 hours in DMEM containing 2% 
serum, Swiss 3T3 cells often detached from the plate. The experiment previously 
performed by Cook (1991), to determine equilibrium labelling conditions was 
repeated, using DMEM + 2% calf serum + 4p.Ci.ml'1 [3H]palmitate to investigate 
the use of a shorter labelling time.
Swiss 3T3 cells were grown in a 24-well plate in DMEM + 10% newborn 
calf serum until approximately 70% confluent. The medium was then replaced with 
DMEM + 2% newborn calf serum containing 4pCi/ml [3H]palmitate for times up to 
48 hours, using a time staggered protocol. At the end of the labelling period, 
medium was removed by aspiration and cells were washed in 1ml of HHBG for 2 
minutes, the medium was then replaced with 0.5ml ice-cold methanol. After 
scraping the well and washing with 0.2ml of methanol, the pooled cell debris was 
extracted into 0.7ml chloroform, vortexed and incubated at room temperature for 15 
minutes. Phases were split by addition of 0.585ml of water and centrifuged at 1000# 
for 5 minutes. The chloroform phase was dried down in vacuo prior to analysis by 
t.l.c.
Isolation of the major individual phospholipids was performed by double 
development in a single direction, on Whatman LK5DF, 20 x 20cm, pre-laned silica
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gel thin layer chromatography plates which had been sprayed with ImM EDTA and 
allowed to air dry, before heat activating. The samples and various phospholipid 
standards were dissolved in chloroform/methanol (19/1, v/v) and applied to the 
plates. The plates were developed until the solvent front was approximately two- 
thirds of the way up the plate, in a lined and fully equilibrated t.l.c. tank, using a 
solvent system of chloroform:methanol:acetic acid:water (75:45:3:1, (v/v)). The 
plate was removed from the tank, allowed to air dry for 5 minutes, then replaced in 
the tank until the solvent front had run three-quarters of the way up the plate. 
Following visualisation with I2 vapour, each lane was divided into 0.5cm sections 
and those sections corresponding to phospholipid standards were scraped and the 
radioactivity quantified by scintillation counting.
Figure 2.1 shows that equilibrium labelling of all the major phospholipids 
was attained by 24 hours of labelling as previously reported (Cook, 1991). 
However, incorporation of [3H]palmitate label into PtdCho and sphingomyelin 
(SphM) decreased after 48 hours of labelling;.this decrease may have reflected a 
decrease in cell number.
The solvent system was unable to exclusively resolve PtdSer from Ptdlns or 
PtdOH from PtdEtn, but, as previously shown, the majority of [3H]palmitate was 
incorporated into PtdCho, with SphM, PtdSer, PtdOH/PtdEtn labelled to a lesser 
extent and only minor incorporation into Ptdlns. After 24 hours of labelling, PtdCho 
contained 65% of the total radioactivity incorporated into total phospholipids (Table 
2.1), whereas Ptdlns contained 3%.
(ii) Preparation of samples.
Measurement of PtdBut formation was by the method of Cook et al (1990). 
Swiss 3T3 cells were grown in 24-well plates in DMEM + 10% newborn calf serum 
for 2 days, until approximately 80% confluent. The growth medium was then 
replaced with 0.5ml of DMEM + 2% newborn calf serum containing 4|iCiml_1 of
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[3H]palmitate and the cells further cultured for 24-36 hours. Prior to the experiment 
the labelling medium was removed by aspiration and the cells were washed for 20 
minutes at 37°C with 0.5ml of HHBG. For kinetic studies cells were incubated for a 
further 5 minutes in 0.5ml of HHBG containing 30mM butan-l-ol at 37°C, prior to 
the addition of HHBG + butan-l-ol + the test reagent at the indicated concentration 
and time. For dose-dependency studies there was no pre-incubation with butan-l-ol. 
Incubations were terminated by aspiration of the medium followed by the addition 
of 0.5ml of ice-cold methanol. Cell debris was scraped into screw-top glass tubes, 
together with a further 0.2ml methanol wash. Lipids were extracted by the addition 
of 0.7ml of chloroform and incubation at room temperature for 15 minutes. After 
addition of 0.585ml of water, tubes were centrifuged for 5 minutes at lOOOg, the 
upper aqueous/methanolic phase discarded and the chloroform phase dried in vacuo. 
Samples were analysed immediately by thin layer chromatography.
(iii) Isolation and identification of phosphatidylbutanol
Dried chloroform  extracts were resuspended in 50p,l of 
chloroform/methanol (19/1) and applied to Whatman LK5DF, 20cm x 20cm, pre- 
laned silica gel thin layer chromatography plates. Once the samples had dried, the 
plates were fully developed once in the organic phase of 2,2,4- 
trimethylpentanerethyl acetate:acetic acid:water (50/110/20/100, v/v) under non­
equilibrium conditions, in an unlined chromatography tank.
After drying, plate lanes were divided into 0.5cm strips, the silica gel 
scraped into scintillation vials and radioactivity counted in 4ml of scintillant. The 
band of radioactivity corresponding to PtdBut was identified by either of the 
following criteria:
(a) its co-migration with an authentic [14C]PtdBut standard developed on the same 
t.l.c. plate.
(b) its unique appearance in the presence of butan-l-ol in response to a suitable 
stimulus.
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Figure 2.1 Time course of incorporation of [3H]paImitic acid into the majo 
phospholipid classes in Swiss 3T3 cells.
Swiss 3T3 cells were grown in a 24-well plate until approximately 70*5 
confluent. The medium was replaced with DMEM containing 2% calf serum whic 
at staggered intervals was removed and substituted with 0.5ml DMEM containin 
2% calf serum and 4fiCiml'1 of [3H]palmitic acid. After 48 hours, the medium wa 
removed and the incubations terminated by the addition of ice-cold methane 
Chloroform extracts were separated by thin layer chromatography and the lipic 
PtdCho (A), SphM (A), PtdEtn/PtdOH, (o), PtdSer/Ptdlns (• )  identified as describe! 
The corresponding regions of the silica gel were scraped and the associate 
radioactivity quantified by scintillation counting. Results are expressed a 
radioactivity in phospholipids (d.p.m., mean ± S.D., n=3) from a single experiment.,
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Table 2.1 Distribution of [^H]palmitic acid in the major phospholipid classes in 
Swiss 3T3 cells after 24 hours of labelling.
Swiss 3T3 cells were grown in a 24-well plate until approximately 70% 
confluent. The medium was replaced with DMEM containing 2% calf serum which 
was removed after 24 hours and substituted with 0.5ml DMEM containing 2% calf 
serum and 4pC i.m l"l of [^H]palmitic acid. After 48 hours, the medium was 
removed, and the incubations terminated by the addition of ice-cold methanol. 
Chloroform extracts were separated by thin layer chromatography and the lipids 
identified as described. The corresponding regions of the silica gel were scraped and 
the associated radioactivity quantified by scintillation counting. Results are 
expressed as radioactivity in phospholipids (d.p.m., mean ± S.D., n=3) from a single 
experiment and as percentage of total [^HJpalm itate incorporated into the 
phospholipids after 24 hours.
Lipid
PtdCho
SphM
PtdEtn/PtdOH
Radioactivity
in
[^H]palmitate
containing
lipid
(d.p.m.)
350560 ± 36218 
124959 ± 36218 
48463 ± 2552
% of total 
[^H]palmitate 
incorporated
65%
23%
9%
PtdSer/Ptdlns 13916 ± 2030 3%
57
The t.l.c. system used, separated PtdBut with Rf of approximately, 0.42 ± 
0.06 (Cook, 1991) though the Rf varied slightly with each batch of running solvent. 
PtdCho, PtdEtn, PtdSer and Ptdlns remained at the origin and monoglyceride, di and 
triglycerides and free fatty acids ran close to the solvent front (Pai et al.t 1988). 
[3H]PtdOH was reported to run slightly further than the phospholipids but could not 
be completely resolved from them without a double development in the same 
dimension. The small peak running before that of [3H]PtdBut (Fig. 2.2) may be due 
to [3H]PtdOH or the production of [3H]bisphosphatidic acid ([3H]bisPtdOH) (van 
Blitterswijk and Hilkmann, 1993), which was found to be produced by stimulants 
capable of elevating DAG levels and activating PLD simultaneously. Using a 
slightly different solvent system of ethylacetate:2,2,4,trimethylpentane:acetic 
acid:water (13/2/3/10, v/v) and double development in the same direction, van 
Blitterswijk and Hilkmann, (1993) separated PtdBut from PtdOH and bisPtdOH.
(b) Assay of PtdCho hydrolysis
(i) Preparation of Dowex-50W-H+
Dowex-50W-H+ cation exchange resin (200-400 mesh) was washed three 
times in three volumes of distilled water and the Tines’ were removed each time. 
The Dowex was then washed three times with three volumes of 1M HC1. Finally, 
the Dowex was washed four or five times with three volumes of distilled water until 
the pH of the wash was approximately 5.5.
Each newly prepared batch of Dowex was characterised by performing an 
elution profile of a mixture of radiolabelled standards of glycerophosphocholine 
(GroPCho), phosphocholine (PCho) and choline, added to a Swiss 3T3 cell extract. 
For experimental use 1ml Dowex-50W-H+ columns were prepared in glass wool 
plugged pasteur pipettes.
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Figure 2.2 Resolution and identification of [3H]PtdBut in bombesin-stimulated 
Swiss 3T3 cells
Swiss 3T3 cells were grown in 24-well plates until approximately 80% 
confluent before replacing the medium for 24 hours with 0.5ml of DMEMcontaining 
2% calf serum and 4p.Ci.ml'1 of [3H]palmitic acid. Cells were washed for 20 
minutes in HHBG at 37°C before incubating in HHBG containing 30mM butan-l-ol 
for 5 minutes. Cells were then stimulated with HHBG containing 30mM butan-l-ol 
and lOOnM bombesin (•), or a vehicle control (o), for a further 1 minute at 37°C.
Incubations were terminated by removal of the medium and addition of 0.5ml of ice- 
cold methanol. Chloroform extracts were resolved on Whatman LK5DF t.l.c. plates, 
using the solvent system described. Each lane of the t.l.c. plate was divided into 
0.5cm sections which were removed by scraping and the associated radioactivity 
determined by scintillation counting. The results are from a single experiment 
representative of nine.
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(ii) Preparation of samples
Swiss 3T3 cells were plated onto 24-well plates and grown until 
approximately 70% confluent in DMEM +10%  calf serum. The cells were then 
labelled to equilibrium for 36-48 hours in DMEM + 2% calf serum + 2|iCimT1 
[methyl -3H]choline chloride. Prior to the experiment the medium was replaced with 
0.5ml of unlabelled DMEM for 2 hours. Cells were then washed at 37°C in medium 
containing DMEM, 1% (w/v) BSA, lOmM glucose and 20mM hepes (DMBGH) for 
3 washes of 5, 10 and 30 minutes. Incubations were performed with 150|il of test 
reagent in DMBGH at the indicated concentration and time. Incubations were 
terminated by the addition of 0.5ml methanol. Cell debris was scraped and 
transferred to a plastic tube and pooled with a further 0 .2 ml methanol wash. 
Phospholipids were extracted by the addition of 310|il of chloroform, vortexed and 
incubated at room temperature for 15-20 minutes or overnight at 4°C. The phases 
were split by the addition of 390|il chloroform and 480|il of water and centrifugation 
at lOOOg for 5 minutes. A 0.8ml sample of the aqueous methanolic phase was 
analysed for [3H]choline content by cation-exchange chromatography.
(iii) Measurement of total choline generation
Analysis of [3H]choline content was performed essentially as described by 
Cook and Wakelam (1989) except that 1M KC1 rather than 1M HC1 was used to 
elute the choline fraction as described by Kanoh et a i, (1991). Figure 2.3 shows 
that 12ml of 1M HC1 was required to recover 85% of the [3H]choline in a relatively 
broad peak, whereas only 7ml of 1M KC1 was needed to give a similar recovery of 
[3 H]choline in a sharper peak. Hence the use of KC1 considerably reduced 
[3H]choline elution volume and enabled the radioactivity in the entire eluant to be 
determined, whereas the larger volume of 1M HC1 required had necessitated the 
counting of a 2 ml aliquot.
The sample of cell extract was added to 4.2ml of water and loaded onto 1ml 
Dowex-50W-H+ columns (section 2.3.1(bi)). The flow through and a further 20ml
60
Figure 2.3 (A & B). Elution profile of [3H]GroPCho, [14C]ChoP an 
pH]choline:
(A) [3H]choline eluted withlM  HC1
(B) [3H]choline eluted withlM  KC1.
A mixture of standards were diluted to 1ml with an aqueous cell extrac 
prepared from quiescent, unlabelled Swiss 3T3 cells by chloroform/methanol 
extraction. Each mixture was applied to separate 1ml Dowex-50-WH+ columns i 
plugged pasteur pipettes and ml by ml elutions were performed with water followe 
by; (A) 1M HC1 or (B) 1M KC1, as indicated. Each fraction was collected an 
counted on a [1 4C] (o) and [3 H] ( • ) , dual label programme. The profile show 
represents radioactivity in each fraction (d.p.m.), and is typical of at least three oth<i 
experiments
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water wash containing glycerophosphocholine (GroPCho) and phosphocholine 
(PCho) was discarded, whilst a final wash with 7ml of 1M KC1 was collected as the 
choline fraction. The radioactivity in the eluant was determined by scintillation 
counting.
2.3.2 Measurement of stimulated formation of total inositol phosphates.
(i) Preparation of dowex-formate.
lOOg of Dowex 1x8-200 anion exchange resin in the chloride form, was 
washed 3 times in distilled water, allowed to settle and the 'fines' discarded after 
each wash. The resin was then washed with 21 of 2M NaOH followed by 61 of water 
and then 0.51 of formic acid. Finally the Dowex was washed with 201 water until the 
pH of the slurry was approximately 5.5. Each preparation of formate form Dowex 
was characterised for measurement of total inositol phosphates by performing ml by 
ml elutions of [3H]Ins(l,4 ,5 )P3 .
(ii) Preparation of samples
Total inositol phosphates were assayed by accumulation in the presence of 
lOmM LiCl as described by Berridge et al., (1982). Swiss 3T3 cells were plated 
onto 24-well plates at a density of approximately 104  cells.ml' 1 in DMEM + 10% 
newborn calf-serum, until approximately 80% confluent. They were then grown in 
0.5ml inositol-free DMEM containing 2% dialysed newborn calf-serum and 
lp.Ci.ml ' 1 of [2-3 H]myo-inositol for 24 hours, after which time the cells were 
confluent, quiescent and labelled to radioactive equilibrium. Prior to the experiment 
the labelling medium was removed and the cells washed twice in 0.5ml HHBG 
containing 0.1% (v/v) BSA (fraction V) for 10 minutes at 37°C, prior to incubation 
for a further 5 minutes in 0.5ml HHBG containing 0.1% (v/v) BSA (fraction V) + 
lOmM LiCl (HHBG.Li). Incubations were commenced by replacing the medium 
with 200pl (or 150pl if reaction was to be terminated with methanol) of the test
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reagent in HHBG.Li, at the times and concentrations indicated. Incubations were 
terminated either by addition of lOOpl of 10% (v/v) perchloric acid (PCA) or 500|il 
methanol and the samples were extracted on ice.
In assays where PCA was used, the wells were scraped and the material 
transferred to an eppendorf tube. Each well was then washed with 50pl water which 
was pooled with the scraped cell debris. The cell extracts were neutralised by 
addition of KOH/hepes (1.5M/60mM) containing universal indicator, after which the 
samples could be stored at -20°C. After thawing, the neutralised extracts were 
centrifuged at 14,000# for 3 minutes at 4°C to remove the precipitated potassium 
perchlorate and the supernatant assayed for total inositol phosphates (section 
2.3.2(iii)).
In assays where methanol was used, the cell debris was scraped and 
removed to a 2ml plastic tube. Each well was then washed with 200|il of methanol 
and pooled with the scraped cell debris. Phospholipids were extracted by addition of 
310JJ.1 of chloroform, vortexed and incubated at room temperature for 15 minutes. 
After addition of 390|il of chloroform and distilled water, samples were centrifuged 
at l,000g for 5 minutes to split phases. 800p.l of the upper aqueous/methanolic 
phases was assayed for total inositol phosphates. In addition, an aliquot of the 
chloroform phase was removed and dried down and the radioactivity in total inositol 
containing lipids determined by scintillation counting.
(iii) Assay of total inositol phosphates
Samples prepared as described above, were mixed with 3ml of 0.5mM 
EDTA/5mM sodiumtetraborate, pH6.7. and 0.5ml Dowex formate (lx8;200-400 
mesh, (section 2.3.2.(i)). Most of the sample was aspirated off and the Dowex 
washed twice with 4ml water. Glycerophosphoinositides were eluted with two 4ml 
washes of 5mM sodiumtetraborate/60mM ammonium formate. The dowex was 
washed twice with 4ml water and was centrifuged for 1 minute at 1000# before the 
final wash was aspirated. Finally, lml of 1M ammonium formate/0.1M formic acid
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was added to elute total inositol phosphates. The radioactivity associated with the 
total inositol phosphates in 800}il of the supernatant was determined by scintillation 
counting.
2.3.3 Determination of the generation of total inositol phosphates and 
phospholipase D transferase activities in the same cell monolayer.
Swiss 3T3 cells were plated onto 24-well plates at a density of 
approximately 104  cells.ml' 1 in DMEM + 10% newborn calf-serum until 
approximately 80% confluent. They were then grown in 0.5ml inositol-free DMEM 
containing 2% dialysed newborn calf-serum and ljiCi.ml' 1 of [2 -3H]my<9-inositol + 
4p.Ci.ml' 1 [3H]palmitic acid for 24 hours. Samples were prepared as described for 
measurement of total inositol phosphates, using methanol to terminate the reaction, 
except that 30mM butan-l-ol was included in addition to lOmM LiCl. The samples 
were processed as described for the assay of total inositol phosphates (section 
2.3.2(iii)) except that cell-debris was transferred to screw-top glass vials instead of 
plastic tubes. On splitting the phases the whole of the aqueous phase was taken for 
total inositol phosphate measurement and the whole of the organic phase dried down 
and analysed for [3H]PtdBut generation (section 2.3.1 (ii - iii)). Table 2.2 shows that 
in cells labelled with [3H]palmitic acid the presence of lOmM LiCl did not affect 
stimulated [3H]PtdBut generation, nor did the presence of butan-l-ol in [3H]inositol 
labelled cells affect stimulated inositol phosphate generation.
2.3.4 Measurement of cyclic AMP generation
Binding protein prepared from bovine heart was kindly donated by 
Professor. M. Houslay.
(i) Preparation of samples
Swiss 3T3 cells were grown in 6 -well plates in DMEM + 10% calf serum
until approximately 80% confluent. The medium was removed and the cells
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Table 2.2 Effect of (A) lOmM LiCl on bombesin-stimulated [3 H ]P tdB ut 
generation in [3 H]paImitate labelled Swiss 3T3 cells and (B) 30mM butan-l-ol 
on bom besin-stim ulated generation of [3 H]total inositol phosphates in 
[3H]inositoI labelled cells.
Swiss 3T3 cells were grown in 24-well plates until approximately 70% 
confluent then labelled for 24 hours with either; (A) 4|iCiml_1 of [3H]palmitate in 
DMEM + 2% calf serum, or (B) lp C im l'1 of [3H]inositol in 0.5ml of inositol-free 
DMEM containing 2% dialysed calfserum.
(A) After washing with HHBG for 20 minutes, cells were preincubated for 10 
minutes in HHBG containing 30mM butan-l-ol in the presence or absence of lOmM 
LiCl. Incubations were commenced by replacing the medium with HHBG + 30mM 
butanol + lOOnM bombesin in the presence or absence of LiCl for 1 minute. Control 
cells were incubated with HHBG + 30mM butan-l-ol, with or without lOmM LiCl. 
Incubations were terminated by replacement of the medium with 0.5ml ice-cold 
methanol Chloroform extracts were prepared and [3H]PtdBut generation quantified 
by t.l.c. as described. Results are expressed as radioactivity in [3H]PtdBut (d.p.m., 
mean ± S.D., n=3) from a single experiment representative of two.
(B) After washing twice with HHBG over 20 minutes, cells were preincubated for’ 
10 minutes in HHBG containing lOmM LiCl in the presnce or absence of 30mMI 
butan-l-ol. Incubations were commenced by replacing the medium with HHBG +* 
lOmM LiCl + lOOnM bombesin in the presence or absence of 30mM butan-l-ol for 
1 minute. Control cells were incubated with HHBG + LiCl with or without 30mM 
butan-l-ol. Incubations were terminated by addition of PCA and the generation of 
[3H]total inositol phosphates determined as described. Results are expressed as 
radioactivity in [3H ]InsP t (d.p.m., mean ± S.D., n=3) and are from a single 
experiment representative of three.
(A) Treatment d.p.m. in PtdBut
ButOH preincubation 655 ± 101
ButOH stimulation
ButOH + LiCl preincubation 633 ± 37
ButOH + LiCl stimulation
ButOH preincubation 2088 ±134
ButOH + bombesin stimulation
ButOH + LiCl preincubation 2219 ± 258
ButOH + LiCl + bombesin 
stimulation
(B) Treatment d.p.m. in total inositol
phosphates
LiCl preincubation 927 + 236
LiCl stimulation
LiCl + ButOH preincubation 981 ± 141
LiCl + ButOH stimulation
LiCl preincubation 2671 ± 356
LiCl + bombesin stimulation
LiCl + ButOH preincubation 
LiCl + ButOH + bombesin 
stimulation
2690 ± 202
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quiesced in DMEM + 2% calf serum for 24 hours prior to the experiment. Cells 
were washed in HHBG for 20 minutes at 37°C , then the medium replaced with the 
test reagent in HHBG at the required concentrations and for the times indicated. 
Incubations were terminated by aspiration of the medium and addition of 0.25ml of 
2% (v/v) PCA. The cell debris was removed by scraping into eppendorf tubes and 
the samples neutralised by the addition of 2M potassium hydroxide /  0.5M 
triethanolamine hydrochloride containing universal indicator. The precipitated 
potassium perchlorate and cell debris were pelleted by centrifugation at 14,000g for 
10 minutes at 4°C. A 50|il aliquot was then removed for assay of cyclic AMP.
(ii) Measurement of cyclic AMP generation
Determination of cyclic AMP content was based on the saturation assay of 
Brown et al, (1972), as described by Whetton et al, (1983). A standard curve was 
constructed by preparing a series of unlabelled-cyclic AMP solutions ranging from 
0-320pmol.ml'1, in a buffer containing 50mM Tris pH 7.4 and 5mM EDTA. (5;8 
-[3H]-adenosine 3'5' cyclic phosphate) in 50% ethanol was diluted in this buffer to 
give approximately 500,000 c.p.m.ml'1. lOOjil of this solution was added to tubes 
containing 5 0 jll1 of assay buffer. 50fil of standard cyclic AMP solution or a 50|il 
aliquot of Swiss 3T3 cell extract was then added. After mixing, 100(il of binding 
protein diluted in assay buffer, was added to the samples, which were mixed once 
again. Tubes were incubated at 4°C for at least 2 hours. Total cyclic AMP binding 
to the protein was determined by incubating the tritiated cyclic AMP in the absence 
of the unlabelled species, whilst non-specific-binding was estimated by the 
incubation of tritiated cyclic AMP in the absence of binding protein as well as 
unlabelled cyclic AMP. Non-specific binding was typically between 10 and 20% of 
total binding. Incubations were terminated by addition of 250|il of ice-cold assay 
buffer containing 2 % activated charcoal and 1 % bovine serum albumin in assay 
buffer, followed by centrifugation at 14,000g at 4^0. A 300|il aliquot of the 
supernatant was removed to a 5ml insert vial and the radioactivity associated was
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. determined. The program used to count the samples had an RIA curve fitting 
program and hence cyclic AMP content was automatically calculated from the 
standard curve. The binding assay gave optimum sensitivity between 0.25 and 
8 pmoles/sample.
2.3.5 Western-blot analysis of tyrosine-phosphorylated proteins.
(i) Preparation of cell lysates.
Swiss 3T3 cells were grown in 6 -well plates or 25cm2 flasks in DMEM + 
10% (v/v) newborn calf serum for 48 hours, then allowed to quiesce in DMEM + 
2%(v/v) calf serum for a further 24 hours. Cells were washed for 20 
minutes in HHBG containing 0.1% BSA (w/v) at 37°C, before treatment with the 
test reagent as indicated. Incubations were terminated by rapidly washing the cells 
three times with lysis wash buffer [50mM hepes pH 7.4, 5mM EGTA, 150mM 
sodium chloride, 100|iM sodium vanadate, 200|iM phenylmethanesulphonyl 
fluoride], lysis buffer was then added [50mM hepes pH 7.4, 1% (v/v) Triton x-100, 
ImM EDTA, ImM EGTA, 50|ig/ml aprotinin, 25mM benzamidine, 5|ig/ml 
leupeptin, lOOjiM sodium vanadate] and the cells placed on ice. The flasks or plates 
were shaken at 4°C for 10-20 minutes subsequent to lysis, then the lysed cells 
removed by scraping into eppendorf tubes. The lysates were centrifuged at 4°C at 
14,000g for 10 minutes to remove the insoluble material and the nuclei and the 
supernatant transferred to fresh eppendorf tubes. Lysates were stored at -20°C until 
required. The protein concentration of the lysates was determined using the micro 
BCA protein assay kit.
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(ii) TCA precipitation of samples for Western-blot analysis.
The protein content of each lysate was corrected to that required in 0.7ml 
with distilled water. 6 .2 |il of 2 % (w/v) sodium deoxycholate was added and the 
solution vortex mixed. The protein was precipitated by the addition of 0.25ml of 
24% (w/v) trichloroacetic acid and the suspension vortexed and incubated at 4°C for 
15 minutes. The precipitated protein was pelleted by centrifugation at 4°C for 5 
minutes at 14,000# and the, supernatant removed by aspiration. 20|il Laemmli buffer 
[30% (w/v) urea, 5% (w/v) SDS, 6 % (w/v) DTT, 20mM Tris/HCl pH 8.0, 0.2% 
(w/v) bromophenol blue].and 20|il of 2M Tris base pH 8  was added to the pellet.
For mini-gels the TCA precipitate was acetone washed. Following removal of the 
supernatant, 2 0 0 pl of ice-cold acetone was added and the pellet again centrifuged at 
4°C for 5 minutes at 14,000#. The supernatant was removed and the process 
repeated. After the second acetone wash, lOp.1 of Laemmli buffer and 10|il of 2M Tris 
base pH 8  was added to the pellet. The pellets were then vortex mixed and boiled 
for 5 minutes to dissolve the precipitated protein.
(iii) SDS-PAGE gel preparation
SDS-PAGE analysis of cell lysates was performed according to the method 
of Laemmli et al, (1970) in 1.5mm or 0.75mm (mini-gels) thick, polyacrylamide 
gels, employing a vertical slab gel or mini-gel apparatus (BioRad) as described by 
the manufacturers.
Proteins were separated using 10% acrylamide resolving gels and 3% 
acrylamide stacking gels. Immediately after preparation, the resolving gel was 
poured into the gel apparatus, overlaid with water-saturated butanol and left to 
polymerise at room temperature. After preparation of the stacking gel, the overlay 
was removed from the polymerised resolving gel and the stacking gel solution 
poured into the electrophoresis apparatus. The well comb was positioned and the 
solution left to polymerise at room temperature
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(iv) SDS-PAGE gel electrophoresis
The polymerised gels were assembled into the buffer reservoir as described 
by the manufacturer's instructions, the well comb removed and the reservoirs filled 
with running buffer [25mM Tris, 190mM glycine, 0.1% (w/v) SDS]. The prepared 
samples (section 2.3.5(ii)) were placed directly into the wells of the stacking gel 
with a Hamilton syringe. Mini-gels were run for 1 hour at 20mA, 150V per gel. 
Large gels were run over-night at 15mA, 100V for 2 gels until the dye-front reached 
the end of the resolving gel
(v) Immuno-blotting of SDS-PAGE gels
After electrophoresis the proteins were transferred to nitrocellulose 
according to the manufacturers instructions (wet-blotting - Hoeffer; semi-dry 
blotting - Sartoblot). Wet-blotting was performed for large gels in buffer containing, 
25mM Tris, 0.19M glycine and 20% (v/v) methanol. For mini-gels blotting was 
performed in buffer containing, 48mM Tris pH 9.2, 39mM glycine, 1.3mM SDS, 
20% (v/v) and methanol, using the semi-dry apparatus. Gels were routinely stained 
with Coomassie-blue [stain; 500ml distilled water, 400ml methanol, 100ml acetic 
acid, 0.1% w/v Coomassie blue: destain; 500ml distilled water, 400ml methanol, 
1 0 0 ml, acetic acid] subsequent to blotting, to check the efficiency of the transfer.
The nitrocellulose was rinsed briefly in Tris buffered saline (TBS) [150mM 
sodium chloride, 20mM Tris pH 7.4], then blocked for 3 hours at 4°C in TBS 
containing 0.05% Tween 20 (TBST), with 3% (w/v) BSA (fraction V,
electrophoresis grade) and 10% (v/v) sheep-serum added. The blot was then 
incubated overnight at 4^C in TBST containing 3% (w/v) BSA and a 1:5000 dilution 
of anti-phosphotyrosine PY54 antibody (Ruff-Jamison et a l , 1991). In earlier 
experiments a mouse monoclonal antibody from U.B.I was used, however due to 
expense and problems in stability the antibody was changed. Blots developed using 
either antibody showed essentially the same results.
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After incubation with first antibody, the blot was washed in TBST for 2 
hours, changing the wash regularly. The nitrocellulose was then incubated at 4°C 
for lhour in TBST supplemented with 3% (w/v) BSA and a 1:2000 dilution of sheep 
anti-mouse IgG linked to horse radish peroxidase and preadsorbed with human 
serum proteins. The blot was then washed repeatedly over 2 hours in TBST. The 
horse-radish peroxidase-labelled proteins were detected by using ECL. 
Luminescence was detected by exposing autoradiograph film to the blot for times 
ranging from 10 seconds to 5 minutes.
2.4 Radio-ligand receptor binding assays
2.4.1 Binding of [3H]AVP and [3H]AVP antagonist to Swiss 3T3 cells
Binding to intact cells was performed as described by Gardner et a l , 1989. 
Cells were grown in 6 - or 12-well plates until approximately 80% confluent. The 
medium was then replaced with DMEM + 2% calf serum and the cells quiesced for 
24 hours. The medium was removed and the cells washed three times over 20 
minutes at 37°C in first wash buffer [serum-free DMEM supplemented with 
glutamine, lOmM hepes pH 7.4 and 0.2% (w/v) bovine serum albumin ]. 
Pretreatments were performed at 37®C for the times indicated with the test reagent at 
the required concentration in incubation buffer [serum free DMEM supplemented 
with glutamine, lOmM hepes pH 7.4, 0.05% (w/v) bovine serum albumin, lOmM 
glucose and 2mM bacitracin ]. After replacing the medium with ice-cold incubation 
buffer the cells were placed on ice and washed 4 times over 15 minutes with 0.5ml 
ice-cold incubation buffer. Incubations were commenced by replacing the medium 
for the times indicated with incubation buffer containing [3H] vasopressin antagonist 
[P-M ercapto-p-p-cyclopenta-m ethylenepropionyl1, 0-Et-Tyr2, Val4, Arg8]- 
vasopressin ([3H]AVP antagonist or [8-Arginine][Phe-3,4,5-3H(n)]vasopressin 
([3H]AVP) at the required concentration. The medium was then removed and the 
wells washed 4 times with ice-cold second wash buffer [serum-free DMEM
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supplemented with glutamine, lOmM hepes pH 7.4 and 0.1% (w/v) bovine serum 
albumin] before the cells were solubilised.
2.4.2 Solubilization of cells and determination of cell-associated radioactivity.
Following the final wash, 0.5ml of solubilization buffer containing 0.5M 
NaOH, 1% (w/v) SDS and lOmM hepes, was added to the wells and the cells left at 
room temperature for 30 minutes. A 0.45ml portion of this solution was transferred 
to a scintillation vial containing 0.45ml 0.5M HC1 and the radioactivity associated 
with the cells determined by liquid-scintillation counting. Non-specific binding, was 
determined as the radioligand not displaced by a 2 0 0 -fold excess of unlabelled 
antagonist or agonist as appropriate. Cell number was determined using one well 
per plate which was treated in the same way, except that no agonist pretreatment or 
radiolabel was added and after the final wash, cells were removed from the well with 
trypsin and counted using a heamocytometer.
2.4.3 Quantification of Internalized Ligand
Measurement of internalised ligand was established using an acidic wash to 
remove surface bound agonist as described by Kuppuswamy and Pike (1989). Cells 
were treated initially as in section 2.4.1. Following the initial wash period, the cells 
were incubated for indicated times with [3H]AVP in incubation buffer (section 
2.4.1) at 37°C. Medium was aspirated and replaced with ice-cold incubation buffer 
before the cells were placed on ice to prevent further internalisation. Surface-bound 
[3H]AVP was determined by washing twice for 2 minutes in buffer containing 
50mM glycine pH 3 and lOOmM sodium chloride, before further washing for four 
times in ice-cold second wash buffer (section 2.4.1). Determination of cell- 
associated radioactivity and cell number was as in section 2.4.2 Internalised 
[3H]AVP was taken as that portion of the total cell-bound [3H]AVP not removed by 
the acid wash treatment.
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2.4.4 Measurement of internalization of ([125I]-Tyr4) gastrin releasing peptide 
in intact Swiss 3T3 cells
Cells were grown in 24-well plates and quiesced as described in section 
2.4.1. Binding experiments were essentially as described by Brown et al. (1987). 
The wells were washed in HHBG containing ImM potassium iodide (HHBG.KI) for 
20 minutes at 37°C, prior to incubation for 1 minute with lOOnM bombesin in 
HHBG.KI containing 0.1fiCi/150|il of ( [^ I J -T y r4) gastrin releasing peptide 
(([125I]-Tyr4)GRP). The medium was then replaced with ice-cold HHBG.KI and the 
cells placed on ice to prevent any further internalisation. Cells were washed twice 
for 2 minutes with buffer pH 3 (section 2.4.4), or with HHBG.KI., before further 
washing for four times in ice-cold HHBG.KI. Cells were solubilised in 0.5M 
sodium hydroxide for 10-20 minutes at 37°C. 400|il of the solubilised sample from 
each well was counted in a gamma counter. Non-specific binding was determined as 
the radioligand not displaced by a 200-fold excess of bombesin. Cell number was 
determined by using one well per plate which was treated in the same way, except 
that no radiolabel was added and after the final wash, cells were removed from the 
well with trypsin and counted using a haemocytometer.
2.5 Permeabilisation of cells using Streptolysin-0
Permeabilisation of cells and all subsequent washes and treatments were 
performed in permeabilisation buffer made up as follows;
Permeabilisation buffer (final free calcium concentration 150nMl
120mM potassium chloride, 20mM hepes pH7.4, 8.49mM magnesium chloride,
61|iM calcium chloride, O.lmM EGTA .
2.5mM ATP and 0.1 % (w/v) BSA (fraction V) were added on day of use and pH 
was adjusted to 7.4.
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2.5.1 Determination of cell permeabilisation using entry of fluorescent dye
Swiss 3T3 cells were scraped from a 75cm2  flask and transferred to a 
centrifuge tube at 37°C for 45 minutes to allow recovery. Cells were then washed 
three times in HHBG and resuspended in permeabilisation buffer containing 
streptolysin-O (0.6U.ml_1) and the fluorescent stain bisbenzamide (lOpg.ml'1). 
After 5 minutes an aliquot of cells was transferred to a slide and examined under a 
fluorescent microscope. At least 90% of cells were found to contain the fluorescent 
dye (Fig. 2.4). Previous findings had demonstrated that 0.611ml'1 of streptolysin-0 
resulted in maximal release of lactate dehydrogenase from Swiss 3T3 cells (Currie, 
1992)
2.5.2 Protocol for Permeabilisation
Swiss 3T3 cells were grown on 24-well plates and labelled with the 
appropriate radioisotopes as described for the relevant assay in intact cells (sections 
2.3.1(i),.2.3.2(ii), 2.3.3 ). After labelling, the monolayers were washed in 0.5ml 
HHBG for 20 minutes. Cells were permeabilised by incubation with 150|il 
streptolysin-O (0.6U.ini'1) in permeabilisation buffer for 5 minutes as previously 
described by Currie and Wakelam (1992). This was followed by washing twice with 
150|il of permeabilisation buffer over 10-15 seconds and stimulation with 150|il of 
the test reagent in permeabilisation buffer at the concentrations and times indicated. 
Following permeabilisation cells were treated exactly as described in the sections 
referring to the appropriate assay in intact cells
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Figure 2.4 Entry of fluorescent dye into permeabilised Swiss 3T3 cells
Swiss 3T3 cells were scraped from a 75cm2 flask, transferred to a centrifuge 
tube kept at 37°C for 45 minutes to allow recovery Cells were then permeabilised 
with streptolysin-O as described, together with the fluorescent stain bisbenzamide. 
The photographs show the cells as seen under a fluorescent microscope and are 
from.a single experiment
Both photographs (A) and (B) are of cells from the same experiment but viewed using 
different light intensities.
(A)
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2.6 Miscellaneous procedures
2.6.1 Activation of sodium orthovanadate
The pH of a lOmM solution of sodium orthovanadate was adjusted to pH 10 
using lMNaOH and 1MHC1. The yellow solution was boiled until clear, then 
cooled to room temperature and the pH readjusted to pH 10. This procedure was 
repeated until the solution remained clear and the pH was stable. Aliquots of 
sodium orthovanadate were stored frozen at -20°C.
2.6.2 Preparation of Peroxovanadate
Pervanadate was prepared as described in (Bianchini et a l 1993). lOmM 
sodium orthovanadate and lOmM hydrogen peroxide were mixed and incubated at 
25°C for 15 minutes. Residual hydrogen peroxide was removed by the addition 
catalase (200|ig.ml_1 final concentration). Control cells were treated with a solution 
where Hanks was substituted for sodium orthovanadate.
2.6.3 Analysis and presentation of results
Unless otherwise stated all experiments were performed at least three times 
and each data point represents the mean ± standard deviation (S.D.) of triplicate 
determinations. Statistical significance was estimated by an unpaired Students *t' test 
on an Apple Macintosh Stat-works program and significance was generally taken as 
values of p<0.05.
EC50  and IC50 values were calculated from dose-response curves fitted to a 
logistic equation (non-linear regression analysis) as defined by Delean et al. (1980). 
However, for presentation purposes dose-response curves were presented as simple 
line graphs from the Apple Macintosh Cricket Graph program.
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Chapter 3
The Regulation of Phospholipase D Activity by Second- Messengers
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3.1 Introduction
Phospholipase D can be activated both by G-protein coupled receptors 
which stimulate PLC-catalysed PtdIns(4 ,5 )P2 hydrolysis, such as those for bombesin 
(Cook and Wakelam, 1989, Cook et al., 1991) and acetylcholine muscarinic 
cholinergic receptors (Qian and DrewesJl989 ) and by receptor tyrosine kinases, 
such as that of the EGF receptor (Wright et al., 1992). A plethora of factors are 
potentially involved in receptor-stimulated PLD activity. The relative contribution 
of the regulatory components to stimulated PLD activity is cell and agonist specific 
(reviewed Billah et al., 1993). The experiments in this chapter aimed to characterise 
the regulatory mechanisms involved in bombesin-stimulated PLD activity in Swiss 
3T3 fibroblasts.
The regulation of Ptdlns-PLC by guanine-nucleotides is now well 
established (reviewed Rhee and Choi, 1992). Evidence is accumulating for the 
involvement of G-proteins in the regulation of PLD activity in a number of cells 
(reviewed Cockcroft, 1992). The differential sensitivity of stimulated PLD activity 
to pertussis-toxin suggested that different G-proteins could regulate PLD activity, in 
an analogous manner to the G-protein regulated Ptdlns-PLC activity (Rhee and Choi, 
1992). The bombesin receptor couples to Ptdlns-PLC through the pertussis-toxin 
insensitive Gq (Plevin et al., 1990; Smrcka et al., 1991). Therefore the possibility 
that bombesin may regulate PLD activity through a G-protein, possibly through the 
same G-protein and/or a different one to that coupled to the hydrolysis of 
PtdIns(4 ,5 )P2 was investigated.
The extent to which receptor-stimulated PLD activity is dependent on PKC 
activation appears to vary with the system studied. Activation of PLD-catalysed 
PtdCho hydrolysis in prostaglandin E-stimulated human erythroleukaemia cells (Wu 
et al., 1992) and fMetLeuPhe (fMLP)-stimulated HL60 cells was PKC independent 
(Rheinhold etal., 1990). However, bombesin-stimulated PLD activity was inhibited 
by approximately 50% by 10|iM of the selective PKC inhibitor Ro-31-8220, a 
concentration at which PMA-stimulated PLD activity was completely abolished
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(Cook et al., 1991). The pathway of PKC-independent activation of bombesin- 
stimulated PLD activity awaits clarification and thus is addressed in this chapter.
A possible PKC-independent regulatory pathway of PLD activity is through 
tyrosine phosphorylation, particularly as bombesin-stimulates the PKC-independent 
tyrosine phosphorylation of a number of proteins in Swiss 3T3 cells (Zachary et al., 
1991). The potential involvement of tyrosine kinases in the activation of PLD 
activity was realised by EGF-stimulation of the enzyme activity (Cook and 
Wakelam, 1992). This was found to occur independently of inositol lipid hydrolysis 
and PKC activation, but activation of the receptor kinase was essential. 
Furthermore, the stimulation of PLD activity through cytosolic tyrosine kinases has 
been reported in cells such as fMLP-stimulated neutrophils (Uings et al., 1992).
The regulation of PLD by Ca2+ appeared to be mediated predominantly by 
PKC (reviewed Cook and Wakelam 1992). Ro-31-8220 inhibited A23187- 
stimulated PLD activity by approximately 50%, whereas the combined presence of 
Ro-31-8220 and EGTA was less than additive in inhibiting bombesin-stimulated 
PLD activity. A possibility to be investigated was therefore that a Ca2+-stimulated 
pathway of PLD activation , independent of PKC activation may exist and that this 
could involve a rise in Ca2+ from intracellular stores alone.
Experiments to elucidate the pathways involved in agonist-stimulated PLD 
activity were therefore undertaken by determining the contributions of components 
of the signal transduction pathway including; G-proteins, tyrosine kinases, Ca2+ and 
cyclic AMP.
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3.2 Results
3.2.1 The regulation of bombesin-stimulated PLD activity by mobilisation of 
Ca2+ from intracellular stores
Experiments were performed to determine if PLD could be activated solely 
through the release of Ca2+ from intracellular stores. This store can be emptied by 
addition of the tumour promoter thapsigargin, an inhibitor of the Ca2+-ATPase in 
non-mitochondrial stores (Thastrup et al., 1990). In Swiss 3T3 cells lp.M 
thapsigargin was shown to stimulate an increase in [Ca2+h comparable with that 
stimulated by lOOnM bombesin. However, kinetics of the thapsigargin-induced 
response were slower, with the maximal [Ca2+]i not attained until approximately 22 
seconds, whereas the bombesin-stimulated [Ca2+]j was maximal by 6  seconds 
(Currie et al., 1992). Figure 3.1 shows that lpM  thapsigargin was without effect on 
the dose/response curve of bombesin-stimulated PtdBut formation. At doses ranging 
from lOnM to 10|iM, thapsigargin alone was unable to stimulate PLD activity during 
a 90s stimulus (results not shown). Longer incubation times were not employed 
because of the possibility of thapsigargin stimulating Ca2+ entry (Takemura et al., 
1989).
3.2.2 The regulation of PLD activity by guanine nucleotides
The effects of GTP analogues on PLD activity was investigated in 
streptolysin-O permeabilised cells. Streptolysin-O, a bacterial cytolysin, has been 
used to permeabilise several cell types including HL60 cells (Stutchfield and 
Cockcroft, 1988) and T lymphocytes (Alexander et al., 1989). This agent generates 
pores in cholesterol -containing membranes of up to 1 2 nm, which permits access of 
nucleotides but not the toxin, hence permeabilisation of intracellular membranes is 
prevented. Streptolysin-O permeabilisation of Swiss 3T3 cells was maximal at a 
concentration of 0.6U.ml_1,
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Figure 3.1 Effect of thapsigargin upon bombesin-stimulated PLD activity.
[3H]Palmitate-labelled cells were stimulated for 1 minute with increasing 
concentrations of bombesin as indicated, in the presence of lpM-thapsigargin (•) , or 
vehicle (0.1% DMSO), (o). Incubations were terminated by replacement of the 
medium with methanol. Chloroform extracts were prepared and [^H ]PtdB ut 
quantified as descibed. Results are expressed as radioactivity in [3H]PtdBut (mean ± 
S.D., d.p.m., n=3) and are from one experiment typical of three.
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measured by the release of LDH activity (Wakelam and Currie, 1992). This 
concentration caused approximately 90% permeabilisation of Swiss 3T3 cells as 
determined by entry of the fluorescent dye bisbenzimide (Fig. 2.4).
All permeabilisation experiments were performed at a resting Ca2+ 
concentration of 150nM in order to maintain physiologically relevant conditions as 
closely as possible. Permeabilisation of cells was found to activate PLD activity as 
determined by [3H]PtdBut accumulation when streptolysin-O was added to cells in 
the presence or absence of 30mM butan-l-ol (radioactivity in [3H]PtdBut, mean ± 
S.D., d.p.m., n=3: permeabilisation -ButOH, 1480 ± 832; permeabilisation + ButOH, 
4547 ± 380, from a single experiment typical of three). All permeabilisations were 
therefore performed in the absence of alcohol, followed by two rapid washes in 
buffer before stimulation in the presence of butanol.
Figure 3.2 shows the time course of GTPyS-stimulated PLD activity in 
Swiss 3T3 cells. In some experiments GTPyS-stimulated [3H]PtdBut accumulation 
was elevated above basal after 1 minute, but was always significant after 5 minutes 
(p=0.015 ±0.015, n=3). The extent of [3H]PtdBut accumulation in response to 5 
minute GTPyS treatment was not affected by washing cells for times up to 15 
minutes subsequent to permeabilisation (results not shown). Fig 3.3(A) shows that 
30pM GTPyS did not affect bombesin-stimulated PLD activity at any concentration 
of bombesin tested. Fig. 3.3(B) shows that at low [GTPyS] the presence of 
bombesin potentiated stimulated-[3H]PtdBut generation. However in all 
experiments, there was no potentiating effect of bombesin on concentrations of 
[GTPyS] of 30|iM and above. Elevation of GTPyS-stimulated PLD activity above 
basal was always significant at a lpM  guanine nucleotide concentration (p= 
0.004±0.004, n=3). 30fiM GTPyS and lOOnM PMA were
synergistic in the generation of [3H]PtdBut over a 10 minute stimulation period 
(p=0.01 ±0.01, n=3) (Fig. 3.4).
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Figure 3.2 Time course of GTPyS-stimulated PLD activity.
[3H]Palmitate-labelled cells were permeabilised with streptolysin-O as 
described (section 2.5), then stimulated for times indicated with 30|iM GTPyS in the 
presence of 30mM butanol. Incubations were terminated by addition of methanol. 
Chloroform extracts were prepared and [3H]PtdBut quantified as described. Results 
are expressed as radioactivity in [3H]PtdBut ± S.D. (mean ± S.D., d.p.m., n=3) and 
are from a single experiment representative of three.
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Figure 3.3 (A) Effect of bombesin on 30jiM GTPyS-stimulated PLD activity;
(B) Effect of GTPyS on 3nM bombesin-stimulated PLD activity.
(A) Effect of 30jiM GTPyS on bombesin-stimulated PLD activity
pH JPalm itate labelled cells were permeabilised using streptolysin-O 
(0.6U.ini'1) and stimulated for 1 minute with increasing concentrations of bombesin 
and 30mM butanol in the presence ( • ) ,  or absence (o), of 30|iM GTPyS . 
Incubations were terminated by the addition of chloroform. Chloroform extracts 
were prepared and [3H]PtdBut quantified as described. Results are expressed as 
radioactivity in [^HJPtdBut generated (mean ± S.D., d.p.m., n=3) and are from a 
single experiment typical of three.
(B) Effect of 3nM bombesin on GTPyS-stimulated PLD activity.
[^H]Palmitate labelled cells were permeabilised using streptolysin-O 
(O.bU.ml'1) and stimulated for 5 minutes with increasing concentrations of GTPyS 
and 30mM butanol in the presence ( • ) ,  or absence (o), of 3nM bombesin. 
Incubations were terminated by addition of methanol. Chloroform extracts were 
prepared and [3 H]PtdBut generated was determined as described. Results are 
expressed as radioactivity in [3H]PtdBut, (mean ± S.D., d.p.m., n=3) and are from a 
single experiment typical of three.
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Figure 3.4 Effect of GTPyS on PMA-stimulated PLD activity.
[3H]Palmitate labelled cells were permeabilised with streptolysin-O 
(0.6U.ml_1) and stimulated for 10 minutes with vehicle, 30uM GTPyS, lOOnM PMA 
or lOOnM PMA + 30|iM GTPyS. All additions contained a final concentration of 
0.01% DMSO and 30mM butanol. Incubations were terminated by the addition of 
ice-cold methanol. Chloroform extracts were prepared and the generation of 
[3H]PtdBut was quantified as described. Results are expressed as radioactivity in 
[3H]PtdBut, (mean ± S.D., d.p.m., n=3) and are from a single experiment typical of 
three.
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The response to bombesin was significantly reduced by pre-incubation of 
permeabilised cells with 2mM GDPpS l the non-hydrolysable GDP analogue
(p=0.02± 0.01), n=3), whereas activation of PKC using PMA, stimulated PLD activity in a manner 
that was unaffected by GDPPS (Table 3.1). The percentage inhibition of bombesin-stimulated 
pHJPtdBut generation, in the presence of GDPpS, over three separate experiments was, 58 ± 19%
Cells were depleted of cellular ATP by treatment with the metabolic 
inhibitors antimycin A and deoxyglucose, thereby preventing the activation of PLC 
and kinases (Nielson et al., 1991; Geny and Cockcroft, 1992). Double-labelling of 
cells enabled the generation of [3H]PtdBut and total [3H]inositol phosphates to be 
measured in the same well. Figure 3.5(B) shows that pretreatment with the 
metabolic inhibitors reduced the stimulation of total [3H] inositol phosphates by 
30jiM GTPyS, lOOnM bombesin or 30pM GTPyS + lOOnM bombesin, to near basal 
levels. Stimulation of PLD activity was reduced to similar levels, or in some 
experiments, was completely abolished. (Fig 3.5(A)).
3.2.3 Regulation of bom besin-stim ulated PLD activity  by tyrosine 
phosphorylation
The analysis of protein tyrosine phosphorylation after exposure of cells to 
stimulant, was determined by immunoblotting of cell lysates with an anti- 
phosphotyrosine monoclonal antibody.
Experiments were performed to control for the antibody specificity. Figure 
3.6 shows that in cells stimulated with pervanadate detetection of tyrosine 
phosphorylated proteins was only possible when both primary and the secondary 
antibody were present. Pervanadate elevates tyrosine phosphorylation of cellular 
proteins through inhibition of phosphotyrosine phosphatase (see later for fuller 
description). In the presence of secondary antibody only, several non-specific bands 
consistently appeared at molecular weights of approximately 200, 97 and 60 kDa,
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Table 3.1 Effect of GDPpS on bombesin- and PMA-stimulated PLD activity.
[3H]Palmitate labelled cells were permeabilised with streptolysin-O 
(O.bUmI'1), then preincubated with 2mM GDPPS for 1 minute. Cells were then 
stimulated in the presence of 30mM butanol with: (A) lOOnM bombesin for 5 
minutes; (B) lOOnM PMA for 10 minutes, where (A) and (B) are from the same 
experiment. Incubations were terminated by addition of methanol. Chloroform 
extracts were prepared and the generation of [3H]Ptdbut was determined as 
described. Results are expressed as radioactivity in [3H]PtdBut (mean ± S.D.,
d.p.m., n=3) and are from a single experiment typical of three.
Treatment (A) bombesin (B) PMA
d.p.m. in 
PtdBut
control 455 ± 40
control +
GDPpS 711 ± 203
stimulated 2559 ± 427
stimulated +
GDPp S 1664 ± 137
d.p.m. in 
PtdBut
562 ± 32
550 ± 42
51271839
6725 ± 550
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Figure 3.5 Effect of cellular ATP depletion on; (A) stimulated PLD activity and 
(B) stimulated generation of total inositol phosphates.
Cells labelled with [3 H] inositol and [^H] palmitate were washed with 
buffer in the presence or absence of lOmM glucose for 20 minutes. 4 minutes prior 
to permeabilisation with streptolysin-O, cells to be metabolically inhibited were 
preincubated in buffer minus glucose containing 6 mM deoxyglucose and 5|iM  
antimycin A. Cells that were not to be metabolically inhibited were preincubated in 
buffer containg 0.01% DMSO and lOmM glucose. Permeabilisations, subsequent 
washes, preincubations and stimulations were performed in the presence or absence 
of metabolic inhibitors. Cells were preincubated for 10 minutes subsequent to 
permeabilisation, with lOmM LiCl and 30mM butanol then stimulated for 5 minutes 
with 30|iM GTPy S, 3nM bombesin or 30pMGTPyS + 3nM bombesin. Incubations 
were terminated by addition of methanol. Chloroform extracts were prepared as 
described and [3H]PtdBut and total [3H]inositol phosphates quantified as previously 
described. Results are expressed as radioactivity in; (A) [3H]PtdBut and (B) total 
[3H]inositol phosphates, (mean ± S.D., d.p.m., n=3) and are from a single 
experiment representative of three. Unshaded columns, control cells; shaded 
columns, cells depleted of cellular ATP.
For cells that were to be depleted of cellular ATP, ATP was omitted from the 
permeabilisation buffer. Cells stimulated with: vehicle, control; 3nM bombesin, bom; 3nM 
bombesin + GTPyS, GTP[S] + bom; GTPyS, GTP[S].
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Figure 3.6 Effect of omitting prim ary or secondary antibody 0n h
e t e c t i ° n  Q*
pervanadate-stim ulated protein tyrosme phosphorylation.
Cells were stimulated with 0.5mM pervanadate for 10 m inutes b f 
lysed. An aliquot of cell lysate containing approximately 30pg 0f pro t. 1 
analysed for protein phosphotyrosine phosphorylation as previously described^! 
blots were incubated in the presence or absence of the primary anti-phosphotym^B 
antibody and secondary anti-mouse IgG peroxidase conjugated antibody. Whe^jB 
primary antibody was omitted, blots were probed in TBST containing 3% g f l  
(fraction V, electrophoresis grade). Where the secondary antibody was om itd 
blots were probed in TBST containing 5% BSA. The numbered photograA 
corresponds to the lanes of the blot incubated as follows;
l(i) control cells probed with primary and secondary antibody
l(ii) pervanadate-treated cells probed with primary and secondary antibody
(2 ) pervanadate-treated cells probed with secondary antibody only
(3) pervanadate-treated cells probed with primary antibody only.
(4) pervanadate-treated cells incubated with no primary or secondary antibody
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h the most prominent being that at 60kDa. In some cases these were only 
arent a f te r  longer exposure to the film than would normally be necessary for 
servation of the bands specific to tyrosine phosphorylated proteins. As the 
condary antibody was anti-mouse IgG, the bands present after incubation with 
econdary antibody alone may have been due to non-specific interactions with the 
mouse Sw iss 3T3 cell-lysates. After incubation with primary antibody alone or with 
neither an tibody  there was no detectable signal after 'ECl' development.
Competition experiments were performed using ImM phosphotyrosine to 
inhibit the binding of the antibody and with Im M  phosphoserine and Im M  
phosphothreonine to control for cross-reactivity with other phosphoamino acids. 
Figure 3.7 shows that whereas the presence of ImM  phosphotyrosine prevented the 
appearance of most bands observable in stimulated cells, ImM phosphothreonine 
and phosphoserine had no detectable effect, either in lysates from pervanadate (Fig. 
3.7 (A)) or bombesin-stimulated cells (Fig. 3.7(B)). The faint bands observed after 
incubation with ImM phosphotyrosine are probably the non-specific bands due to 
the presence of the secondary antibody alone, as shown in Figure 3.6.
The time course and dose-response of bom besin-stim ulated tyrosine 
phosphorylated proteins was comparable with that first reported by Zachary et al., 
(1991) using immunoprecipitation and incubation with [y-32P]ATP. The time course 
showed a rapid increase in bands of m olecular weight of approxim ately, 1 1 0 - 
130kDa, 80-85kDa, 65-70kDa. and 40kDa (results not shown).
Pervanadate (peroxide of vanadate) was used to investigate whether 
increasing tyrosine phosphorylation in the absence of a receptor stimulation event 
could activate PLD. Pervanadate, prepared by combining vanadate and H 2 O 2 
(section 2 .6 .2 ), is a known insulin mimetic being 1 0 2- 1 0 3 more potent than vanadate 
ai°ne (Kadota et al., 1987). It has been reported to be a potent inhibitor of a 
Phosphotyrosine phosphatase (Fantus et al., 1989) and also to stimulate tyrosine
Figure 3.7 Effect of probing with anti-phosphotyrosine antibon I
presence of phosphotyrosine, phosphothreonine and phosphoserine on-
(A(a)) and (A(b)) Cells stimulated with lOOnM bombesin for 2 m inutes
(B) Cells stimulated with 0.5mM pervanadate for 10 minutes.
Cells were stimulated: (A(a)) and (A(b)) for 2 minutes w i t h a l
190ny
bombesin or HHBG; (B) for 10 minutes with vehicle or 0.5mM pervanadate ■■e.
were lysed and an aliquot of the lysates, corresponding to approximately 3n« J 
protein was analysed for protein phosphotyrosine phosphorylation as previo^B 
described. Incubations with anti-phosphotyrosine anti-body were performed i j i  
presence of ImM phosphotyrosine, ImM phosphothreonine, ImM phosphoserine a  
with the anti-phosphotyrosine antibody alone. The numbered lanes in
I
photograph correspond to proteins from cell lysates analysed for phosphotyrosine 1 
content under the different incubation conditions as follows; 
l(i) Control cell lysates incubated with primary antibody alone. 1
l(ii) Stimulated cell lysates incubated with primary antibody alone.
(2) Stim ulated cell lysates incubated with prim ary antibody + ImM 
phosphotyrosine.
(3) Lysates from stimulated cells, incubated with primary antibody + ImM j 
phosphothreonine.
(4) Lysates from stimulated cells, incubated with primary antibody + l®" I 
phosphoserine.
The two photographs (A(a)) and (A(b)) are from the same experiment but aftff | 
different lengths of exposure of the film to the blot.
Results are from a single experiment representative of three.
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sphorylation in a number of cells including human platelets and T-cells (Blake et 
t j9 9 3 ; Secrist et al.,1993).
Figure 3.8 shows that the time course of 0.5mM pervanadate-stim ulated 
rosine phosphorylation was rapid, com m encing by 30 seconds and increasing 
steadily over the time measured, up to 30 minutes. Tyrosine phosphorylation of 
rotein bands with a molecular weight of approximately; 200kDa, 110-130kDa, 
97kDa, 80kDa, 65kd and 45kDa were observed. Figure 3.9 shows that pervanadate 
treatment also stimulated the formation of [3H]PtdBut and total [3 H ]in o sito l 
phosphates, though both these time courses lagged behind that for protein tyrosine 
phosphorylation. Elevation of [3H]PtdBut and total [3H]inositol phosphates were 
always significant above basal after 10 minutes of stimulation. W hilst the extent of 
stimulation varied considerably between experim ents, the generation o f total 
[3H]inositol phosphates was generally less than that of [3H]PtdBut.
Figure 3.10 (A) shows that lOpM R o-31-8220 had a negligible effect on a 
10 minute stimulation of tyrosine phosphorylation with 0.5mM pervanadate, but 
slightly reduced the phosphotyrosine content of proteins in cells stimulated with 
lOOnM bombesin and pervanadate. Similar results were achieved using a 5 minute 
stimulation with 0.5mM pervanadate and 3nM bombesin (Fig. 3.10(B)). IOjiM Ro- 
31-8220 did not attenuate the [3H]PtdBut accumulation attained after a 10 minute 
stimulation with 0.5mM pervanadate (Table 3.2). Experiments were also performed 
where 0.1 nM bombesin was used to activate PLD for 5 minutes in the presence of 
0.5mM pervanadate. After this time tyrosine phosphorylation was elevated but no 
pervanadate-stimulated PLD activity was observed. These experiments showed that 
bombesin-stimulated PLD activity was not potentiated in the presence of 
Pervanadate (results not shown).
Having shown that PLD could potentially be activated by elevation of 
Protein tyrosine phosphorylation, the effect of tyrosine kinase inhibitors on 
bombesin-stimulated PLD activity was investigated. Lavendustin, the erbstatin 
analogue methyl 2,5-dihydroxycinnamate and Genistein (reviewed W orkman et al.,
Figure 3.8 Time course of protein tyrosine-phosphorylation in perva
nadate.
treated cells.
Cells were stimulated with vehicle or 0.5mM pervanadate f0r
indicated. Cells were lysed and an aliquot, containing 30pg of protein wa
d'N analy&er I
for protein tyrosine phosphorylation as described The Western blot was proh 
the U.B.I. anti-phosphotyrosine antibody. Results are from a single experjj 
representative of three.
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Mr 97
69
46 t
0 30s 1min 2min 5min 10min 30min 30 min
control
92
Figure 3.9 Time course of PLD activity and generation of total inositol 
phosphates in pervanadate-treated, double-labelled cells
Cells labelled with [3H]palmitate and [3H]inositol were preincubated for 10 
minutes with lOmM LiCl and 30mM butanol, then stimulated for times indicated 
with 0.5mM pervanadate (•) , or vehicle (o). Chloroform extracts were prepared and 
the generation of (A) [3H]PtdBut and (B) [3H]total inositol phosphates, quantified as 
described. Results are expressed as radioactivity in (A) [3H]PtdBut or (B) total 
[3H]inositol phosphates, (mean ± S.D., d.p.m., n=3) and are from a single 
experiment representative of three.
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Figure 3.10 Effect of bombesin and Ro-31-8220 on 
phosphorylation in pervanadate-treated cells.
Protein
Cells were preincubated with vehicle (0.1% DMSO) or 10pM 
for 1 0  minutes, then stimulated in the presence o f Ro-31-8220 or v* 
DMSO) as follows;
(A) For 10 minutes with 0.5mM  pervanadate, vehicle or lOOnM bombesin. *  
were lysed and an aliquot o f  cell lysate corresponding to approx,mately 15„  
protein was analysed for protein phosphotyrosine phosphorylation as « J  
described.
(B) For 5 minutes with 0.5mM pervanadate, vehicle or 3nM bombesin. Cells uert 
lysed and a portion of cell lysate containing approximately 30p.g protein wjj 
analysed for protein phosphotyrosine phosphorylation as previously described. 
Phosphotyrosine containing proteins were detected  using the U.B.I. anti- 
phosphotyrosine antibody.
Results are from single experiments representative of three.
Pervanadate abbreviated to PV; bombesin to Bom.
t 1 1 1 1' 1 tPV 100nM Bom +
Bom Ro-31-8220
Control
Ro-31-8220 PV + Bom + PV + Bom + 
Ro-31-8220 Ro-31-8220 PV
t t t t t t
Control PV B B + PV + Ro-31-8220
PV Ro
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Table 3.2 Effect of bombesin and Ro-31-8220 on pervanadate-stimulated PLD 
activity
[3H]Palmitate labelled cells were preincubated with vehicle (0.1% DMSO) 
or 10|iM Ro-31-8220 for 10 minutes in the presence of 30mM butanol, then 
stimulated for 10 minutes in the presence or absence of 0.5mM pervanadate, with 
vehicle or lOOnM bombesin. Incubations were terminated by the addition of ice- 
cold methanol. Chloroform extracts were prepared and the generation of [3H]PtdBut 
quantified as described. Results are expressed as radioactivity in [3H]PtdBut (mean 
± S.D., d.p.m., n=3) and are from a single experiment representative of three.
Treatment
control 
control + Ro-31-8220 
pervanadate 
bombesin 
bombesin + Ro-31-8220 
pervanadate + Ro-31-8220
d.p.m. in PtdBut
1191 ± 418  
1499 ± 67 
6356± 1104 
6 7 7 0 1 6 1 2  
3428 ± 433 
5162 ±741
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1992), were screened for their ability to affect the protein tyrosine phosphorylation 
following a 2 minute stimulation with 3nM bombesin. Neither Erbstatin or 
Lavendustin significantly inhibited bombesin-stimulated protein phosphotyrosine 
content (Fig. 3.11), nor did they affect bombesin-stimulated [3H ]P tdB ut 
accumulation (results not shown). Figure 3.12 shows that 100|iM Genistein 
consistently inhibited protein tyrosine phosphorylation in lysates from cells 
stimulated with 3nM bombesin. Genistein also decreased the basal protein tyrosine 
phosphorylation in cell lysates. lOOfiM Genistein significantly inhibited bombesin- 
stimulated PLD activity by approximately 50% (p=0.011 ± 0.006). No significant 
inhibition was observed at lower concentrations of the inhibitor tested (Table 3.3).
The effect of the PKC inhibitor Ro-31-8220 and 100}iM Genistein on 
lOOnM bombesin-stimulated [3H]PtdBut was investigated. Fig 3.13 shows that 
although IOOjiM Genistein did not significantly attenuate bombesin-stimulated 
[3H]PtdBut generation, Ro-31-8220 partially inhibited the stimulation of PLD 
activity, whilst the presence of Genistein and Ro-31-8220 completely abolished the 
bombesin response.
3.2.4 Regulation of PLD activity by other signalling pathways
The effect of cross-talk between the adenylyl-cyclase signalling pathway 
and that activating PLD was investigated using agents known to elevate cyclic AMP. 
Pretreatment with lOpM-forskolin and lOOpM isobutylmethylxanthine (IBMX) for 5 
or 10 minutes, or ImM dibutyryl cyclic AMP for 15 minutes were shown to elevate 
cyclic AMP in cells by 20-30-fold above basal (Table 3.4). Bombesin alone had no 
effect, neither did it augment cyclic AMP generation in response to forskolin or 
dibutyryl cyclic AMP. Table 3.5 shows that similar treatments with forskolin and 
dibutyryl cyclic AMP had no effect upon subsequent bombesin-stimulated PLD 
activity.
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Figure 3.11 Effect of E rbsta tin  and Lavendustin on bombesin
•stil»uiat
protein tyrosine phosphorylation
Cells were preincubated for lhour with 10|iM of the erbstatin
atedfor
aniS »
methyl [2,5,-dihydroxy] cinnamate, 5|iM lavendustin, or vehicle, then stimul
2 minutes with a final concentration of 3nM bombesin and lysed. An aliqUot ■
each
lysate corresponding to approximately 25}ig of protein was analysed fn
or Protein
phosphotyrosine content as described. The numbered lanes in the phost J
fctaph
correspond to protein phosphotyrosine in lysates from cells treated as follows-
(1) Preincubated with 0.2% DMSO , stimulated with HHBG.
(2) Preincubated with 0.2% DMSO, stimulated with bombesin.
(3) Preincubated with HHBG, stimulated with HHBG.
(4) Preincubated with HHBG, stimulated with bombesin.
(5) Preincubated with erbstatin, stimulated with HHBG.
(6 ) Preincubated with erbstatin, stimulated with bombesin.
(7) Preincubated with 0.5% DMSO, stimulated with HHBG.
(8 ) Preincubated with 0.5% DMSO, stimulated with bombesin.
(9) Preincubated with lavendustin, stimulated with HHBG.
(10) Preincubated with lavendustin, stimulated with bombesin.
Results are from a single experiment typical of three.
1 2 3 4 5 6 7 8 9  10
200  -
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Figure 3.12 Effect of genistein on bombesin-stimulated protein
tyi*ou
phosphorylation °sine
a te d f o r 2
Cells were preincubated for lhour with vehicle or genistein, stimU[ 
minutes with vehicle or a final concentration of 3nM bombesin and i 
aliquot of each lysate corresponding to approximately 25|ig of protein  wa
s analyscd
for protein tyrosine phosphorylation as described. The numbered lanes •
lri the
phostograph correspond to protein phosphotyrosine in lysates from cells tr
trea ted as
follows;
(1) Preincubated with 0.2% DMSO, stimulated with HHBG
(2) Preincubated with 0.2% DMSO, stimulated with 3nM bombesin.
(3) Preincubated with lOOqM genistein, stimulated with HHBG.
(4) Preincubated withl00(iM genistein, stimulated with 3nM bombesin.
(5) Preincubated with 30pM genistein, stimulated with 3nM bombesin.
(6) Preincubated with 10|iM genistein, stimulated with 3nM bombesin.
(7) Preincubated with ljiM  genistein, stimulated with 3nM bombesin.
Results are from a single experiment representative of three.
Table 3.3 Inhibition of bom besin-stim ulated PLD activity by genistein.
[^H]Palmitate labelled cells were preincubated for 1 hour with increasing 
concentrations of genistein or vehicle (0.1%) DMSO, prior to a 10 minute preincubation 
with 30mM b u tan -l-o l. Cells were then stimulated for 2 minutes with 3nM bombesin. 
Incubations were terminated by the addition of ice-cold methanol. Chloroform extracts 
were prepared and the generation of [3H]PtdBut quantified as described. R esults are 
expressed as mean ± S.D.%, where n=3, of the bombesin-stimulated [^HJPtdBut 
accumulation in the absence of genistein and are from a single experiment typical of three. 
Mean basal values where vehicle or genistein alone was used in the preincubation period 
was subtracted before % values were determined. Mean basal d.p.m.: 0.1% DMSO 
preincubation, 1145 ± 216; genistein only (100p.M) preincubation, 773 ± 233; 3nM 
bombesin, no genistein, 2185 ± 177.
1 2 3 4 5 6 7
200  -
97.4 -
69 -  * i n
46 -
[gen iste in ]|iM  % of bom besin-stim ulated
[3H ]P tdB ut in absence of genistein
0 100 ±17
0.1 124 ± 29
1 104 ± 15
10 99 ±45
30 81 ±15
100 40 ± 10
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Figure 3.13 Effect of Ro-31-8220 and genistein on bombesin-stimulated PLD 
activity.
[^HJPalmitate labelled cells were preincubated for 1 hour with vehicle 
(0.1% DMSO) or 100|iM genistein, prior to a 10 minute treatment with 10}iM Ro- 
31-8220 or vehicle (0.1% DMSO v/v) and 30mM butanol. Cells were then 
stimulated by the addition of vehicle or lOOnM bombesin. Incubations were 
terminated by the addition of ice-cold methanol. Chloroform extracts were prepared 
and the generation of [^H]PtdBut quantified as described. Results are expressed as 
mean % ± S.D., where n = 3, of the bombesin-stimulated [^HJPtdBut accumulation 
in the absence of genistein and are from a single experiment representative of three. 
Mean basal values where vehicle or genistein alone was used in the preincubation 
period was subtracted before % values were determined. Mean basal d.p.m.: 0.1% 
DMSO preincubation, vehicle stimulation, 525 ± 124; 0.1% DMSO preincubation, 
lOOnM bombesin stimulation, 2603 ± 278; 100pM genistein preincubation + Ro-31- 
8220 preincubation, vehicle stimulation, 988 ±251.
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Table 3.4 Effect of cyclic AMP elevating agents on cyclic AMP levels in Swiss 
3T3 cells.
Quiescent cells were pretreated with: (A) vehicle, containing 0.1% ethanol 
and 0.1% DMSO; (B) IOjiM forskolin and O.lmM IB MX; (C) vehicle, containing 
0.1% DMSO; (D) ImM dibutyryl cyclic AMP and IBMX ; for times indicated. 
Cells were then stimulated with HHBG or lOnM bombesin for 5 minutes or 30 
seconds as shown. Incubations were terminated by replacement of the medium with 
2% PCA. Samples were neutralised and assayed for their cyclic AMP content as 
described (section 2.3.4). Results are shown as [cAMP] in pmol.ml'1 where n=3 and 
are from a single experiment representative of three.
T reatm ent
5 min. vehicle 
pretreatment,
5 min. forskolin + 
IB MX pretreatment,
10 min. vehicle 
pretreatment
10 min forskolin + 
IB MX pretreatment,
15 min. vehicle 
pretreatment, 5 min. 
stimulation
15 min. dibutyryl 
cyclic AMP 
pretreatment, 5 min. 
stimulation.
C ontrol cells 
[cyclic AMP] 
pm ol.m l*1
5 min.stim. 5.3±0.5 
30s stim. 4.4 ± 1 .2
N.D.
5 min. stim. 2.2 ±1 .9  
5 min. stim. 48.1 ± 33
1.48 ± 0.3
34 ±16
bom besin- 
stim ulated cells 
[cyclic AMP] 
pm ol.m l*1
5 min stim. 3.5 ± 2.42 
30s stim. 6.7 ±4.1
5 min. stim. 125 ± 28 
30s stim. 115 ±35
N.D.
N.D.
N.D.
N.D.
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Table 3.5 Effect of cyclic AMP elevating agents upon bombesin-stimulated 
PLD activity.
[3H]Palmitate labelled cells were preincubated with 10pM forskolin, 
O.lmM IB MX, or ImM dibutyryl cyclic AMP as stated, for the indicated times. The 
cells were then stimulated with bombesin for 5 minutes in the presence of 30mM 
butanol. Incubations were terminated by the addition of ice-cold methanol. 
Chloroform extracts were prepared and the generation of [3H]PtdBut quantified as 
described. Results are expressed as radioactivity in [^HjPtdBut (mean ± S.D., 
d.p.m., n=3) and are from a single experiment representative of three.
Pre-treatment [bombesin]nM Control cells Pre-treated cells
d.p.m. in PtdBut d.p.m. in PtdBut
5 minutes with 
Forskolin + IB MX
1558 ± 300 1629 ±99
10 2231± 264 2394 ±289
10 minutes with 
forskolin and IB MX
0 772 ±226
1882 ±265
1142 ±104
1610 ±305
10 2022 ± 124 2338 ± 39
15 minutes with 
dibutyryl cyclic 
AMP andlBMX
0
10
589 ±115
2296 ± 749
620 ± 107
1687 ± 366
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3.3 Discussion
3.3.1 Mobilisation of Ca2+ from intracellular stores alone is insufficient to 
activate PLD activity
Thapsigargin-stimulated Ca2+ release from intracellular stores has been 
reported to occur through inhibition of the Ca2+-ATPase pump on non-mitochondrial 
stores (Thastrup et al., 1990) and in the absence of inositol phosphate release 
(Jackson et al., 1988). Treatment with thapsigargin was found to be insufficient to 
activate PLD directly, nor did it affect the EC50 for bombesin-stimulated [3H]PtdBut 
generation (Fig. 3.1). This suggested that Ca2+ did not play an essential stimulatory 
role in itself, but in view of previous results, appeared to be a co-factor for activation 
of PKC (Cook et al., 1991). The 30% of bombesin-stimulated PLD activity that 
remained after treatment with EGTA and Ro-31-8220 and 50% of A23187- 
stimulated PLD activity that remained after Ro-31-8220 treatment, may therefore be 
attributable to another pathway. This could involve the interaction of Ca2+ with 
other second-messengers.
3.3.2 Bombesin-stimulated PLD activity is regulated through a G-protein.
Experiments in permeabilised cells with GTPyS and bombesin suggested 
that bombesin regulated PLD activity through a G-protein. The lag phase of up to 5 
minutes before GTPyS-stimulated [3H]PtdBut was elevated above control levels 
(Fig 3.2) probably reflected the slow exchange rate of GDP for GTP in the absence 
of receptor activation. Similar findings were reported for GTPyS-stimulated 
Ins(l,4,5)P3 generation both in electropermeabilised (Plevin et al., 1990) and 
streptolysin-O permeabilised Swiss 3T3 cells (Currie, 1992). The failure of a 
maximal concentration of GTPyS to affect bombesin-stimulated [3H] PtdBut 
accumulation (Fig. 3.3(A)), however, differed from that of bombesin-stimulated total 
[3H]inositol phosphates production (Plevin et al., 1990; Currie 1992). Significant 
potentiation of the accumulation of total [3H] inositol phosphates was observed with
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all concentrations of bombesin tested, but as for bombesin-stimulated [3H]PtdBut 
generation, the EC50 for bombesin-stimulated inositol-phosphate generation was not 
significantly affected. It has been suggested that this may be due to different modes 
of peptide-receptor coupling to PLC or that there is no receptor reserve for bombesin 
on Swiss 3T3 cells (Plevin et al., 1990). This contrasted with findings in ATP- 
stimulated turkey erythrocyte membranes where GTPyS shifted the dose/response 
curve for agonist-stimulated generation of inositol phosphates to the left (Boyer et 
al, 1989). One difference between the experiments on the bombesin-stimulated 
generation of total [3H]inositol phosphates and [3H]PtdBut is that experiments on 
PLC activity were performed for 30 minutes whereas times up to 5 minutes were 
used for determination of PLD activity.
Fig. 3.3(B) showed that potentiation of 3nM bombesin-stimulated 
[3H]PtdBut accumulation was only observed at concentrations of GTPyS which were 
less than maximal and the EC50  was not significantly changed in the presence of 
bombesin. This is probably again a reflection of the accelerated GDP/GTP exchange 
rate in the presence of agonist, compared to the rate achieved during partial 
activation of the G-protein mediated pathway. This may occur through either 
incomplete receptor occupancy or stimulation with sub-maximal concentrations of 
GTPyS. The inhibition of bombesin-stimulated [3H]PtdBut by GDPpS provided 
further evidence for a G-protein regulated PLD activity (Table 3.1).
Ca2+ was buffered to 150nM in all permeabilised experiments and was 
hence sufficient to permit agonist and GTPyS-stimulated [3H]PtdBut accumulation,
however the effect of increasing [Ca2+] was not examined. In HL60 cells (Billah et 
al., 1989) and neutrophils (Kessels et al., 1991) fMLP-stimulated PLD activity was 
dependent on changes in [Ca2+]. GTPyS-stimulated PLD activity in HL60 cells was 
found to be observable at low [Ca2+] but was greatly potentiated by increases in 
[Ca2+] to levels greater than 10|iM. PMA-stimulated PLD i  activity was less 
sensitive to [Ca2+] (Geny and Cockcroft, 1992). The experiments with HL 60 cells 
however bore little physiological relevance due to the high [Ca2+] used, moreover
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the addition of an agonist did not elicit a response (S. Cockcroft, personal 
communication). Therefore comparisons between findings in this system and those 
in Swiss 3T3 cells, both in this chapter and in chapter 5 are open to interpretation in 
various ways. The necessity of increased [Ca2+] for full activation of G-protein 
regulated PLD activity was also reported in GTPyS-stimulated platelet membranes 
(Van der Meulen and Haslam 1990) and for PMA and GTPyS-stimulated PLD 
activity in sub-cellular fractions from neutrophils (Olson et al., 1991). However, 
these experiments in Swiss 3T3 cells are the first demonstration of agonist- 
stimulated PLD activity in a permeabilised cell or membrane system.
In HL-60 cells GTPyS-stimulated PLD activity was significantly reduced if 
cells were left for 15 minutes after permeabilisation prior to stimulation, although 
the presence of GTPyS exerted some protection against the attenuation (Geny and 
Cockcroft, 1992). The authors suggested that G-protein dependent cytosolic factors 
were required for full activation of PLD, supported by experiments in sub-cellular 
fractions from neutrophils and granulocyte homogenates (Olson et al., 1991; Anthes 
et a l., 1991). The observation in Swiss 3T3 cells that the extent of G TPyS-
stimulated [3H]PtdBut accumulation was not significantly reduced even after 
washing permeabilised cells for up to 15 minutes, implied that a cytosolic factor was 
unnecessary for stimulation of PLD activity. This was further suggested by the 
ability of bombesin to stimulate [3H]PtdBut generation in the absence of added 
GTPyS. Although this could be explained by the presence of residual cellular GTP,
this seems unlikely when the dilution factor caused by the presence of the medium in 
the well is considered.
The synergy observed between PMA and GTPyS production upon PLD 
activation (Fig. 3.4) and the lack of effect of GDPpS suggested that PMA-stimulated 
PLD activity was not mediated through a G-protein. Both pathways converge 
presumably at the point of PKC activation to stimulate [3H]PtdBut formation. 
Similar synergistic activation of PLD between PMA and non-hydrolysable GTP 
analogues have been reported in rabbit platelet membranes (Van der Meulen and
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Haslam 1990) and streptolysin-O permeabilised HL60 cells (Geny and Cockcroft
1992).
An indirect G-protein/PLD coupling was suggested by the failure of 
bombesin or GTPyS to activate PLD when total cellular ATP and Ptdlns-PLC 
activity was depleted by the presence of inhibitors of the mitochondrial respiratory 
chain (Fig. 3.5). This implied that a kinase intermediate was essential to the 
stimulation of PLD activity in Swiss 3T3 cells. These findings contrasted to similar 
experiments in HL60 cells. Although PLC activation was minimal, a significant 
GTPyS stimulation of PLD activity was observed suggestive of a direct G-protein 
coupling (Geny and Cockcroft, 1992). However as previously described the GTPyS- 
stimulation was only observable at concentrations of Ca2+ above lOfiM. 
Furthermore, in rat pheochromocytoma PC 12 cells ATP and Ca2+ was found to be 
essential for GTPyS-stimulated PLD activity (Kanoh et al., 1993) whereas that in 
U937 promonocytic leukocytes was found to proceed by both ATP dependent and 
independent pathways (Kusner et al., 1993). Thus the mode of G-protein regulation 
of PLD activity appears to vary between cell types.
Experiments were unable to conclusively determine whether bombesin- 
stimulated PLD activity and Ptdlns-PLC activity was regulated through the same G- 
protein. The lack of effect of pertussis toxin on bombesin-stimulated PLD activity 
was consistent with bombesin-receptor coupling through Gq> as for receptor- 
mediated activation of Ptdlns-PLC (Plevin et al., 1990; Smrcka et al., 1991). 
However the bombesin-receptor may couple to more than one G-protein as has been 
suggested for bombesin-stimulated PLA2 activation in Swiss 3T3 cells (Currie,
1992). In neutrophils it has been proposed that fMLP may not only stimulate PLD 
through the pertussis-toxin sensitive G-protein activity coupled to Ptdlns-PLC but 
also directly, through a putative G-protein termed Ge, designated as the G-protein 
regulating exocytosis (Cockcroft, 1992). For further discussion on the theoretical G- 
protein regulation of stimulated PLD activity see chapter 5.
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3.3.3 The PKC-independent pathway of bombesin-stimulated PLD activity is 
due to activation of tyrosine kinases.
Bombesin-stimulated protein tyrosine phosphorylation, determined by 
immunoblotting cell lysates with an anti-phosphotyrosine antibody, was similar to 
that reported by Zachary et al. (1991). The increase in tyrosine phosphorylation of 
these bands was reported not to relate to the bombesin receptor, GTPase activating 
protein (GAP), PLCy, or PtdIns-3-kinase. Bombesin was reported to stimulate the 
tyrosine phosphorylation of the p i25 focal adhesion kinase (pl25fak), which was 
constitutively associated with GAP (Leeb-Lundberg and Xin-Hua, 1993) and also 
p i30 a major phosphotyrosyl protein in src -transformed cells (Zachary et al., 1992). 
The 70-75kDa bands have been suggested to be paxillin (Zachary and Rozengurt,
1992) which is another cytoskeletal component.
Pervanadate treatment of cells was shown to elevate the tyrosine 
phosphorylation of proteins with a molecular weight similar to those phosphorylated 
in response to bombesin (Fig 3.8). The stimulation of [3H]PtdBut and 
total[3H]inositol phosphates by pervanadate was not significant above basal levels 
until 10 minutes (Fig. 3.9) and thus lagged considerably behind that of protein 
tyrosine phosphorylation which was observable within 30 seconds (Fig. 3.8). This 
suggested that protein tyrosine phosphorylation, through inhibition of tyrosine 
phosphatases, could lead to activation of Ptdlns-PLC and PLD activity. In HL-60 
cells pervanadate-stimulated protein tyrosine phosphorylation was found to precede 
that of PLD activity by about 1 minute, with a high degree of correlation between the 
two events (Bourgoin and Grinstein, 1992). In most experiments the pervanadate- 
stimulation of PLD activity occurred concomitantly with that of Ptdlns-PLC activity 
with the accumulation of total [3H] inositol phosphates being generally being lower 
than that of [3H]PtdBut. The elevation of total [3H]inositol phosphates implied that 
pervanadate activated a PLCy. Pervanadate was reported to stimulate protein 
tyrosine phosphorylation and activation of PLCyl in human platelets (Blake et al.,
1993) and PLCy2 in HL60 cells (Bianchini et al., 1993). However, it is difficult to
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directly compare pervanadate-stimulated and bombesin-stimulated second- 
messenger events in view of the different modes of elevation of tyrosine 
phosphorylation. PDGF and EGF-stimulated production of total [3H]inositol 
phosphates has been proposed to arise through tyrosine phosphorylation and hence 
activation of PLCy (Meisenhelder et a l, 1989; Nishibe et al., 1990). However there 
is no evidence for bombesin-stimulated tyrosine phosphorylation of PLCy in Swiss 
3T3 cells.
Pervanadate-stimulated PLD activity has been reported in human 
neutrophils (Uings et a l, 1992), HL60 cells (Bourgoin and Grinstein, 1992) and 
phagocytic leucocytes (Dubyak et al., 1993). The observation that a 5 minute 
stimulation of PLD activity with 0.1 nM bombesin was slightly attenuated by the 
presence of pervanadate, may be explained by the finding that pervanadate was 
found to inhibit Ca2+ uptake in HL60 cells possibly by closure of the influx pathway 
or by uncoupling of Ca2+ entry from the intracellular stores (Bianchini et al., 1993). 
At longer times of stimulation and at higher concentrations of bombesin the possible 
inhibitory effect of pervanadate on Ca2+ entry may be masked by the greater 
contribution of other signalling pathways to the activation of PLD.
The failure of the PKC inhibitor Ro-31-8220 to attenuate pervanadate- 
stimulated protein tyrosine phosphorylation (Fig. 3.10) or PLD activity (Table 3.2), 
suggested that the contribution of pervanadate stimulated production of total [3H] 
inositol phosphates must play a minimal role in pervanadate-stimulated PLD 
activity. A PKC-independent mechanism of pervanadate-stimulated PLD activity 
and tyrosine phosphorylation was also reported in HL 60 cells (Bourgoin and 
Grinstein 1992) and for pervanadate-stimulated generation of total [3H] inositol 
phosphates and protein tyrosine phosphorylation in human platelets (Blake et al.,
1993).
Vanadate has been reported to activate G-proteins by forming a stable 
complex with GDP at the nucleotide binding site, thus acting as an analogue of the y- 
phosphate of GTP (Bigay et al., 1987). Furthermore, the effects of vanadate in some
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cells were inhibited by pertussis toxin treatment, such as vanadate-stimulated 
generation of total [3H] inositol phosphates in hamster fibroblasts (Paris and 
Pouyssegur, 1987). Though the possibility that pervanadate may also affect G- 
proteins in Swiss 3T3 cells could not be eliminated, the finding that pervanadate- 
stimulated [3H]PtdBut accumulation was PKC independent argued against the 
involvement of Gqin pervanadate-stimulated PLD activity. Furthermore mM 
concentrations of vanadate was required to activate transducin (Bigay et al., 1987) 
suggesting that the pervanadate concentration of 0.5mM used would be too low to 
activate G-proteins. Similarly, G-protein stimulation was not responsible for 
pervanadate-stimulated PLD activity in HL60 cells, as GTPyS and pervanadate-
effects were additive in these cells (Bourgoin and Grinstein, 1992).
Genistein, an isoflavone and a specific competitive inhibitor with respect to 
ATP (Akiyama et al., 1987). w&s the only tyrosine kinase inhibitor of the range 
tested, that consistently attenuated tyrosine phosphorylation in cells stimulated with 
a sub-maximal dose of bombesin (Table 3.3). Concomitant with the decrease in 
tyrosine phosphorylation, lOOpM Genistein partially reduced bombesin-stimulated 
PLD activity. This concentration of Genistein is below that thought to inhibit PKC 
activity. The failure of the erbstatin analogue and lavendustin to affect bombesin- 
stimulated tyrosine phosphorylation may have reflected cell specific tyrosine kinases 
or poor entry into the cell. In support of this, neither lavendustin nor the erbstatin 
analogue inhibited stimulated PLD activity in phagocytic leucocytes, whereas 
genistein was inhibitory (Dubyak et al., 1993). Similarly pervanadate-stimulated 
PLD activity in HL-60 cells was inhibited by the tyrosine kinase inhibitor ST638, 
but not by erbstatin or tyrphostins (Bourgoin and Grinstein, 1992). However, 
erbstatin has been used to inhibit tyrosine phosphorylation and PLD activity in the 
human neutrophil (Uings et al., 1992). Bradykinin-stimulated generation of total 
[3H]inositol phosphates in Swiss 3T3 cells was reported to be inhibited 40-50% by 
Genistein whereas 70-80% of the tyrosine phosphorylation was inhibited. This
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suggested that tyrosine phosphorylation may be involved in bradykinin-stimulated 
formation of total [3H]inositol phosphates (Leeb-Lundberg and Song, 1991).
Genistein had no significant effect on lOOnM bombesin-stimulated PLD 
activity. Though 10|iM Ro-31-8220 alone only partially attenuated lOOnM 
bombesin-stimulated PLD activity, the abolishment of [3H]PtdBut accumulation in 
the additional presence of 100(iM Genistein suggested that PLD activity was 
regulated through both PKC and tyrosine kinases (Fig. 3.13). The failure of 
Genistein alone to significantly affect lOOnM bombesin-stimulated [3H]PtdBut 
accumulation maybe because the small contribution of tyrosine kinases to PLD 
activity could not be observed within the limits of experimental error in cases where 
maximal doses of agonist are used. In support of the PKC-independent nature of 
tyrosine phosphorylation, PMA and A23187 have been reported to have a weaker 
effect on tyrosine protein kinase activity compared to that stimulated by bombesin in 
Swiss 3T3 cells (Zachary et al., 1991). The authors also reported that down- 
regulation of PKC had no effect on bombesin-stimulated tyrosine kinase activity.
The extent to which tyrosine kinases control the stimulation of PLD activity 
in different cell types may depend on the regulatory contribution of other second 
messenger pathways. FMLP- and ET-1- stimulated PLD activity in neutrophils and 
A 10 cells respectively, was completely attenuated by tyrosine kinase inhibitors. 
fMLP-stimulated PLD activity is PKC independent thus may be entirely regulated 
by tyrosine kinases. Though ET-1 stimulated PLD activity has a PKC dependent 
and independent component, reports suggested that mitogenesis was regulated by 
tyrosine kinases which could be PKC dependent or independent (Simonson and 
Herman, 1993). ET-1, A VP and Angiotensin II-stimulated tyrosine phosphorylation 
in glomerular mesangial cells was suggested to occur through PKC-dependent and 
independent pathways, though PKC activation was not necessary (Force et al.y 
1991).
The mechanism of PLD activation through elevation of protein tyrosine 
phosphorylation is unclear especially without knowledge of the kinases involved and
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their possible substrates (see chapter 5 for further discussion). Proposed pathways of 
regulation have included direct phosphorylation of PLD upon tyrosine residues, or 
removal of a consitutive inhibitor upon protein tyosine phosphorylation (Bourgoin 
and Grinstein 1992).
3.3.4 Bombesin-stimulated PLD activity is not regulated by cyclic AMP
The failure of cyclic AMP elevation (Table 3.4) to effect bombesin- 
stimulated [^H]PtdBut accumulation argued against the involvement of the adenylyl 
cyclase signalling pathway in the regulation of PLD activity in Swiss 3T3 cells (Fig. 
3.6). It was notable that in contrast to reports by Millar and Rozengurt (1988), the 
presence of bombesin did not enhance cyclic AMP generation in the presence of 
forskolin. A positive effect of 'cross-talk' was reported in human endothelial cells 
where elevation of cyclic AMP augmented thrombin-stimulated PLD activity 
(Garcia et al., 1992). This was suggested to be due to the effect of PKA on PKC, 
PLD or receptor G-protein coupling. However, fMLP-stimulated PLD activity in 
neutrophils was attenuated by the elevation of cyclic AMP, though there was no 
effect on phosphoinositide hydrolysis suggesting that cyclic AMP was affecting the 
receptor-linked activation of PLD (Agwu et al., 1990; Tyagi et al, 1990). However, 
PMA-stimulated PLD activity was unaffected by the cyclic AMP-elevating agents 
implying that the enzyme itself was not the target. Furthermore Kessels et al.. 
(1993) reported that an inhibitor of PKA enhanced fMLP-stimulated PLD activity. 
This led to the proposal that activation of PKA in response to fMLP inhibited the 
activation of PLD at the level of the receptor or receptor/coupled G-protein.
Receptor phosphorylation is commonly associated with uncoupling from the 
G-protein linked effector mechanisms such as for the (3-adrenergic receptor. 
Moreover phosphorylation of the G a subunits appears to be sub-type specific. 
Phosphorylation of Golyi, G az and G(X2  have been reported, however it is unclear 
how the modification affects function (Gunderson and Devreotes, 1990; Carlson et 
al., 1989). The ability of cyclic AMP to affect fMLP-stimulated PLD activity may
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be therefore be related to the regulatory pertussis-toxin sensitive G-protein involved 
(Agwu et al., 1989). Bombesin was found not to stimulate the phosphorylation of 
Gq in Swiss 3T3 cells (P. Kaur, personal communication) nor is there any evidence 
for phosphorylation of the bombesin receptor. The bombesin receptor or G- 
protein(s) coupled to Ptdlns-PLC and PLD activation may therefore not be substrates 
for the cyclic AMP mediated modifications.
Bombesin-stimulated PLD activity was found to be regulated through a 
series of interacting pathways. Regulation of stimulatable PLD activity occurred 
indirectly, through a pertussis-toxin insensitive G-protein and was mediated by 
PKC-dependent and -independent pathways. The PKC-independent pathway of 
bombesin-stimulated PLD activity was found to be mediated through tyrosine 
kinases. Neither the rise in [Ca2+]i alone nor the elevation of cyclic AMP was 
sufficient to activate PLD or affect the extent of bombesin-stimulated [3H]PtdBut 
generation.
I l l
Chapter 4
Desensitisation and Resensitisation of Agonist-stimulated 
Phospholipase D Activity
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4.1 Introduction
Desensitisation is a key characteristic of second-messenger pathways and is 
represented by diminished reponsiveness to persistent agonist stimulation. A well 
characterised example of desensitisation is the P-adrenergic receptor coupled to 
adenylyl cyclase (Hausdorff et al., 1990;Collins et al., 1992). The initial rapid 
desensitisation of the P-adrenergic receptor (P-AR) is due to phosphorylation of the 
receptor by protein kinase A (PKA) and P-adrenoreceptor kinase (pARK) leading to 
uncoupling of the receptor from Gs, followed by sequestration defined as a loss in 
the ability of receptors to bind hydrophilic but not hydrophobic ligands (Yu et al.,
1993). Prolonged agonist exposure results in receptor down regulation, a distinct 
event from sequestration, in that a decrease in the total number of receptors is 
observed (reviewed Hausdorff et al., 1990). Receptor internalisation is reversible 
after short agonist treatments, even in the continual presence of agonist (Kurz and 
Perkins, 1992).
Recent research has focussed on the desensitisation of phosphoinositidase 
C-linked receptors. A notable feature of Ptdlns-PLC-linked receptors is the very 
rapid desensitisation to agonist, characterised by a decrease in the rate of 
phosphoinositide hydrolysis, the extent of which is receptor specific (Sugiya et al., 
1987; Martin and Harden 1989; Palmer et al., 1991). The mechanism of this rapid 
loss of responsiveness has yet to be clarified but may, as for early desensitisation 
events associated with p-AR, involve receptor phosphorylation and internalisation 
(reviewed Wojcikiewicz et al., 1993). More prolonged exposure to agonist generally 
results in receptor downregulation, (Dorn II 1992; Millar and Rozengurt 1990) 
which is apparently distinct from events involved in acute desensitisation and 
comparable to desensitisation of the P-AR after longer agonist stimulation.
Structural analysis has suggested that the first phase of bombesin-stimulated 
DAG generation originates from PtdIns(4,5)P2 generation, whilst the second is 
derived from PtdCho (Pettit and Wakelam, 1993). The second sustained phase 
however, cannot be fully accounted for by dephosphorylation of the PtdOH
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generated by PLD-catalysed PtdCho hydrolysis. When butanol was included to 'trap' 
any PtdOH being formed by PLD activation, the sustained phase of bombesin- 
stimulated DAG was only attenuated by 30%. PMA-stimulated DAG was 
diminished by 70% during similar treatment (Cook et al, 1991). The time-course of 
bombesin-stimulated [3H]PtdBut accumulation showed that PLD was activated 
within 15 seconds, though by 1 minute the generation of [3H]PtdBut appeared to 
have ceased with no further increase until about 10 minutes. However, PMA- 
stimulated [3H] PtdBut formation continued to increase after an initial lag phase, for 
at least 15 minutes. Taken together the data indicated that in fibroblasts, activation 
of PLD is not exclusively responsible for the sustained phase of DAG generation, 
indicating a possible desensitisation of bombesin-stimulated PLD activity.
The hydrolysis of both PtdIns(4,5)P2 and PtdCho were found to both be 
rapidly desensitised in vasopressin-stimulated A 10 vascular-smooth-muscle cells 
(VSMC) (Plevin and Wakelam, 1992) and in thrombin- and carbachol-stimulated 
fibroblasts transfected with Ml muscarinic receptors (McKenzie et al., 1992). To 
date there have been no studies concerning the desensitisation of stimulated PtdCho 
breakdown in Swiss 3T3 cells.
The research in this chapter characterises the rapid desensitisation and 
resensitisation of agonist-stimulated PLD activity in Swiss 3T3 cells in an attempt to 
determine more fully the function and regulation of PLD in mitogenic signalling.
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4.2 Results
4.2.1 Rapid desensitisation and resensitisation of agonist-stimulated PLD 
activity
To investigate the possibility that bombesin-stimulated [3H]PtdBut rapidly 
desensitised during continual receptor activation, the transphosphatidylation assay 
was modified as described by Plevin and Wakelam (1992).
The cells were first exposed to lOOnM bombesin in the absence of butanol, 
the alcohol was then added in order to determine any subsequent PLD activity. 
Figure 4.1 shows that the subsequent loss in stimulated-[3H]PtdBut accumulation 
with lOOnM bombesin was found to be rapid and significant by 15 seconds of 
pretreatment with lOOnM bombesin (p=0.007) and had decreased to basal levels by 
40 seconds of pretreatment. In some experiments the onset of desensitisation was 
slightly slower and was only significant after 20 seconds of pretreatment. A similar 
time course of desensitisation was observed with 3nM bombesin , a concentration 
close to the EC5 0  for bombesin-stimulated [3H]PtdBut accumulation, and also for 
30nM vasopressin (data not shown). Figure 4.2 shows the dose-response curve of 
the bombesin-stimulated loss in [3H]PtdBut accumulation, determined by pretreating 
cells for 1 minute with increasing concentrations of bombesin, then adding butanol 
for 2 minutes in the presence of lOOnM bombesin. The IC50  for the [bombesin] used 
in a 1 minute pretreatment, which desensitised the generation of [3H]PtdBut 
generation to a subsequent stimulation with lOOnM bombesin, was 0.2 ± O.lnM, 
calculated from three separate experiments.
Desensitisation of bombesin-stimulated PLD activity was reversible. The 
rate of resensitisation was examined in cells that had been pretreated for 1 minute 
with lOOnM bombesin. The cells were then washed for increasing periods of time 
and the formation of [3H]PtdBut was determined in response to a 1 minute
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Figure 4.1. Time course of bombesin-mediated homologous desensitisation of 
bombesin-stimulated PLD activity.
[^HJPalm itate-labelled cells were pretreated with buffer or lOOnM 
bombesin for increasing times, in the absence of butanol, then stimulated with a final 
concentration of buffer or lOOnM bombesin for 30 seconds in the presence of 30mM 
butanol. Incubations were terminated by replacement of the medium with ice-cold 
methanol. Chloroform extracts were prepared and [^HJPtdBut determined by t.l.c. 
as described (section 2.3.1(iii)). Results are expressed as radioactivity in [3H]PtdBut 
(d.p.m., mean ± S.D. n=3) and are from a single typical experiment representative of 
three, (o), cells pretreated with buffer, stimulated with lOOnM bombesin + butanol; 
( • ) ,  cells pretreated with lOOnM bombesin, stimulated with lOOnM bombesin + 
butanol; (A), cells pretreated with buffer, stimulated with buffer + butanol.
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Figure 4.2 Dose-response of bombesin-mediated homologous desensitisation of 
bombesin-stimulated PLD activity.
[3H]Palmitate-labelled cells were pretreated for 1 minute with increasing 
concentrations of bombesin, in the absence of butanol, then stimulated for 2 minutes 
with lOOnM bombesin in the presence of 30mM butanol. Incubations were 
terminated by addition of 0.5ml of ice-cold methanol. Chloroform extracts were 
prepared and [3H]PtdBut quantified by t.l.c. as described. Results are expressed as 
radioactivity in [3H]PtdBut (d.p.m., mean ± S.D., n=3), from a single experiment 
representative of three. Mean basal d.p.m., 699±60, where vehicle was used for both 
the pretreatment and stimulations.
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stimulation with lOOnM bombesin in the presence of butanol. Figure 4.3 shows that 
the recovery of bombesin-stimulated PLD activity was rapid, with [3H]PtdBut 
generation recommencing after a total wash time of 4.5 minutes (p=0.007). At best, 
up to 80% of the control enzyme activity was ever recovered, even after a total wash 
time of 41.5 minutes. Incomplete resensitisation was not due to depletion of labelled 
PtdCho, since similar results were obtained when [3H]palmitate was included in the 
experimental incubation medium (Table 4.1).
To confirm that the desensitisation of bombesin-stimulated [3H]PtdBut 
accumulation was a direct reflection of PLD-mediated PtdCho hydrolysis, the effect 
of a 1 minute bombesin pretreatment upon total [3H]choline generation in response 
to a subsequent bombesin stimulation, was determined in cells labelled with 
[3H]choline. Cells were washed for the times indicated after the bombesin 
pretreatment, before addition of buffer or bombesin for a 1 minute period. Figure
4.4 shows that bombesin-stimulated choline production was clearly attenuated to 
levels comparable with that of cells, which were pretreated with bombesin but 
restimulated with buffer. Significant choline production, above that of control, was 
always observed 11.5 minutes after agonist removal (p=0.01) and in some 
experiments after 6.5 minutes of washing.
Table 4.2 shows the effect of rechallenging the cells with bombesin after 
allowing the cells to partially resensitise. There was no significant difference in the 
extent of resensitization observed 11.5 minutes after removal of the final 
pretreatment, between cells that were challenged only once and those that were 
rechallenged up to three times. The stimulation of [3H]PtdBut in cells could also be 
completely desensitised to bombesin if, following the initial challenge, 11.5min 
recovery period and rechallenge, cells were immediately stimulated for 1 minute 
with bombesin in the presence of butanol (data not shown). The agonist requirement 
in resensitisation was determined by pretreating cells for 1 minute with bombesin 
then washing briefly, before exposing cells, in the presence of butanol, to buffer or 
bombesin. Figure 4.5 shows that unless bombesin was present in the medium, no
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Figure 4.3 Resensitisation time course of bombesin-stimulated PLD activity 
after a 1 minute bombesin pretreatment
Cells labelled with [3H]palmitate, were pretreated for lminute with lOOnM 
bombesin or HHBG in the absence of butanol, then washed with HHBG for 3 x 30 
seconds, followed by a fourth wash for the times indicated. Cells were then 
stimulated for 1 minute with lOOnM bombesin or HHBG, in the presence of 30mM 
butanol. Incubations were terminated by removal of the medium and addition of ice- 
cold methanol. Chloroform extracts were prepared and assayed for [3H]PtdBut by 
t.l.c. as described. Results are expressed as radioactivity in [3H]Ptdbut (d.p.m., 
mean ± S.D., n=3) and are from a single typical experiment representative of four, 
(o), cells pretreated with buffer, stimulated with lOOnM bombesin + butanol; ( • ) ,  
cells pretreated with lOOnM bombesin + butanol, cells stimulated with lOOnM 
bombesin + butanol; (A), cells pretreated with buffer, stimulated with buffer + 
butanol.
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Table 4.1 The effect of the continual presence of [3H ]palm itate on 
desensitisation and resensitisation of bombesin-stimulated PLD activity.
[3H]Palmitate-labelled cells were pretreated for 1 minute with lOOnM 
bombesin or HHBG, then washed for 3 x 30 seconds with HHBG. The cells were 
then stimulated for 1 minute with bombesin or HHBG, containing 30mM butanol, or 
were washed for a further 10 minutes with HHBG. Cells which had been washed for 
a total of 11.5 minutes, were then stimulated for 1 minute with lOOnM bombesin or 
HHBG, containing 30mM butanol. For cells that were to be treated in the continual 
presence of [3H]palmitate, all pretreatments, washes and stimulations were 
performed in medium containing 4p.Ci.mT1 of [3H]palmitate. Incubations were 
terminated by replacement of the medium with ice-cold methanol. Chloroform 
extracts were prepared and [3H]PtdBut quantified by t.l.c. as described. Results are 
expressed as radioactivity in [3H]PtdBut (d.p.m., mean ± S.D., n=3) and are from a 
single experiment representative of three.
Treatment no [^H]palmitate
d.p.m. in PtdBut
+ [3H]palmitate 
d.p.m. in PtdBut
HHBG pretreatment 
1.5min wash 
HHBG + ButOH 
stimulation
HHBG pretreatment 
1.5min wash 
bombesin + ButOH 
stimulation
bombesin pretreatment
I.5min wash 
bombesin + ButOH
stimulation
HHBG pretreatment
II.5min wash 
HHBG + ButOH
stimulation
HHBG pretreatment 
11.5min wash 
bombesin + ButOH 
stimulation
bombesin pretreatment 
11.5min wash 
bombesin + ButOH 
stimulation
578 ± 98
3967 ± 496
718 ± 9 3
690 ± 126
4136 ± 366
2493 ± 287
744 ± 112
3481 ± 725
877 ± 113
839 ± 94
3785 ± 175
2229 ± 61
1 2 0
Figure 4.4 Desensitisation and resensitisation of bombesin-stimulated total 
choline production after a 1 minute bombesin pretreatment.
[^H]Choline labelled cells were pretreated for 1 minute with lOOnM 
bombesin, then washed for 3 x 30 seconds with DMBGH, followed by a fourth wash 
for various times. After times as indicated, the cells were treated for 1 minute with 
lOOnM bombesin or DMBGH. Incubations were terminated by addition of ice-cold 
methanol. Chloroform extracts were prepared and total choline quantified using 
Dowex-H+ chromatography as described in the materials and method section. 
Results are expressed as radioactivity in [^HJcholine (d.p.m., mean ± S.D., n=3) and 
are from a single experiment representative of three, (o), cells pretreated with 
lOOnM bombesin, stimulated with buffer, ( • ) ;  cells pretreated with lOOnM 
bombesin and stimulated with lOOnM bombesin; (A), cells pretreated with buffer, 
stimulated with buffer. Control stimulation in absence of bombesin pretreatment: 
basal d.p.m., 3535 ±461; 1 minute with lOOnM bombesin d.p.m., 5126±385.
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Table 4.2 Effect of rechallenging with bombesin on the extent of resensitisation 
of bombesin-stimulated PLD activity.
[3H]Palmitate-labelled cells were pretreated for 1 minute with HHBG or 
lOOnM bombesin before washing the cells for 3x 30 seconds, followed by a fourth i
i
wash for 10 minutes. Cells were then either subjected to a further challenge for 1 
minute with HHBG or lOOnM bombesin and the washing process repeated as 
described above, or stimulated for 1 minute with HHBG or lOOnM bombesin in the 
presence of 30mM butanol. The pretreatment and washing procedure was repeated 
for a maximum of three challenges as indicated. Incubations were terminated by the 
addition of ice-cold methanol. Chloroform extracts were prepared and [3H]PtdBut 
quantified as described. Results are expressed as mean ± S.D.% of the [3H]PtdBut 
generated after the cells were challenged for the appropriate number of times with 
HHBG before stimulation with bombesin. Mean basal values, where vehicle was 
used in the pretreatments and stimulations, were subtracted before % values were 
determined. Results are combined from three separate experiments where n=3 for 
each experiment.
&£
Number of challenges with % of unpretreated PtdBut 
lOOnM bombesin generation, 11.5 minutes after
removal of final challenge
40 ± 14
38 ± 12
3 30 ±8
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[3H]PtdBut formation was observed.
Since, readdition of agonist was required for resensitisation of stimulated- 
[3H]PtdBut accumulation, the effect of sustained stimulation with bombesin was 
examined. The cells were desensitised by a 1 minute bombesin pretreatment in the 
absence of butanol, the alcohol was then added and the formation of [3H]PtdBut 
examined over a 1 hour time course. Figure 4.6 illustrates that there was a pattern of 
desensitisation/resensitisation which appeared to repeat four times over the 1 hour 
time period.
4.2.2 Desensitisation and resensitisation of bombesin-stimulated generation of 
total inositol phosphates.
Bombesin-stimulated PtdIns(4,5)P2 hydrolysis in Swiss 3T3 cells is also 
rapidly desensitised. Bombesin-stimulated total [3H]inositol phosphate generation is 
biphasic, with a rapid increase up to 1 minute, followed by a second phase at a 
reduced rate (Cook et al., 1991). Resensitisation of bombesin-stimulated generation 
of total [3H]inositol phosphates was examined in a similar manner to that of 
[3H]PtdBut, except that following the various wash times LiCl was substituted for 
butanol during the 1 minute stimulation. A 1 minute pretreatment with lOOnM 
bombesin was found to reduce subsequent bombesin-stimulated production of total 
[3H]inositol phosphates to between 20-50% of that observed with a vehicle 
pretreatment, as described by Palmer et al., (1991). Figure 4.7 shows that an 
increase in total [3H]inositol phosphates generation in cells stimulated for 1 minute 
with lOOnM bombesin, over that remaining after the bombesin pretreatment, varied 
over several experiments, but was never observed until at least 6.5 minutes after the 
agonist pretreatment (Fig. 4.7, p=0.005 at 8.5 minutes after agonist pretreatment). 
Subsequently, recovery in the generation of total [3H]inositol phosphates occurred 
rapidly, being complete after 11.5 minutes.
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Figure 4.5 Effect of the presence of bombesin on resensitisation of bombesin- 
stimulated PLD activity
[3H]Palmitate-labelled cells were pretreated for 1 minute with HHBG or 
lOOnM bombesin then washed for 3x30 seconds, before being stimulated for 1 or 10 
minutes with, HHBG or lOOnM bombesin containing 30mM butanol. Incubations 
were terminated by the addition of ice-cold methanol. Chloroform extracts were 
prepared and [3H]PtdBut generation quantified as described. Results are expressed 
as radioactivity in [3H]PtdBut (d.p.m., mean ± S.D., n=3) and are from a single 
experiment representative of three. - (pt), cells pretreated with buffer; - (st), cells 
stimulated with buffer + butanol; BOM (pt), cells pretreated with lOOnM bombesin; 
BOM (st), cells stimulated with lOOnM bombesin + butanol.
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Figure 4.6 Time course of bombesin-stimulated PLD activity in the continual 
presence of lOOnM bombesin, after a 1 minute pretreatment with lOOnM 
bombesin.
[3H]Palmitate-labelled cells were pretreated for 1 minute with lOOnM 
bombesin, in the absence of butanol, prior to the addition of 30mM butanol for the 
times indicated. Incubations were terminated by removal of the medium and 
addition of ice-cold methanol. Chloroform extracts were prepared and [3H]PtdBut 
generation quantified by t.l.c. as described. Results are expressed as radioactivity in 
[3H]PtdBut (d.p.m., mean ± S.D., n=3) and are taken from a single experiment 
typical of three, (o), cells pretreated with buffer, stimulated with buffer + butanol; 
( • )  cells pretreated with lOOnM bombesin, stimulated with lOOnM bombesin + 
butanol. The numbers refer to the significance values obtained from an unpaired t- 
test comparing the following time points: 1, 4 minutes vs lminute p=0; 2, 7 minutes 
vs 4 minutes p=0.003; 3, 16 minutes vs 7 minutes p=0.009; 4, 22 minutes vs 16 
minutes p=0.0012; 5, 28 minutes vs 22 minutes p=0.085; 6, 34 minutes vs 28 
minutes p=0.041; 7, 49 minutes vs 34 minutes p=0.047.
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Figure 4.7 Resensitisation time course of bombesin-stimulated generation of 
total inositol phosphates after a 1 minute bombesin pretreatment.
Cells labelled with [^H] inositol, were pretreated for 1 minute with lOOnM 
bombesin or HHBG, in the absence of LiCl, then washed with buffer for 3 x 30 
seconds, followed by a fourth wash for the times indicated. Cells were then 
stimulated for 1 minute with lOOnM bombesin or HHBG, in the presence of lOmM 
LiCl. Incubations were terminated by replacing the medium with ice-cold methanol. 
Chloroform extracts were prepared and generation of total [3H]inositol phosphates 
was determined by batch chromatography, as described in the materials and 
methods. Results are expressed as radioactivity in total [3H]inositol phosphates 
(d.p.m., mean ± S.D., n=3) and are from a single experiment representative of three, 
(o), cells pretreated with buffer, stimulated with bombesin + LiCl; ( • ) ,  cells 
pretreated with lOOnM bombesin and stimulated with lOOnM bombesin + LiCl; (A), 
cells pretreated with buffer and stimulated with buffer + LiCl.
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4.2.3 The role of protein kinase C in bombesin-stimulated homologous 
desensitisation of PLD activity
In contrast to the rapid but transient bombesin-stimulation of [3H]PtdBut 
accumulation, PMA-induced [3H]PtdBut accumulation did not commence until 2 
minutes after addition but continued for at least 15 minutes, at a rate reduced from its 
initial rapid production (Cook et al., 1991). Table 4.3 shows that there was only a 
partial loss of [3H]PtdBut generation stimulated with lOOnM PMA, after 
pretreatment with lOOnM PMA, compared to the [3H]PtdBut formed in unpretreated 
cells. These observations suggested that desensitisation of stimulated PLD activity 
was independent of PKC.
The loss and recovery of lOOnM bombesin-stimulated [3H ]P tdB ut 
accumulation after a 1 minute pretreatment with lOOnM bombesin was investigated, 
subsequent to preincubation with the selective protein kinase C inhibitor Ro-31-8220 
(Davis et al., 1989). Table 4.4 shows that Ro-31-8220 did not prevent bombesin- 
mediated desensitisation of bombesin-stimulated [3H]PtdBut accumulation, nor did 
it affect the extent of resensitisation observed after cells had been washed for 11.5 
minutes and restimulated.
4.2.4 The internalisation and recycling of cell-surface receptors in intact Swiss 
3T3 cells.
Binding studies were performed to compare agonist-m ediated 
desensitisation and resensitisation of stimulated [3H]PtdBut accumulation with the 
extent of agonist binding to cell-surface receptors. Gastrin releasing peptide (GRP) 
has the same affinity for the bombesin receptor as bombesin (Nagalla et al., 1992), 
thus [125I-GRP] was used to investigate the effect of washing the cells on the 
binding of bombesin to its receptor. Equilibrium binding of [125I-GRP] is achieved 
at 37°C after 30 minutes (Zachary and Rozengurt, 1985). However a binding period 
of 1 minute was used to closely mimic the experimental conditions used in the 
determination of agonist-mediated desensitisation of stimulated PLD activity.
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Table 4.3 Effect of a 5 minute PMA pretreatment on PMA-stimulated 
[3H]PtdBut accumulation
pHJPalmitate-labelled cells were pretreated for 5 minutes with lOOnM 
PMA or vehicle (0.01% (v/v) DMSO). Cells were then stimulated for times 
indicated with lOOnM PMA or vehicle, containing 30mM butanol. Incubations were 
terminated by removal of the medium and addition of ice-cold methanol. 
Chloroform extracts were prepared and [3H]PtdBut generation quantified by t.l.c. as 
described. Results are expressed as radioactivity in [3H]PtdBut (d.p.m., mean ± 
S.D., n=3), where results are from a single experiment representative of three.
Treatment d.p.m. in PtdBut
5 min vehicle pretreatment 
10 min vehicle stimulation
5min vehicle pretreatment 
5min PMA stimulation
5min vehicle pretreatment 
lOmin PMA stimulation
5 min PMA pretreatment 
5 min PMA stimulation
3394 ± 325
10390 ± 1527
14000 ± 467
5721± 336
Table 4.4 Effect of Ro 31-8220 on bombesin-mediated (A) desensitisation and 
(B) resensitisation, of bombesin-stimulated PLD activity.
(A) [3H]Palmitate-labelled cells were preincubated with vehicle (containing 0.04% 
(v/v) DMSO) or IOjiM Ro-31-8220 for 5 minutes before pretreating the cells for 1 
minute, in the absence of butanol, with vehicle, lOfiM R o-31-8220, lOOnM 
bombesin or lOOnM bombesin plus 10|iM Ro 31-8220. The cells were then 
stimulated for 1 minute with vehicle, lOpM Ro-31-8220, lOOnM bombesin or 
lOOnM bombesin plus IOjiM Ro 31-8220, each in the presence of 30mM butanol. 
All additions contained 0.04% (v/v) DMSO. Incubations were terminated by 
replacement of the medium with ice-cold methanol. Chloroform extracts were 
prepared and [3H]PtdBut quantified as described. Results are expressed as % means 
± S.D., where n=3, of the [3HJPtdBut obtained in the absence of Ro 31-8220, after a 
vehicle pretreatment and stimulation for 1 minute with lOOnM bombesin and are 
from a single experiment typical of three. Mean basal values, where vehicle or 
10|iM Ro 31-8220 only was used in pretreatments and stimulations, were subtracted 
before % values were determined. Basal d.p.m.: vehicle, 1100 ± 331; Ro 31-8220, 
1023± 238.
(B) The cells were pretreated as above. They were then washed with vehicle ± 
10p.M Ro 31-8220 for 3 x 30 seconds followed by a fourth wash for 10 minutes. 
Cells were then stimulated for 1 minute with vehicle, lOOnM bombesin or lOOnM 
bombesin plus IOj iM  Ro 31-8220. Incubations were terminated and [3H]PtdBut 
generation determined as in (A). Results are % means ± S.D., where n=3, of the 
[3H]PtdBut obtained in the absence of Ro 31-8220 after a vehicle pretreatment, 
washes for 3 x 30 seconds and 10 minutes, followed by a lOOnM bombesin 
stimulation for 1 minute. The data is from a single experiment typical of three 
Mean basal values, where vehicle or lOfiM Ro 31-8220 only was used in 
pretreatments and stimulations were subtracted before % values were determined. 
Basal d.p.m.: vehicle, 644 ± 51; Ro 31- 8220, 694±106.
(A)
Treatment
vehicle pretreatment + Ro-31-8220 
Ro-31-8220 + bombesin stimulation
bombesin pretreatment 
bombesin stimulation
Ro-31-8220 + bombesin 
pretreatment
Ro-31-8220 + bombesin stimulation
Treatment
vehicle pretreatment +Ro-31-8220 
Ro-31-8220 + bombesin stimulation 
after lOmin wash
bombesin pretreatment 
bombesin stimulation after lOmin 
wash
Ro-31-8220 + bombesin 
pretreatment
Ro-31-8220 + bombesin stimulation 
after lOmin wash
% of the PtdBut generated in 
the absence of pretreatment
29 ± 17
9 ±14
-11 ± 5
(B)
% of the PtdBut generated 
in the absence of pretreatment
33 ± 8
33 ± 7
14 ± 6
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Initial experiments suggested that the washing procedure had no effect on the 
amount of cell-associated [125I-GRP]. To investigate whether the failure of the 
washing procedure to remove bound ligand was due to its internalisation, the cells 
were washed with a glycine buffer pH3. Washing cells with a low pH buffer is used 
to remove all surface-bound ligands and permits an estimation of the extent of 
receptor internalisation (Kuppuswamy and Pike 1989). All the cell associated 
radioactivity present after washing at pH 7.4 (section 2.4.4) remained after the acid 
wash, implying a rapid internalisation of the bombesin receptor (mean specific 
c.p.m. bound/106 cells: no acid wash, 245 +/- 27; with acid wash 285 +/- 65, n=3, 
results from a single experiment typical of three).
To investigate the possibility that the internalised receptor subsequently 
returned to the surface at 37°C, cells were pretreated for 1 minute with lOOnM of 
unlabelled bombesin, then washed for 3 x 30 seconds and a fourth wash of 
increasing lengths of time. Cells were then incubated for 1 minute at 37®C with 
[125I-GRP] then placed on ice. The results suggested that there was indeed an 
increase in the binding of [ 125I-GRP] to the cells over time, after removal of the 
unlabelled bombesin. However it proved impossible to generate statistically valid 
data due to the very low levels of specific binding under these conditions.
Rather than pursuing the experiments with [125I-GRP], which not only 
produced difficulties with high levels of non-specific binding, but were also 
hazardous and expensive, studies were continued on the vasopressin receptor using 
[3H] [Arg8] Vasopressin ([3H]AVP) and the radiolabelled antagonist [3H][p- 
M ercap to -p -p -cy c lo p en ta -m eth y len ep ro p io n y l1, O-Et-Tyr2’ V al4, Arg8] 
Vasopressin ([3H]AVP antagonist). The presence of a class of high affinity 
vasopressin (AVP) receptors on Swiss 3T3 cells with a K^of approximately lOnM, 
with 105 binding sites per cell has previously been reported (Collins and Rozengurt, 
1983).
The time course of AVP-stimulated PLD activity (results not shown) and 
rate of decrease in AVP-stimulated [3H]PtdBut generation following a short AVP
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pretreatment was similar to that observed with bombesin (section 4.2.1). 
Experiments showed that AVP-stimulated [3H]PtdBut accumulation resensitised to 
an extent comparable with that generated in response to bombesin, after the 
desensitising pretreatment was removed and the cells washed for 11.5 minutes, prior 
to a 1 minute stimulation (mean ± S.D.% of unpretreated response: AVP, 57 ± 16; 
bombesin, 54 ± 10, n=3, results from a single typical experiment of three). [3H]AVP 
antagonist was used for binding studies, since the coupling of receptors to G-proteins 
results in a shift in receptor affinity for agonist from a high to lower state whereas 
the affinity for antagonists remains unchanged. However, in this study, 
determination of the number of cell-surface receptors, after exposure to unlabelled 
agonist at 37°C, was performed at 4°C to prevent further receptor internalisation 
(Briner et al., 1992). Therefore any change in receptor affinity state was limited.
Results presented are those performed with [3H]AVP antagonist, though 
most experiments were repeated with [3H]AVP. Figure 4.8(A) shows the specific 
binding of [3H]vasopressin antagonist at 4°C as a function of ligand concentration. 
Non-specific binding, defined as that observed in the presence of 200-fold excess of 
unlabelled antagonist, varied linearly with antagonist concentration and was between 
15-50% of total binding. Scatchard analysis of [3H]vasopressin antagonist binding 
gave a Kd of 2.5nM and a Bmax. of approximately 50,000 receptors per cell (Fig. 
4.8(b)). These results were comparable to those of Collins and Rozengurt (1983). 
Figure 4.9 shows that equilibrium binding of [3H]vasopressin antagonist at 4°C was 
reached after 1 hour of binding, with only a small increase in bound antagonist 
observed at longer incubation times. A 1 minute pretreatment with unlabelled AVP 
at 37°C was found to reduce subsequent [3H]vasopressin antagonist binding at 4°C 
by 70% (Table 4.5). Washing the cells at 37®C for 11.5 minutes allowed subsequent 
binding at 4°C to recover to 70-90% of that observed in unpretreated cells. 
Pretreatment with bombesin did not affect the binding of [3H]AVP antagonist to the 
receptor, implying that the loss of receptor binding sites was agonist specific. 
Similar results were observed using binding of [3H]AVP at 4°C (n=2). Preliminary
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experiments suggested that pretreatment at 37°C with a sub-maximal concentration 
of AVP only reduced [3H]AVP binding by 30-40% and 11.5 minutes after agonist 
removal, binding was comparable to that observed in the unpretreated cells (results 
not shown, n=2).
To determine whether the loss in binding could be due to internalisation of 
the receptor/ligand complex, cells were incubated with [3H]AVP for increasing 
times at 37°C, then placed on ice to prevent further receptor internalisation as 
described previously. Surface bound ligand was then removed by an acidic wash. 
As for [125I GRP], [3H]vasopressin binding does not reach equilibrium until 30 
minutes at 37^C (Collins and Rozengurt, 1983). The experiment was again 
performed using shorter times of binding, to mimic experimental conditions used for 
determinations of the desensitisation and resensitisation of agonist-stimulated PLD 
activity. Figure 4.10 shows that although all the bound ligand was on the surface 
after a 1 minute exposure [3H]AVP to after 10 minutes all the agonist had apparently 
been internalised and could not be removed with an acidic wash.
Experiments were performed using pretreatments at 37°C with maximal 
concentrations of unlabelled AVP antagonist. This reduced the number of binding 
sites accessible to agonist or antagonist, to a similar extent to that observed with 
unlabelled agonist pretreatment. The effect of a 1 minute pretreatment with 30nM 
antagonist did not significantly reduce vasopressin-stimulated PLD activity in most 
experiments, though in some, vasopressin-stimulated PLD activity was decreased by 
approximately 25%. In all experiments a 1 minute AVP pretreatment completely 
desensitised subsequent AVP-stimulated PLD activity (results not shown).
4.2.5 Heterologous desensitisation of agonist-stimulated PLD activity
The nature of agonist-desensitised PLD activity was investigated, by 
pretreating cells with maximal concentrations of bombesin or vasopressin for 1 
minute in the absence of butanol, washing cells briefly, then stimulating with a 
different agonist in the presence of butanol. Figure 4.11 shows that pretreatment for
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Figure 4.8 Scatchard analysis of [3H]AVP antagonist binding to intact Swiss 
3T3 cells at 4°C
Swiss 3T3 cells were grown in 6-well plates, in DMEM + 10% calf serum, 
until 80% confluent. The medium was then removed and the cells allowed to 
quiesce for a further 24 hours in DMEM + 2% calf serum. Cells were washed at 
37°C, then at 4°C before being incubated for 1 hour at 4°C with [3H]AVP antagonist 
at concentrations indicated. Cell associated radioactivity was determined as 
described (section 2.4.2). Non-specific binding at each concentration was 
determined in the presence of a 200-fold excess of AVP antagonist and was 
subtracted from total binding to give the specific binding shown. Results are 
expressed as: (A) a saturation isotherm of total (o), specific ( • )  and non-specific (A) 
binding, of [3H]AVP antagonist in fmol/well, (B) the derived Scatchard plot where, 
Bmax = 24 fmol , Kd = 2.5nM. Each point was performed in duplicate and results 
were taken from a single experiment representative of three. The number of cells per 
well determined as described (section 2.4.2) was approximately 2.8 x 105.
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Figure 4.9 Time course of [3H]AVP antagonist binding to intact Swiss 3T3 cells 
at 4°C.
Quiescent Swiss 3T3 fibroblasts were washed at 37°C, then at 4°C, before 
being incubated for times indicated with InM [3H]AVP antagonist. Cell-associated 
radioactivity was determined as described in materials and methods. Non-specific 
binding was determined in the presence of 0.2pM of unlabelled AVP antagonist and
!
was subtracted in each case to give the specific binding shown. Results are^ 
expressed as specific bound [3H]AVP antagonist in fmol/well (n=2) and results are 
taken from a single experiment representative of two. The number of cells per well 
was approximately 3.1 x 105.
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Table 4.5 Effect of a 1 minute pretreatment at 37°C with 30nM unlabelled AVP ,
1
or lOOnM bombesin on [3H]AVP antagonist binding at 4°C.
Swiss 3T3 fibroblasts were grown in 6-well plates, in DMEM + 10% calf | 
serum, until 80% confluent. The medium was replaced with DMEM + 2% calf 
serum and the cells allowed to quiesce for a further 24 hours. After washing, cells 
were pretreated for 1 minute with 30nM AVP, lOOnM bombesin or incubation buffer 
alone at 37°C. For cells that were not to be washed further, the medium was then 
replaced with ice-cold incubation buffer and the cells placed on ice. Cells that were 
to be washed received 3 x 30 second washes with incubation buffer at 37°C, 
followed by a fourth wash for the time indicated. After the final wash the medium 
was replaced with ice-cold incubation medium and the cells placed on ice. The 
binding of [3H]AVP antagonist was performed at 4°C for 2 hours, before the cells 
were washed and solubilised as described in the materials and method section. Non­
specific binding was determined at each time point, by including a 200-fold excess 
of unlabelled AVP antagonist (lp.M) in the binding medium. Results are expressed 
as : specific bound [3H]AVP antagonist in fmol/well, after subtracting non-specific 
binding (mean ± S.D., n=2); also as % of [3H]AVP antagonist bound, where 
incubation buffer was used during the pretreatment period (mean ± S.D.%, n=2). j 
Results are taken from a single experiment representative of two. The number of J 
cells per well was approximately 1.8 x 105. I
Specific [3H]AVP % of [3H]AVP 
antagonist bound antagonist bound in 
Treatment (fmol/well) the absence of
pretreatment
no pretreatment,
Omin wash 15.9 ± 0.6 100±4
1 min AVP 
pretreatment,
Omin wash 5.2 ± 0 .1  33 ± 1
1 min bom 
pretreatment
0 min wash 14.9 ± 1.7 94 ± 9
1 min AVP 
pretreatment
6.5 min wash 10.5 ± 1.9 66 ± 10
lmin AVP 
pre treatment
11.5 min wash 12.5 ± 0.8 78 ± 5
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1 minute with lOOnM bombesin or vasopressin completely prevented a subsequent 
generation of pH]PtdBut, in response to a 1 minute stimulation in the presence of 
butanol, with the same agonist. However, if after pretreatment, a different agonist 
was used for the stimulation, between 20-30% of the agonist-stimulated pH]PtdBut 
generation attained in the absence of any pretreatment, remained.
To investigate whether agonist-induced desensitisation was also 
heterologous with respect to GTPyS-stimulation of PLD activity, permeabilised cells 
were pretreated for 1 minute with bombesin (Fig 4.12(A)), or vasopressin (Fig 4.12
(B)), washed briefly and stimulated for 5 minutes with 30p.M GTPyS. Both 3nM 
bombesin and 30nM vasopressin partially reduced the subsequent generation of 
pH]PtdBut in response to GTPyS in the presence of butanol, to approximately 50% 
of that attained in the absence of pretreatment. Fig 4.12 (A) also shows that a 1 
minute pretreatment with 30fiM GTPyS did not reduce the subsequent GTPyS 
stimulated pHJPtdBut accumulation
4.2.6 The effect of a short agonist pretreatment on subsequent stimulation of 
PLD activity by PMA.
Experiments were performed to determine if agonist-induced desensitisation 
of stimulated pHJPtdBut generation was also heterologous with respect to the 
stimulation of PLD by PKC-activating phorbol esters. Figure 4.13 shows that a 1 
minute pretreatment with bombesin, which attenuated the activation of PLD by a 
subsequent 1 minute stimulation with bombesin, had no effect on a 10 minute PMA- 
stimulation of PLD activity. In the same experiment, the short bombesin 
pretreatment partially attenuated the generation of [3H]PtdBut in response to a 10 
minute bombesin-stimulation, whilst in the presence of 30mM butanol alone no 
[^HJPtdBut generation above that of basal was detected, as previously described 
(section 4.2.1).
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Figure 4.10 Effect of an acidic wash on cell-associated radioactivity afte 
preincubation at 37°C with [3H]AVP.
Quiescent Swiss 3T3 fibroblasts were washed thoroughly at 37°C, the 
incubated for times indicated, with a final concentration of 30nM AVP, of whic 
5nM was [3H]AVP. Cells were placed on ice immediately following the incubatio 
with [3H]vasopressin, to prevent further receptor internalisation. Wells were washe 
and those indicated subjected to a low pH wash before determination of cel 
associated radioactivity, as described in materials and methods (section 2.4.3). Not 
specific binding was determined by including 6(iM unlabelled vasopressin in ttj 
binding medium and was subtracted from cell-associated radioactivity to give tf 
specific binding shown. Results are expressed as radioactivity in specific bour 
[3H]vasopressin per well (d.p.m., mean ± S.D., n=2), where results are from a sing 
experim ent representative of three. The number of cells in each well w; 
approximately 1.8 x 105. Unshaded columns represent specific AVP bound in cell 
that were not washed with the low pH buffer; shaded columns represent specif] 
AVP bound in cells subject to an acidic wash.
sp
ec
ifi
c 
AV
P 
bo
un
d 
d
.p
.m
./w
el
l
I
 ^ '  *'■.'* -yj /  s  * v'
\ f  * <r wv  * -  ^ e *
S S S
' -?;\ ' &.
* •> s  »  \r  S ' s  %v" < X S < A#* * *\'S' * *y **.< * >'
* * v - r  S ' *•
1 minute 10 minutes
Time of [3H] AVP binding
137
Figure 4.11 Heterologous desensitisation of agonist-stimulated PLD activity.
[3H]Palmitate-labelled cells were pretreated for 1 minute with HHBG, 
lOOnM vasopressin or lOOnM bombesin in the absence of butanol, then washed for 3 
x 30 seconds with HHBG. Cells were stimulated for 1 minute in the presence of 
30mM butanol with, HHBG, lOOnM bombesin or lOOnM AVP. Incubations were 
terminated by replacement of the medium with ice-cold methanol. Chloroform 
extracts were prepared and the generation of [3H]PtdBut quantified as previously 
described. Results are expressed as radioactivity in [3H]Ptdbut (mean d.p.m. ± S.D., 
n=3) and are from a single experiment typical of three. - (pt), cells pretreated with 
buffer; - (st), cells stimulated with buffer + butanol; BOM (pt), cells pretreated with 
lOOnM bombesin; BOM (st), cells stimulated with lOOnM bombesin + butanol; VP 
(pt), cells pretreated with lOOnM AVP; VP (st), cells stimulated with lOOnM AVP + 
butanol.
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Figure 4.12 Effect of agonist pretreatment on GTPyS-stimulated PLD activity.
[3H]Palmitate-labelled cells were permeabilised with streptoIysin-O 
(0.6Uml_1), then pretreated for 1 minute in the absence of butanol, with HHBG or;
(A) 3nM bombesin or GTPyS; (B) 30nM vasopressin. Cells were washed 3 times 
over 10s, then stimulated for 5 minutes with vehicle or 30jiM GTPyS in the presence 
of 30mM butanol. Incubations were terminated by direct addition of ice-cold 
methanol. Chloroform extracts were prepared and the generation of [3H]PtdBut 
determined by t.l.c. as described. Results are expressed as radioactivity in 
[3H]PtdBut (mean d.p.m. ± S.D., n=3) and are from a single experiment 
representative of three. - (pt), cells pretreated with buffer; - (st) cells stimulated with 
buffer + butanol; BOM (pt), cells pretreated with lOOnM bombesin; VP (pt), cells 
pretreated with lOOnM vasopressin; GTP[S] (pt), cells pretreated with GTPyS; 
GTP[S] (st), cells stimulated with GTPyS + butanol.
Treatment
(pt), GTP[S] (st).
BOM (pt), GTP[S] (st).
GTP[S] (pt), GTP[S] (st).
GTP[S] (pt), - (st).
I I I I ---I 1-------------- 1---------
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Figure 4.13 Effect of a 1 minute bombesin pretreatment on PMA-stimulated 
PLD activity
[3H]Palmitate-labelled cells were incubated for 1 minute, with HHBG or 
lOOnM bombesin. Cells were washed for 3x 30 seconds, then stimulated in the 
presence of 30mM butanol for 10 minute with, HHBG, lOOnM bombesin or lOOnM 
PMA. Incubations were terminated by replacement of the medium with ice-cold 
methanol. Chloroform extracts were prepared and [3H]PtdBut quantified by t.l.c. as 
described. Results are expressed as radioactivity in [3H]PtdBut (mean ± S.D., 
d.p.m., n=3) and are from a typical experiment representative of three.
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4.2.7 The effect of elevating intracellular calcium on bombesin-stimulated PLD 
activity
The stimulated increase in intracellular calcium by bombesin in Swiss 3T3 
cells is transient (Takuwa et al., 1987; Currie et al., 1992), thus the decline in 
calcium levels could play a role in desensitisation, particularly in light of the 
suggestion that in some cells, PLD activity may be regulated by changes in 
intracellular [Ca2+]. It has been suggested that heterologous desensitisation of 
stimulated-PLD activity is due to short term depletion of an intracellular Ca2+ 
pool(McKenzie et al., 1992). Therefore the effect of maintaining an elevated 
intracellular calcium level by treating with the calcium ionophore A23187 on 
stimulated PLD activity was examined. Figure 4.14 shows that A23187 stimulated 
rapid [3H]PtdBut accumulation, which plateaued between 30 seconds and 1 minute 
consistent with the theory of homologous desensitisation. Thus maintaining an 
elevated intracellular [Ca2+] using A23187 could not prevent homologous 
desensitisation of A23187-stimulated [3H]PtdBut accumulation. However, a 
pretreatment with ionophore only caused a 40% reduction in bombesin-stimulated 
PLD activity (Table 4.6). Furthermore pretreating with lOOnM bombesin for 1 
minute completely abolished any subsequent bombesin- or A23187-stimulated 
[3H]PtdBut accumulation.
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Figure 4.14 Time course of A23187-stimulated PLD activity
[3H]PtdBut accumulation was determined in [3H]palmitate-labelled cells, 
stimulated with 5|iM A23187 for increasing times in the presence of butanol, after a
!
5 minutes preincubation with 30mM butanol. Incubations were terminated by the, 
addition of ice-cold methanol. Chloroform extracts were prepared and [3H]PtdBut 
generation quantified by t.l.c. as described, (o), control cells (0.1% (v/v) 
dimethylsulphoxide); (•), stimulated cells. Results are expressed as radioactivity in 
[3H]PtdBut (d.p.m., mean ± S.D., n=3) and are from a single experiment 
representative of three.
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Table 4.6 Effect of elevating [Ca2+] j on bombesin-stimulated PLD activity. j
[3H]Palmitate-labelled cells were pretreated with vehicle, 5|nM A23187 or
j
lOOnM bombesin for 1 minute, before washing for 3 x 30 seconds with HHBG. The ■
j
cells were then stimulated for 1 minute with vehicle, lOOnM bombesin or 5p.M .
I
A23187, in the presence of 30mM butan-ol. All pretreatments and stimulations 
contained 0.1% (v/v) DMSO. Incubations were terminated by the addition of ice- 
cold methanol. Chloroform extracts were prepared and [3H]Ptdbut was determined 
by t.l.c. as described. Results are expressed as % mean ± S.D., of basal, where 
vehicle was used in the pretreatment and stimulation. Results are from a single 
experiment representative of three, where each point was performed in triplicate. 
Mean basal d.p.m., 1527 ± 255.
Treatm ent
no pretreatment 
1 min bombesin stimulation
no pretreatment 
1 min A23187 stimulation
bombesin pretreatment 
1 min vehicle stimulation
A23187 pretreatment 
1 min vehicle stimulation
bombesin pretreatment 
1 min bombesin stimulation
bombesin pretreatment 
1 min A23187 stimulation
A23187 pretreatment 
1 min A23187 stimulation
d.p.m.in PtdBut 
% of basal
291± 78
200± 36
94 ± 18
86 ± 18
115 ± 19
118 ± 17
100 ± 15
A23187 pretreatment 
1 min bombesin stimulation 200 ± 3 1
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4.3 Discussion.
4.3.1 Desensitisation of bombesin-stimulated [3H]PtdBut accumulation is rapid 
and reversible
Agonist-stimulated PLD activity was found to be tightly regulated and 
subject to rapid desensitisation (Fig.4.1). The IC5 0  f°r bombesin-induced 
desensitisation of a 2 minute lOOnM bombesin stimulation of [3H]PtdBut generation 
was 0.2 ± 0.1 nM (Fig. 4.2) and was comparable to the IC5 0  of 0.35 ± 0.47nM 
obtained for the bombesin-mediated homologous desensitisation of stimulated- 
In s(l,4 ,5 )P 3  mass (Palmer et al., 1991). The kinetics of desensitisation of 
[3H]PtdBut generation to bombesin are very similar those described for the 
desensitisation of bombesin-stimulated Ins(l,4,5)P3 generation, suggesting that they 
may occur through similar processes. Desensitisation of bombesin-stimulated PLD 
activity may possibly occur downstream from that of stimulated PtdIns(4,5)P2 
hydrolysis. Similar correlations between the time courses of stimulated 
PtdIns(4,5)P2 hydroysis and PLD-catalysed PtdCho hydrolysis were reported in A 10 
vascular smooth muscle cells (Plevin and Wakelam, 1992) and in Chinese hamster 
lung fibroblasts transfected with the human Ml receptor (McKenzie et al., 1992).
The IC50 values for desensitisation of bombesin-stimulated Ins(l,4,5)P3 
mass and [3H] PtdBut accumulation are notably ten-fold lower than the reported 
EC50  values for other bombesin receptor-linked responses in Swiss 3T3 cells such 
as: DNA synthesis, EC50 InM (Rozengurt and Sinnett-Smith, 1983); inositol 
phospholipid hydrolysis, EC50 1.78 ± 0.03 (Plevin et al., 1990); PtdCho generation, 
EC50 2.30 ± 0.57 (Cook and Wakelam, 1989) and [3H]PtdBut generation, EC50  1.3 
± 0.3InM (Cook et al., 1991). This suggests that desensitisation may be due to post­
receptor events, possibly the result of a signalling cascade.
Resensitization of bombesin-stimulated PLD activity, though incomplete 
after 41.5 minutes of washing, commenced as early as 4.5 minutes after removal of 
the desensitising pretreatment (Fig 4.3). Similarly in A 10 VSMC, removal of AVP
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from its receptor for at least 3 minutes, was found to be necessary for response to a 
fresh stimulus (Caramelo etal, 1991).
4.3.2 Bombesin-stimulated desensitisation and resensitisation of PtdCho 
hydrolysis
The determination of total [3H]choline production at increasing times after 
the initial pretreatment with bombesin (Fig 4.4), proved that the desensitisation and 
resensitisation of bombesin-stimulated [3H]Ptdbut generation was reflected in the 
hydrolysis of PtdCho and was not solely a phenomenon connected with the 
transphosphatidylation activity of phospholipase D. The difference in resensitisation 
time between experiments measuring [3H]PtdBut and [3H]choline generation 
probably reflects the fact that the former is an accumulation assay and the latter is 
measuring a product that can be metabolised by a number of different pathways. In 
this respect, choline production from the cells, pretreated with bombesin and 
stimulated with buffer, decreased with increasing wash time. This presumably 
reflected metabolism of the choline produced from the initial bombesin stimulation.
4.3.3 Desensitisation is not due to a limitation in labelled substrate or butanol.
PtdCho constitutes approximately 50% of the total membrane lipid and it 
has previously been reported that stimulation of Swiss 3T3 cells with a maximal 
concentration of either bombesin or PMA caused the loss of only about 5% of the 
label from the total PtdCho fraction (Cook and Wakelam 1989). Thus 
desensitisation is probably not due to limitation of labelled substrate.
This argument was strengthened by the finding that desensitisation of 
bombesin-stimulated [3H]PtdBut was not affected by experiments performed in the 
continual presence of [3H]palmitate (Table 4.1). Pretreatments that desensitised the 
cells to further agonist stimulation of PLD activity, were performed in the absence of 
butan-l-ol, whereas the stimulations were in the presence of butanol. Hence 
limitation of butan-l-ol was probably not responsible for desensitisation.
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Furthermore, PMA-stimulated [3H]PtdBut continued for at least 15 minutes 
demonstrating that labelled substrate and butanol was an unlikely limiting factor in 
desensitisation of agonist-stimulated PLD activity. It was possible however, though 
unproven, that PMA hydrolyses a different pool of [3H]PtdCho to that affected by 
bombesin.
4.3.4 The extent and kinetics of resensitisation of bombesin-stimulated 
generation of total [3H]inositol phosphates differs from that of [3H]PtdBut 
accumulation.
As desensitisation of bombesin-stimulated [3H]PtdBut generation appeared 
to be closely correlated with that of PtdIns(4,5)P2 hydrolysis, the relationship 
between resensitisation of bombesin-stimulated accumulation of total [3H]inositol 
phosphates and that of [3H]PtdBut was determined. Li+ uncompetitively inhibits 
inositol monophosphatase (reviewed Nahorski et a l, 1991), allowing measurement 
of Ptdlns-PLC activity through accumulation of total [3H]inositol phosphates. 
However, at stimulation times greater than 5 minutes L i+ can inhibit 
phosphoinositide synthesis (Berridge, 1993). The resensitisation of bombesin- 
stimulated production of total [3H]inositol phosphates was determined when LiCl 
was only present during the 1 minute bombesin stimulation, thus the disruptive 
effects of LiCl were likely to be minimal. An increase in total [3H ]inositol 
phosphates stimulated by lOOnM bombesin, over the attenuated level attained after a 
1 minute bombesin pretreatment, was observed within 8.5 minutes after agonist 
removal with complete recovery after 11.5 minutes (Fig. 4.7). The difference in the 
kinetics and extent of resensitisation of bombesin-stimulated generation of total 
[3H]inositol phosphates from that of [3H]PtdBut may suggest mechanistic 
differences. The resensitisation of bombesin-stimulated accumulation of total 
inositol phosphates contrasted with the recovery of bombesin-induced loss of 
stimulated Ins(l,4,5)P3 mass, which did not commence until at least 10 minutes after 
removal of the stimulus, not reaching completion even after 60 minutes (Palmer et
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a l., 1991). Measurement of Ins(l,4,5)P3 mass, however, has the problem that its 
metabolism is not accounted for. Thus small increases in bombesin-stimulated 
Ins(l,4,5)P3, following removal of the desensitising stimulus, may not be detected.
The resensitisation of the stimulated production of total [3H ]inositol 
phosphates determined in the presence of LiCl, apparantly occurred at times when 
Ins(l,4,5)P3 mass levels were still at basal. The transient formation of Ins(l,4,5)P3 
could be due to rapid activation of Ins(l,4,5)P3 5-phosphatase and 3-kinase, a 
depletion of PtdIns(4,5)P2 or activation of different isoforms of Ptdlns-PLC having 
different substrate specificities. There is increasing evidence that, although the 
initial event of receptor-activated Ptdlns-PLC is the hydrolysis of PtdIns(4,5)P2, at 
later times the hydrolysis of Ptdlns may become more important. Plevin and 
Wakelam (1992) reported that A VP-stimulated Ins(l,4,5)P3 mass generation and the 
decrease in PtdIns(4,5)P2 mass levels was transient and suggested that another 
inositol-containing phospholipid other than PtdIns(4,5)P2.may be hydrolysed during 
longer exposures of A10 VSMC to agonist. Similar findings were reported in 
hormone-stimulated rat pituitary cells (Imai and Gershengom 1986), lithium treated 
rats (Ackerman et al., 1987) and thrombin stimulated platelets (Wilson et al., 1985). 
However in carbamoyl-stimulated neuroblastoma cells polyphosphoinositides were 
found to be the major source of inositol phosphates (Fisher et al., 1990).
4.3.5 The internalisation and recycling of agonist occupied receptors is a 
potential mechanism for desensitisation and resensitisation of bombesin- 
stimulated PLD activity.
The loss of cell surface receptors after exposure to agonist is a common 
event in transmembrane signalling systems. Many reports suggest that after short 
exposure to stimulus, some proportion of the internalised receptors can also recycle 
to the cell surface (Hoxie, et al., 1993; Briner et al., 1992; Zachary and Rozengurt, 
1987). However, experiments with the fo-AR have shown that such sequestration is 
not important for the initial desensitisation but is essential for resensitisation after
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short agonist exposure (Yu et al., 1993). Receptor binding studies therefore 
examined the loss of cell surface binding sites with agonist exposure as a possible 
mechanism of desensitisation and/or a prerequisite for resensitisation.
A receptor-ligand complex can be processed by several different pathways: 
(a) internalisation of the complex, with subsequent dissociation of the ligand from 
the receptor, degradation of the ligand and recycling of the receptor to the cell 
surface, as reported for endothelin in human VSMC (Resink et al., 1990); (b) 
internalisation of the complex, followed by recycling of intact unit and its 
extemalisation as described for receptor-mediated transport of IgG across the new­
born rat intestine (Abrahamson and Rodewald, 1981); (c) internalisation and 
lysosomal degradation of the whole complex, such that protein synthesis is required 
for expression of new cell surface receptors, as for EGF in human fibroblasts 
(Carpenter and Cohen, 1976); (d) transcytosis of the complex without lysosomal 
processing or recycling, as described for a transmembrane precursor of secretory 
component in epithelial cells (Mostov and Blobel 1982).
Acid washing of Swiss 3T3 cells, after the addition of [12^IGRP] for 1 
minute to Swiss 3T3 cells at 37°C, showed that all the cell associated radioactivity 
was internal after this time. Since non-equilibrium binding conditions were 
employed to examine GRP-receptor interactions, high non-specific binding varying 
from 40-85% of total binding was a problem with these experiments. As explained 
in the results section of this chapter, further binding experiments were performed 
with [3H]AVP and [3H]AVP antagonist.
A short AVP pretreatment at 37°C which completely abolished subsequent 
AVP-stimulation of [3H]PtdBut accumulation, only partially reduced [3H]AVP 
antagonist binding (Table 4.5). Acid-washing removed most of the cell associated 
radioactivity after 1 minute of [3H]AVP binding at 37°C, but not after 10 minutes of 
binding (Fig 4.10). This implied that the receptors must be on the surface accessible 
to acid stripping, but not to ligand binding after 1 minute, perhaps in a stage before 
entering early endosomes and it is not until later that the receptor/ligand complex is
148
internalised. These findings are supported by investigations of thrombin receptor 
internalisation (Hoxie et al., 1993). Using receptor-directed antibodies, thrombin 
receptors were found to be clustered in and around coated pits in the membrane after 
1 minute of stimulation. Prelysosomes were not detected until after 10 minutes of 
thrombin exposure . The difference between the kinetics of internalisation between 
[125I]GRP and [3H]AVP, where studies suggested all the [125I]GRP was internalised 
after 1 minute, may be due to the different receptors or the fact that any [125I]GRP 
that was removed by the low pH wash was masked by the level of non-specific 
binding.
It appears that A VP-mediated desensitisation of stimulated [3H] PtdBut 
generation and loss of cell-surface binding occurs more rapidly than the 
internalisation of receptors. The reduction in cell-surface binding before the 
detection of internalisation may be due to a conformational change in the receptor 
perhaps due to phosphorylation. As previously discuused (section 4.3.1) the IC50 for 
bombesin-stimulated desensitisation of PLD activity suggested a post-receptor 
mechanism was involved. It is thus possible that a similar mechanism of rapid 
desensitisation to that occurring for the p-AR also occurs for desensitisation of the 
bombesin-receptor. Uncoupling of the receptor from G-protein/effector system by 
receptor phosphorylation is postulated to be the primary mechanism of 
desensitisation of the P2 -AR. Subsequent receptor sequestration is a necessary event 
for receptor reactivation (see chapter 5 for fuller discussion). However this 
comparison is purely speculative as although uncoupling of the receptor/effector 
mechanism may occur prior to internalisation there is no evidence for bombesin 
receptor phosphorylation.
Evidence for the involvement of both receptor and post receptor 
mechanisms in desensitisation exists for other receptors-linked to PtdIns(4,5)P2 
hydrolysis. Although receptor number and binding affinity was not determined after 
agonist pretreatment in this study, several studies have shown that a decrease in 
binding of cell surface receptors can occur without a change in receptor affinity. For
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example, homologous desensitisation in response to a 2 hour preincubation with 
AVP in vascular smooth muscle cells was reported to cause a 30-40% decrease in 
receptor number with no change in receptor affinity and a 60-80% decrease in 
inositol phosphate production (Grier et al., 1989). This suggested that AVP also has 
an effect on post-receptor sites in these cells. The decrease in inositol phosphate 
production was not blocked by the V ia antagonist and was therefore receptor 
specific. Desensitisation of A VP-induced Ca2+ mobilisation in VSMC (Caramelo et 
al., 1991) and thrombin-stimulated phosphoinositide breakdown in fibroblasts (Paris 
et al., 1988) was reported to still occur at 4°C, a temperature at which internalisation 
is blocked, suggesting that in these cells receptor internalisation was not important 
for desensitisation .
The increase in [3H]AVP antagonist receptor binding, after removal of the 
AVP pretreatment, was generally greater than the resensitisation of AVP-stimulated 
[3H]PtdBut observed (Table 4.5). The recovery of antagonist binding probably 
reflects a recycling of the internalised receptor. Thus both receptor and post-receptor 
mechanisms may also be involved in the regulation of resensitised, agonist- 
stimulated PLD activity. Recycling of the AVP receptor was also reported by Briner 
et al., (1992), who showed that recovery of AVP binding sites in VSMC occurred in 
a protein-synthesis independent manner.
Preliminary experiments suggested that pretreatment with [3H ]A V P 
antagonist could also reduce the binding of radiolabelled ligand to cells. However, 
antagonist pretreatment either had little or no effect on subsequent AVP-stimulated 
PLD activity. Furthermore, after washing the cells for 11.5 minutes there was no 
difference between those that were unpretreated and those that had been pretreated 
with antagonist, though cells pretreated with agonist were still partially desensitised. 
The antagonist does not have any effect on intracellular signalling events nor should 
it be internalised. One explanation for the effect of the antagonist on binding is that 
it binds to the receptor with high affinity hence blocking agonist binding. The 
failure of the AVP antagonist to have a significant effect on stimulated PLD activity
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suggested that binding to the receptor alone is insufficient to induce desensitisation 
processes. Similarly, the binding of a fluorescent-labelled AVP analog to A-10 
VSMC, that bound to the V ia receptor, but did not initiate intracellular events or 
endocytosis, implied that receptor activation was essential to receptor internalisation 
(Lutz etal., 1992).
In support of bombesin-receptor internalisation Zachary and Rozengurt 
(1987) investigated the binding of [125I]GRP to Swiss 3T3 fibroblasts. After 5 
minutes at 37°C approximately 50% of specific cell-associated radioactivity was 
internalised, with 20% remaining resistant to acid after 30 minutes. The 
internalisation of the receptor-ligand complex was accompanied by lysosomal 
degradation of [125I]GRP and recycling of the receptor. Similar results were 
reported using 125I-[Tyr4]bombesin (Brown et al., 1988; Wang et al., 1993). 
Bombesin receptor internalisation has also been reported in guinea pig pancreatic 
acini (Pandol et al., 1982). Although preincubations of 90 minutes were used to 
study desensitisation, a virtual complete recovery of the response was attained 
following washing for 2 to 3 minutes, which was proposed to be due to receptor 
recycling.
Despite the partial resensitisation of bombesin-stimulated [3H]PtdBut 
accumulation 11.5 minutes after removal of the desensitising pretreatment, a further 
challenge with bombesin resulted in complete desensitisation to a short stimulation 
in the presence of butanol. There was no difference in the extent of resensitisation, 
even if the cells were subjected to several pretreatment/wash cycles before 
stimulation in the presence of butanol (Table 4.2). This suggests resensitised 
receptors must be free of any modifications that may have caused the initial 
desensitisation although post-receptor events may prevent the full resensitisation of 
receptors. Rechallenge may commence a new cycle of receptor/effector uncoupling 
and sequestration.
Cells, pretreated with bombesin, in the absence of butanol for 1 minute, 
then stimulated in the presence of the alcohol, exhibited a continual increase in
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|pH]PtdBut accumulation at a rate reduced that produced from the initial stimulus. This 'suggested 
that resensitisation| occurred even in the continual presence of agonist which is an 
unusual phenomenon. Transient resensitisations of muscarinic-stimulated muscle 
contractility was reported to occur even in the continual presence of the agonist, 
although the phenomenon correlated with changes in the affinity of carbachol for the 
receptors (Hishinuma et a l, 1993). The rate changes of bombesin-stimulated PLD 
I activity may have been due to continuous cycles of receptor internalisation
and recycling. Although it was not possible to prove this continuous receptor 
trafficking from binding studies, it has been reported that prolonged exposure to 
bombesin or GRP for up to 3 hours did not affect the binding of GRP to its receptor 
even in the presence of cycloheximide (Zachary and Rozengurt 1987). In contrast to 
EGF receptors, the bombesin receptors are therefore not down-regulated in Swiss 
3T3 cells after short exposure to agonist. The inability of Swiss 3T3 fibroblasts to 
down-regulate bombesin receptors over relatively short exposure to agonist appears 
to be cell specific. A decrease in receptor binding during continuous exposure for 90 
minutes to bombesin, was reported in both rat pancreatic acini and in HIT-T15 islet 
cells (Zhu et a l,  1991; Swope and Schonbrunn, 1990).
Receptor sequestration and return to the cell surface in the continual 
presence of agonist has been reported for (3-AR (Kurz and Perkins, 1992) and 
guanylate cyclase/atrial natriuretic factor receptors (Pandey, 1993). The recycling of 
the |3-AR was found to occur through similar pathways irrespective of the continual
presence of agonist. The kinetics of bombesin-stimulated PLD activity may have been due to 
continuous cycles of receptor internalisation and recycling to the plasma membrane. The initial 
desensitisation may reflect the rapid transfer of receptors to endosomes with the resensitised rate 
of PLD activity due to the attainment of a steady state of receptor trafficking.
A role for the receptor in resensitisation is supported by the requirement for 
bombesin to be present in the medium for recovery of [2H]PtdBut accumulation after 
a bombesin pretreatment (Fig 4.5). This suggested that receptors were recycling to 
the surface, but reoccupancy of the receptors by agonist was necessary for
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restimulation of PLD activity. Bombesin may therefore have dissociated from the 
receptor before it recycled. Endolysosomal processing of the AVP-receptor complex 
in vascular smooth muscle cells (Briner et al., 1992) was found to be essential for 
the recycling process.
It is thus proposed that receptors do recycle in the presence or absence of 
agonist however the mechanism of PLD activation by the bombesin-activated, 
recycled receptor is unclear. As previously discussed, at longer times of agonist 
exposure the production of inositol phosphates may be due to the hydrolysis of 
Ptdlns. The production of DAG at longer stimulation times is apparently not derived 
solely from PLD-catalysed PtdCho hydrolysis in Swiss 3T3 cells (Cook et al., 1992; 
Pettit and Wakelam, 1993). In other cell types it has been proposed that DAG may 
be produced from Ptdlns hydrolysis such as in A10 vascular smooth muscle cells 
(Plevin and Wakelam, 1992) or de novo synthesis, for example in neutrophils (Rossi 
et al., 1991). Receptor recycling may therefore permit the continual production of 
DAG which in the absence of Ins(l,4,5)P3-mediated Ca2+ rises could activate the 
Ca2+-independent isoforms of PKC such as PKC8 and hence stimulate PLD activity. 
In accordance with this proposal, phases of bombesin-stimulated DAG and PKC 
activity may be expected to precede those of [3H]PtdBut generation. Although there 
is no evidence for this in Swiss 3T3 fibroblasts, three phases of PKC activity were 
detected over 60 minutes in IFNy-stimulated endothelial cells although these were 
subsequent to increases in choline, PtdOH and DAG (Mattila and Renkonen, 1992). 
Furthermore, a multiphasic generation of DAG was observed in a-throm bin-
stimulated human platelets in response to sub-threshold levels of agonist (Werner et 
al., 1992). It is also possible that interactions with products from other 
phospholipase-catalysed phospholipid hydrolysis may regulate PLD activity. 
Recently it was reported that oleate, presumably generated from PLA2 -catalysed 
PtdCho hydrolysis, stimulated DAG formation through effects on PLD and PAP 
(Siddiqui and Exton, 1992).
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However, as previously described, resensitisation of stimulated PLD 
activity is incomplete and may be also under the control of post-receptor events. 
The mechanism of activation of PLD through PKC and tyrosine kinases is unclear 
but may directly modify PLD itself or upstream components of the signalling 
pathway such as the receptor or G-protein. Such phosphorylation may occur 
transiently and be under the control of tyrosine or serine and threonine kinases and 
phosphatases. Bombesin has also been reported to activate MAP kinase (Pang et al., 
1993) which may feed back to regulate PLD activity . Moreover biphasic activation 
of MAP kinase was observed in a-thrombin stimulated fibroblasts (Kahan et al.,
1992) and a recent report demonstrated that MAP kinase could activate a 
phosphatase which dephosphorylated the EGF receptor (Griswold-Prenner et al.,
1993).
However, whether bombesin stimulates PLD activity through the same 
pathways irrespective of whether the receptor is recycled in the continual presence or 
in the absence of the agonist is uncertain.
4.3.6 Bombesin-stimulated desensitisation and resensitisation of PLD activity is 
PKC independent.
The continuous generation of PMA-stimulated [3H]PtdBut over 15 minutes 
suggested that desensitisation may be independent of PKC. Table 4.4 shows that 
complete desensitisation of bombesin-stimulated PLD activity occurred even in the 
presence of the selective PKC inhibitor Ro-31-8220, at a concentration which 
reduced PMA-stimulated PLD activity to basal levels and has been reported to be 
selective for inhibition of PKC (Davis et al., 1989). A recovery in PKC activity is 
unlikely to be involved in a mechanism by which resensitisation occurs, since 
preincubation with the kinase inhibitor resulted in a similar percentage inhibition of
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the partially resensitised bombesin-stimulated [3H]PtdBut accumulation as that of 
bombesin-stimulated PLD activity observed in unpretreated cells. Previous reports 
suggest that bombesin and AVP-stimulated homologous desensitisation of 
Ins(l,4,5)P3 (Palmer et al., 1991; P.Kaur personal communication) was also PKC 
independent. Furthermore, AVP-stimulated desensitisation of Ca2+ mobilisation was 
found to be PKC dependent in VSMC (Caramelo et al., 1991).
4.3.6 Agonist-stimulated desensitisation of PLD activity is both homologous 
and heterologous.
The loss in stimulated [3H]PtdBut generation induced by a short 
pretreatment with agonist was found to be partially heterologous. Figure 4.11 shows 
that after a 1 minute pretreatment in the absence of butanol, the stimulation of PLD 
activity using an agonist different from that used in the pretreatment, was attenuated 
by about 70%. As agonist-stimulated PLD activity is reduced by 50-70% with Ro- 
31-8220 and heterologous desensitisation of stimulated-PLD activity resulted in such 
a large attenuation of the response, it proved impossible to demonstrate the 
involvement of PKC in the phenomenon. Figure 4.13 shows that a 1 minute 
pretreatment with bombesin did not affect a subsequent PMA stimulation of PLD 
activity. This suggested that agonist pretreatment of cells did not affect the 
stimulation of PLD through the activation of PKC. AVP and bombesin-stimulated 
heterologous desensitisation of Ins(l,4,5)P3 has also been reported in Swiss 3T3 
cells (P. Kaur personal communication).
Vasopressin receptor binding studies showed that a 1 minute pretreatment, 
with a maximal dose of bombesin at 37°C, did not affect the binding of [3H] AVP or 
[3H]AVP antagonist at 4°C (Table 4.5). This suggested that heterologous 
desensitisation was not receptor mediated. Prolonged AVP pretreatment was 
reported not to alter the number, affinity or internalisation capacity of bombesin- 
receptors in Swiss 3T3 cells (Millar and Rozengurt 1989).
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4.3.7 A short agonist pretreatment partially reduces GTPyS-stimuIated PLD 
activity
Bombesin and vasopressin receptors in Swiss 3T3 cells couple through the 
pertussis-toxin insensitive G-protein, Gq to activate PLCpl (Smrcka et al., 1991). 
Results presented in Chapter Three showed that bombesin-stimulated PLD activity 
was also G-protein regulated. Experiments were thus performed to investigate 
whether a short agonist exposure could affect the stimulation of PLD activity 
through G-protein activation alone. Agonist-pretreated cells were found to reduce 
GTPyS-stimulated PLD activity in permeabilised cells by approximately 50% (Fig. 
4.12). This suggested that agonist-induced desensitisation of PLD activity is not due 
solely to receptor/G-protein uncoupling which has been suggested to be the site of 
PMA inhibition of bombesin-stimulated Ins(l,4,5)P3 generation (Plevin etaLy 1990). 
Therefore a component of the signalling pathway at, or downstream of the G-protein 
is also affected. The agonist-induced reduction in G-protein regulated PLD activity 
may account for the attenuation of stimulated PLD activity observed in response to a 
second agonist (Fig. 4.11). This may occur if the receptors for both agonists use the 
same pool of G-proteins to activate PLD as proposed for the ai-adrenoreceptor and 
the AVP receptor in hepatocytes (Dasso and Taylor, 1992). The finding that GTPyS 
pretreatment of cells did not decrease a subsequent GTPyS-stimulation of PLD 
activity suggested that activation of the G-protein itself, is insufficient for 
desensitisation but that receptor activation and coupling to the G-protein is essential. 
This contrasts with desensitisation of the p-AR where stimulation of adenylyl 
cyclase through the activation of Gs was not affected despite loss of responsiveness 
to the agonist and alterations in the function of Gs did not affect desensitisation of p- 
AR (Green and Clark, 1981).
It is possible that the receptor and the G-protein regulating PLD activity 
(possibly Gq) could be internalised together. An internalisation of Gqa  with the 
receptor could perhaps account for the continued generation of inositol phosphates, 
if PLC and phosphoinositides were accessible in the cytoplasmic structures. In
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support of this, internalisation of muscarinic receptors with G-proteins has been 
reported in human astrocytoma cells and in rat brain homogenates, with the release 
of G0a GjCX detected in the latter (Harden et a/.,1985; Ho et al., 1991). However 
only muscarinic receptors present at the cell surface were able to activate Ptdlns- 
PLC in neuroblastoma cells (Thompson and Fisher, 1991). Furthermore, Gs was 
reported to be released from the membrane upon stimulation of the p-adrenergic 
receptor (Ransnas et al., 1992). Although loss of GTPyS-stimulated PLD activity 
could be also due to an agonist dependent modification of the G-protein itself, no 
phosphorylation of GqCt was detected in bombesin-stimulated Swiss 3T3 cells (P. 
Kaur personal communication).
4.3.9 The calcium dependency of homologous and heterologous desensitisation 
of stimulated PLD activity.
Heterologous desensitisation of agonist-stimulated Ca2+ mobilisation in 
astrocytoma cells (McDonoughs al-, 1988), hepatocytes (Joseph et al., 1985) and in 
bombesin-stimulated human small cell lung cancer cell lines (HeikkilaS al., 1987) 
has been suggested to be due to emptying of the Ins(l,4,5)P3 sensitive Ca2+ pools. 
Carbachol-mediated desensitisation of a-thrombin stimulated PLD activity in 
Chinesehamster lung fibroblasts was also proposed to be due the depletion of 
intracellular Ca2+ stores (Mckenzie et al., 1992). It was thus possible that [Ca2+]i 
may be involved in the decrease in PLD activity in response to bombesin in Swiss 
3T3 cells.
However, in addition or alternatively to depletion of Ca2+ stores, the 
Ins(l,4,5)P3 receptor may become insensitive to any further increases in Ins(l,4,5)P3 
due to addition of a second agonist. Ins(l,4,5)P3 binding or its effect on the Ca2+ 
release channel of the endoplasmic reticulum is regulated by [Ca2+]i in a biphasic 
manner. This mode of regulation is thought to account to a significant extent for the 
transient rise in [Ca2+] elicited by agonists which stimulate PtdIns(4,5)P2 hydrolysis 
and for the repetitve Ca2+ oscillations observed in some cells in response to
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continual elevation of Ins(l,4,5)P3 (Lino and Endo, 1990). The effect of 
Ins(l,4,5)P3 is enhanced at lower [Ca2+]i, whilst the inhibition of Ins(l,4,5)P3 
binding at high [Ca2+] is thought to be mediated partly through the interaction of the 
Ca2+-binding protein calmedin with the receptor (Danoff et a l , 1988). Furthermore, 
the affinity of the Ins(l,4,5)P3 receptor was reported to switch from a low to a high 
affinity, inactive state, in the presence of high [Ca2+]i (Rouxel et al., 1992; Pietri et 
al., 1990). Other possible inhibitory mechanisms of Ins(l,4,5)P3-stimulated Ca2+ 
release may occur through the depletion of ATP levels such that the enhancement of 
Ca2+ release through the high affinity ATP recognition site is reversed (Ferris et al.,
1990). Phosphorylation of the receptor by PKC and Ca2+ activated calmodulin- 
dependent protein kinase may also be involved (Ferris et al., 1991; Ferris and 
Snyder, 1992). Reversal of these inhibitory effects may depend on the refilling of 
the Ins(l,4,5)P3-sensitive pool and the return of Ca2+ to basal levels. The above 
effects may therefore explain heterologous desensitisition in cells where agonist- 
stimulated Ins(l,4,5)P3 remains elevated such as in astrocytoma cells (McDonough 
et a l ,  1988). However in other cell types heterologous desensitisation of 
Ins(l,4,5)P3 generation may occur which would also abbrogate the ability of the 
second agonist to mobilise Ca2+ from intracellular stores. In support of this, 
heterologous desensitisation of agonist-stimulated Ins(l,4,5)P3 generation has been 
observed in Swiss 3T3 cells (P.Kaur personal communication).
The time course of A23187-stimulated [3H]PtdBut accumulation (Fig. 4.14) 
was similar to that stimulated by bombesin and vasopressin, with stimulation of PLD 
activity apparently ceasing after about 1 minute. This suggested that continuous 
elevation of intracellular calcium levels could not prevent homologous 
desensitisation of A23187-stimulated PLD activity. Pretreatment of cells with 
bombesin, completely abolished a subsequent A23187 stimulation of [^H]PtdBut 
accumulation. Pretreatment with A23187 only reduced bombesin-stimulated PLD 
activity by 40% (Table 4.6). This suggests that bombesin-mediated homologous 
desensitisation is a Ca2+-independent pathway. The effect of the ionophore
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pretreatment on a bombesin stimulation may be a result of the activation of Ca2+- 
dependent protein kinase C a  isozyme as it has previously been shown that Ro-31- 
8220 can inhibit 50% of the stimulation of PLD activity by A23187 (Cook et al.,
1991). However the previous experiments have demonstrated that such a bombesin 
pretreatment did not affect the PMA-stimulation of PLD activity. These differences 
may be resolved by the possibility that the Ca2+-independent forms of PKC are 
unaffected by a short bombesin pretreatment and these can thus stimulate 
[3H]PtdBut accumulation. The partial attenuation of bombesin-stimulated PLD 
activity by A23187 pretreatment may therefore reflect the Ca2+-dependent protein 
kinase C a  dependency of heterologous desensitisation.
It is possible that A23187-induced desensitisation of bombesin-stimulated 
[3H]PtdBut formation is mediated through a different mechanism to agonist-induced 
heterologous desensitisation, as the ionophore does not stimulate PtdIns(4,5)P2 
hydrolysis. A23187 may also have acted as an ionophore for intracellular Ca2+ 
stores, thus by depleting Ca2 + pools it may have mimicked the proposed 
heterologous effects of agonist pretreatment. It is possible that both depletion of 
Ca2+ pools and PKC are involved. This argument is supported by the finding that a 
30 minute carbamoylcholine treatment of permeabilised pancreatic acinar cells, 
decreased the affinity and maximal response of Ins(l,4,5)P3 induced Ca2+ release 
(Willems et al., 1989). The decrease in affinity was mimicked by PMA 
pretreatment, suggesting that the effect was partly PKC mediated. As it was not 
possible to demonstrate conclusively, that PKC was involved in heterologous 
desensitization of agonist-stimulated PLD activity, the involvement of other second 
messengers must also be considered.
The conclusions that can be drawn from this chapter are firstly, that 
bombesin-stimulates a rapid, dose dependent and PKC independent homologous 
desensitisation of stimulated [3H]PtdBut accumulation. Homologous desensitisation 
occurs via receptor and post receptor mediated mechanisms and is reversible, even in 
the continual presence of agonist. Receptor internalisation and recycling is probably
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responsible, not only for the observed partial resensitisation after agonist removal 
and washing, but also for the rate changes in stimulated-PLD activity observed in the 
continual presence of bombesin. Agonist-induced heterologous desensitisation is 
incomplete and apparently mediated through post-receptor mechanisms.
1 6 0
Chapter 5 
General Discussion
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The experiments in this thesis show that agonist-stimulated PLD activity in 
Swiss 3T3 fibroblasts can be regulated by a number of interacting pathways 
involving G-proteins, Ca2+, protein tyrosine phosphorylation and PKC. In addition, 
the results in Chapter 4 show that the mechanisms by which PLD activity is 
controlled are finely tuned to generate a rapid deactivation of the signal upon 
receptor activation followed by a reactivation. The possible mediators of agonist- 
stimulated desensitisation and resensitisation of PLD activity can be compared and 
contrasted to those involved in the control of receptor-linked responses in other 
systems. Perspectives of such tight control through the production of second- 
messengers are interpretable in a number of different ways.
5.1 Regulation of agonist-stimulated PLD activity through G-proteins and 
tyrosine kinases.
5.1.1 The involvement of heterotrimeric G-proteins.
Experiments have clearly shown that PLD can be regulated through a 
receptor coupled G-protein. Interaction between the G-protein and PLD is indirect 
and occurs probably via a kinase intermediate such as PKC and/or a tyrosine kinase. 
Although the precise nature of the G-protein that couples to PLD is unclear, at least 
50% of bombesin-stimulated PLD activity is regulated through PKC activation, 
presumably due to receptor coupled GqOt activation.
Interaction between tyrosine kinases and G-proteins have also been 
reported. Immunopecipitated c-src was reported to phosphorylate Gsa and Gt in 
vitro, slightly enhancing their activites (Hausdorff et al., 1992) and epinephrine was 
found to stimulate direct association of c-src with Gia in human platelets (Torti et 
al., 1992). Although the phosphorylation sites were not determined, the tyrosine 
residues are conserved, not only in Gas, Goti, G a0 and Gat but also in G(Xq. This 
suggested that a similar interaction may occur for pertussis-toxin insensitive G- 
proteins coupled to PtdIns(4,5)P2 hydrolysis. In support of this, c-src was found to
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be involved in pertussis toxin insensitive endothelin-stimulated transcriptional 
regulation and mitogenic signalling in glomerular mesangial cells (Simonson and 
Herman, 1993). Furthermore, it was proposed that ET-1 stimulated cell growth was 
controlled through Gotq. However, phosphorylation of Gotq in response to bombesin 
in Swiss 3T3 cells was not detected (P. Kaur, personal communication).
It is conceivable that more than one G-protein could be involved in the full 
activation of agonist-stimulated PLD activity as suggested for fMLP-stimulated PLD 
activity in neutrophils (Cockcroft, 1992). It is possible that two G-proteins may 
regulate the PKC-dependent and PKC-independent pathways of PLD activation. 
This proposal implies that in Swiss 3T3 cells a G-protein other than Gotq (G d) may 
be coupled directly to bombesin-stimulated tyrosine kinase activity.
However, bombesin may activate tyrosine kinases independently of G- 
proteins. Depletion of cellular ATP would have abolished any kinase activity in 
addition to PLC-catalysed PtdIns(4,5)P2 hydrolysis. A direct stimulation of PLD 
through kinases would therefore not have been distinguished from that regulated by 
G-proteins. The bombesin-stimulated activation of G-protein and tyrosine kinase 
mediated second-messenger pathways may act in parallel to stimulate the same or 
different PLD isoforms. Clarification of these possibilities await the purification and 
cloning of the PLD enzymes. This will allow in vitro reconstitution experiments 
and in vivo experiments involving overexpression of PLD enzymes and gene 
knockout of PLD isoforms using anti-sense mRNA.
5.1.2 The regulation of PLD activity by small molecular weight G-proteins
The monomeric G-proteins are structurally related to the ras oncogene and 
have been divided by sequence homology into four sub-families, ras, rho, rab and 
arf (reviewed Hall, 1990). It has been suggested by both Cockcroft and Stemweiss 
(personal communications) that the small molecular weight G-protein arf is the 
cytosolic component essential for the full activation of stimulated-PLD activity in 
neutrophils. Whether arf acts downstream, upstream or in parallel with the
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heterotrimeric G-protein to regulate PLD activity remains to be determined. 
Furthermore, it has been proposed that this may constitute the guanine nucleotide 
regulatory component of PLD-mediated exocytosis.
There are six known members of the arf family (reviewed Moss and 
Vaughan, 1992; Serventi et al., 1992), raising the possibility of differential 
intracellular localisations and functional properties for each isoform. A rf  was 
originally isolated as a cofactor necessary for the ADP-ribosylation of Gs by Cholera 
toxin (Kahn and Gilman, 1986). Although members of the a r f  family are 
predominantly cytosolic, N-terminal myristoylation may permit their membrane 
association (Kahn e ta l., 1988).
The G-protein regulation of PLD in permeabilised neutrophils is clearly 
different to that in Swiss 3T3 cells and may be a reflection not only of the function of 
PLD in the different cell types, but also the fact that neutrophils are suspension cells 
whereas Swiss 3T3 fibroblasts are adherent. Agonists stimulated PLD activity in 
permeabilised Swiss 3T3 cells in the absence of added GTPyS and Ca2+, with 
minimal loss in GTPyS-stimulated PLD activity over 15 minutes. This contrasted 
with reports in neutrophils where both membrane and cytosol in the presence of Ca2+ 
were required to fully reconstitute GTPyS-stimulated PLD activity (Olson et al., 
1991; Anthes et al., 1991). In the absence of GTPyS, stimulatable-PLD activity was 
rapidly lost from permeabilised HL60 cells (Geny and Cockcroft, 1992). These 
findings suggest that whereas a soluble form of arf has been proposed to be the 
cytosolic factor essential for the full activation of PLD activity in neutrophils, a 
membrane associated form, if any, would be involved in Swiss 3T3 cells.
A rf is thought to be involved in intracellular vesicular transport by 
regulating the assembly of the non-clathrin protein coat and hence the budding, of 
Golgi-derived vesicles (Orci et al., 1993). The binding of arf to Golgi membranes 
was reported to be essential for the membrane binding of one of the subunits P-COP 
of the polypeptide complex (coatomer) (Donaldson et al., 1992a) which forms the 
major constituent of the vesicle coat (Waters et al., 1991). Furthermore, reversible
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association of arf with Golgi membranes has been found to be under the control of a 
membrane bound guanine-nucleotide exchange factor (Donaldson et al., 1992b; 
Helms and Rothman, 1992).
Endocytosis of receptors may occur through clathrin-coated or non-coated 
vesicles. Arf was recently been reported to be important in endocytosis in vitro and 
was found to be present in clathrin-coated vesicles. The association with these 
vesicles was suggested to be mediated through the adaptins present in the clathrin 
coat (Lenhard et al., 1992). This proposal is supported by the association between 
PCOP and arf described above and the homology between (3-COP and p-adaptin 
(Waters et al., 1991). Constitutive recycling of receptors, such as the transferrin 
receptor occurs through clathrin coated vesicles (Brown et al., 1983). Using epitope 
tagging and immunofluorescence Von Zastrow and Kobilka (1992) reported that 
ligand-regulated internalisation of P2 -AR occurred through coated pits. Furthermore, 
the P2 -AR were found to colocalise with transferrin receptors. However, previous 
reports have suggested that non-clathrin coated vesicles may also be involved in P2 - 
AR receptor internalisation, such as in A431 cells (Raposo e ta l., 1989). Differences 
in these findings may be due to cell specific regulation or the degree of non­
specificity of immunocytochemical staining. Other receptors such as that of 
vasopressin (Cantau et al., 1988) and the epidermal growth factor (Wiley et al.,
1991) were reported to be internalised through coated pits, whereas muscarinic 
acetylcholine receptors were found to be sequestered in uncoated vesicles (Raposo et 
al., 1987). The pathway of bombesin and vasopressin receptor sequestration in 
Swiss 3T3 cells is unknown. This could be resolved by the use of epitope tagging 
and immunofluorescence to detect the localisation of the receptor. A hypothetical 
regulation of the internalisation of agonist-occupied receptors in Swiss 3T3 
fibroblasts by a membrane associated arf could perhaps be envisioned.
Bombesin may however regulate PLD activity through the small GTP- 
binding protein rho. Ridley and Hall, (1992) reported that the ras related protein 
rho regulated the formation of focal adhesions and actin stress fibers in response to
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bombesin and other growth factors in Swiss 3T3 cells. As previously described 
(section 1.2.4) bombesin stimulated the tyrosine phosphorylation of the src - 
substrate p l25 fakin Swiss 3T3 fibroblasts (Zachary and Rozengurt, 1991, 1992). 
Other cytoskeletal components have also been reported to be tyrosine 
phosphorylated in v-src transformed cells including vinculin and talin (Sefton and 
Hunter, 1981; Pasquale et al., 1986). Vinculin was also reported to be 
phosphorylated upon tyrosine in thrombin-stimulated platelets (Vostal and Shulman, 
1993). Furthermore, the clustering of integrins (non-covalently linked glycoprotein 
heterodimers) during the formation of adhesive contacts was found to enhance the 
tyrosine phosphorylation of pi 25fak (Komberg et al., 1991).
It is therefore possible that tyrosine kinases such as c-src may be activated 
through cytoskeletal changes controlled by rho and hence constitute the pathway of 
tyrosine kinase stimulated PLD activity.
5.1.3 Possible sequestration of G-proteins by acylation/ reacylation cycles.
Recent reports have found that thioester-linked palmitoylation of G-protein 
a-subunits can occur, including that of Gotq (Linder et al. 1993, Parenti et al., 1993). 
As the palmitoylation occurred post-translationally it was proposed that reversible 
acylation may play a regulatory role in the membrane localisation of G-proteins. The 
control of membrane association by reversible palmitoylation has also been reported 
for other proteins such as for the src -related tyrosine kinase lek (Paige et al., 1993) 
and for ras (Magee et al., 1987). The cellular compartment in which palmitoylation 
occurs is probably that in which the biosynthesis of the receptor occurs. However 
the site of reversible acylation may occur in other compartments, as proposed for 
reacylation/acylation cycles of proteins in erythrocytes (Staufenbiel, 1988).
Experiments showed that a short agonist pretreatment attenuated the 
GTPyS-stimulated PLD activity. As bombesin- and AVP-stimulated receptors were 
apparently sequestered following a short agonist exposure it is possible that G a 
subunits and small molecular weight G-proteins involved in the stimulation of PLD
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activity, may also be rapidly released from the membrane. The G-proteins or G a 
subunits may be internalised with the agonist-bound receptor as suggested in section 
4.3.7. Release of the GTP binding proteins from the plasma membrane may be due 
to deacylation, initiated by G-protein coupling to an activated receptor. It has also 
been suggested that palmitoylation alters the association between receptors and 
adapters present in the coated pits in which many proteins are thought to be 
internalised (Chin et al., 1989). Thus deacylation may not only promote release of 
the proteins from the membrane but also their seqestration in vesicles.
The return to the membrane of G a could be triggered by its deactivation 
and/or possible dissociation from the activated receptor. This could be elicited in a 
number of ways including GTP hydrolysis, dephosphorylation of the receptor or a 
conformational change in the receptor caused by degradation of the bound agonist. 
Reacylation or reassociation with (3y subunits (for heterotrimeric G-proteins) could 
be associated with the return of the G-proteins to the membrane and the recovery of 
agonist-stimulated responses. In support of the role of acylation in release of G- 
proteins from the membrane, a palmitoylation mutant of the transferrin receptor was 
found to be defective in endocytosis. However acylation of the receptor was not 
required for recycling to the plasma membrane (Alvarez et al., 1990).
Epitope tagging could be utilised to study the relationship between the 
sequestration of G a subunits and/or small molecular weight G-proteins and the 
receptor. Epitope tagging of G as was used to study its cellular localisation in 
response to isoproterenol (Levis and Bourne, 1992). When expressed in a s-deficient 
S49 eye ' cells the epitope tagged G as was rapidly released into the soluble fraction 
subsequent to isoproterenol treatment which was followed by a return of the G a 
subunit to the particulate fraction.
However, whether the G-protein or G a subunit is internalised and recycles 
to the membrane with, or separately from the receptor, or whether it is degraded 
along with the ligand is a further uncertainty. It could be argued that a degradation 
of a proportion of internalised G-proteins may play a role in the incomplete
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resensitisation of PLD activity. However, if bombesin-stimulated PLD and Ptdlns- 
PLC activity are both regulated through G aq, the incomplete recovery of bombesin- 
stimulated PLD activity is more likely to be due to down-stream signals as agonist- 
stimulated generation of total inositol phosphates completely resensitised (section 
4.2.2).
5.1.4 The involvement of Ca2+ in the tyrosine kinase stimulated PLD activity.
Experiments in Chapter 4 suggested that tyrosine phosphorylation was 
responsible for the PKC-independent pathway of agonist-stimulated PLD activity. It 
is probable, though as yet unproven, that the A23187-stimulated PLD activity 
remaining after treatment with Ro-31-8220 and EGTA could also be due to 
activation of tyrosine kinases. However, the relationship between [Ca2+]i and 
activation of tyrosine kinases remains a matter for investigation. A23187 was 
however reported to stimulate a small increase in tyrosine phosphorylation in Swiss 
3T3 fibroblasts (Zachary and Rozengurt, 1991). It is possible that although the 
thapsigargin-induced rise in [Ca2+]i may have stimulated protein tyrosine 
phosphorylation, the activation of PLD through this pathway alone was too small to 
be significantly detected above basal.
Ca2+-dependent tyrosine phosphorylation has been reported in angiotensin 
II-stimulated rat liver epithelial cells (Huckle et al., 1990) and thrombin-stimulated 
muscle cells (Offermanns et al., 1993). Ca2+ was proposed to act directly or 
indirectly, where indirect activation may occur through a Ca2+-binding protein such 
as calmodulin. Despite the established role for such proteins in the activation of 
serine/threonine protein kinases (Edelman et al., 1987), there is no evidence that they 
may also control tyrosine kinases. It may be however that [Ca2+]i may contribute to 
the activation of tyrosine kinases which also require the input of a receptor-coupled 
G-protein (section 5.1, 5.1.2).
As previously proposed, it is probable that one of the tyrosine kinases 
involved in bombesin-stimulated PLD activation is c-src or a related kinase. In
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support of this possibility the activation of v-src in Rat-1 cells (Wyke et al.y 1992) 
and Balb/c3T3 cells (Song and Foster, 1993) was found to stimulate PLD-catalysed 
PtdCho hydrolysis.
Src - related tyrosine kinases (reviewed Cooper and Howell, 1993) are 
inactive under normal conditions, through an intramolecular reaction involving the 
binding of an SH2 region to a C-terminal tyrosine phosphorylated residue (Liu et al., 
1993). Activation involves both dephosphorylation of this residue and 
phosphorylation of a residue in the catalytic domain of the protein (Kmiecik et al.t
1988). Ca2+ may promote the interaction of substrates with tyrosine kinase, for 
example, Ca2+ was found to enhance the association of a src substrate with 
phospholipid and actin (Glenney, 1986). It is also conceivable that Ca2+ could 
inhibit tyrosine phosphatases to enhance tyrosine phosphorylation. Experiments 
showed that inhibition of tyrosine phosphatases by pervanadate stimulated PLD 
activity in Swiss 3T3 cells and in liver epithelial cells. Moreover A23187 was found 
to synergise with pervanadate in stimulating PLD activity (Huckle et al., 1990). 
Activation of tyrosine kinases rather than inhibition of tyrosine phosphatases 
however, is likely to be responsible for the elevation of bombesin-stimulated protein 
tyrosine phosphorylation due to the inhibitory effect of the tyrosine kinase inhibitor 
Genistein. However, whether artificial elevation of Ca2+ through the use of 
ionophores could increase tyrosine phosphorylation by the same mechanism as 
agonists is unclear.
5.1.5 Alternative pathways of bombesin-stimulated PLD activity through 
protein tyrosine phosphorylation.
Elevation of protein tyrosine phosphorylation using pervanadate was found 
to stimulate the accumulation of inositol phosphates, implying an activation of PLCy. 
Whether bombesin could also stimulate PLCy activity in Swiss 3T3 fibroblasts was 
not assessed but could be determined by immunoprecipitating agonist-stimulated cell
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lysates with an anti-PLCy antibody, followed by immunublotting with anti- 
phosphotyrosine antibodies or performing an in vitro assay.
The membrane association of PLCy may be facilitated through the binding 
of SH2 regions to the phosphotyrosine of cytoskeletal components, aided by the 
interaction of SH3 regions with the cytoskeleton. The activation of PLCy could 
perhaps then arise through tyrosine phosphorylation catalysed by the cytoskeletal 
associated tyrosine kinases such as p l25fak, however the substrates of pl25fak are 
not known.
It is possible that bombesin-stimulated tyrosine kinase activity could 
activate MAP kinase which could then feedback to regulate PLD activity either by a 
direct effect on the enzyme or on other components of the regulatory pathway. This 
proposal could be compared to the activation of PLA2  by MAP kinase which acts in 
conjunction with mobilisation of intracellular Ca2+ to result in full enzyme activation 
(Lin et al., 1993). In support of this, MAP kinase has been shown to be activated by 
a number of G-protein coupled receptors such as those in bombesin-stimulated Swiss 
3T3 cells (Pang et al., 1993), thrombin-stimulated NIH 3T3 cells and thrombin and 
LPA-stimulated Rat 1 cells (Cook etal., 1993; Gardner et al., 1993).
Ras -GAP a GTPase-activating protein which not only enhances the 
intrinsic rate of GTP hydrolysis but is also a putative effector of ras (Duchesne et 
al., 1993) has been reported to associate with src- related protein tyrosine kinases 
both in vitro (Park et al., 1992) and in thrombin-stimulated platelets (Cichowski et 
al., 1992). G-protein linked receptors which activate src like tyrosine kinases such 
as c-src may therefore be capable of stimulating ras - dependent signalling 
pathways and hence activate MAP kinase.
Cycling of ras between inactive GDP-bound states and active GTP-bound 
states is like arf (section 5.1.2), controlled by nucleotide exchange. The exchange 
factor for ras is thought to be a mammalian homologue of the Drosophila Son of 
sevenless gene (Sos) which resembles a yeast ras exchange factor (see Downward 
and Buday, 1993). Activation of Sos and hence ras by growth factor receptors
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(Downward and Buday, 1992) occurs through adapter molecules, the SH2 containing 
protein (She) (Pelicci et al., 1992) and growth factor bound protein 2 (GRB2) which 
contains one SH2 and two SH3 domains (Lowenstein et al., 1992). Although both 
She and GRB2 both contain src homology regions they possess no intrinsic catalytic 
activity. She can be phosphorylated by intrinsic receptor tyrosine kinases and was 
also reported to be phosphorylated in v-src transformed cells, thus demonstrating 
possible regulation by cytosolic tyrosine kinases (Rozakis-Adcock et al., 1992). The 
GRB2 protein binds to autophosphorylated receptors and also to phosphorylated She, 
hence translocating Sos, to the plasma membrane (Egan e ta l ., 1993).
Activation of ras thus leads to the activation of a cascade of kinases, 
including Raf kinase (Wame et al., 1993; Zhang et al., 1993) and mitogen activated 
protein kinase kinase (MAPKK) (Adams and Parker, 1992; Gardner et al., 1993). 
MAP kinase is subsequently activated by MAPKK-mediated phosphorylation on 
both tyrosine and threonine residues.
Gardner et al. (1993), proposed that the thrombin and EGF-stimulated 
signals converged at MAPKK (reviewed Crews and Erikson, 1993). However, Cook 
et al. (1993), showed that the receptor tyrosine kinases and G-protein coupled 
receptors used ras as a common pathway. Nevertheless, ras - independent pathways 
of MAP kinase activation have been reported (Gallego, et al., 1992), therefore the 
extent to which mitogens use ras in signalling may be both cell and agonist specific.
5.2. The role of stimulated PLD activity in the production of PtdOH and DAG 
in Swiss 3T3 cells
The rapid desensitisation of agonist-stimulated PLD activity, together with 
previous reports on the partial attenuation of agonist-stimulated DAG in the presence 
of butanol (Cook et al., 1992), suggested that the role of PLD activation in Swiss 
3T3 fibroblasts was to produce PtdOH as an effector. This contrasts with previous 
proposals that PtdOH may function solely as a precursor of DAG. As PMA- 
stimulated PLD activity appeared however to generate DAG, it may be that the PLD
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isoform activated through PKC, is responsible for the generation of DAG from 
PtdOH. PKC-independent pathways of PLD activation may generate DAG due to 
the production of PtdOH species with a fatty acid content which may be poor 
substrates for PAP. However there is no evidence that PAP posseses substrate 
specificity at the level of acyl chain structure.
The possibility that the activation of PLD by different second-messenger 
pathways may catalyse the hydrolysis of PtdCho species with different fatty acid 
composition is supported by the finding that thev-jrc stimulated PLD activity in 
Balb/c 3T3 cells was found to be distinct from that activated by phorbol esters (Song 
and Foster, 1993). The two activities were differentiated by labelling with 
arachidonate or alkyl-lysoPtdCho but not myristate or palmitate, suggesting that they 
were specific for a sub-population of PtdCho. However, both pathways of 
stimulation resulted in the same extent of DAG production. The substrate specificity 
of PLD may therefore relate to the existence of several differentially regulated 
isoforms.
Although bombesin-stimulated desensitisation of PLD activity was also 
reflected in choline production, a more definitive determination of the regulation of 
PLD-catalysed hydrolysis of different pools of PtdCho would require labelling with 
different fatty acids such as myristate and palmitate. Alternatively, stimulated-PLD 
activity could be determined in the presence of [3H]butanol thus obviating the need 
for labelling of cellular PtdCho.
5.3 Regulation of agonist-stimulated PLD activity through receptor inactivation 
and reactivation
5.3.1 Receptor phosphorylation and its possible contribution to receptor- 
stimulated PLD activity.
Uncoupling of the P-adrenergic receptor from its G-protein commences 
initially through phosphorylation of the receptor on serine and threonine residues
172
catalysed by p-adrenergic receptor kinase (p-ARK) (Benovic et al., 1987) and PKA 
(Hausdorff et al., 1989), followed by binding of the cytosolic factor p-arrestin 
(Pitcher et al., 1992). p-ARK phosphorylation sites were found to be predominantly 
in the C-terminus (Dohlman et al., 1987), whereas PKA preferentially 
phosphorylated sites in the third cytoplasmic loop (Bouvier et al., 1989). The role of 
receptor phosphorylation in agonist-stimulated desensitisation was implicated by the 
findings that p-ARK-catalysed phosphorylation occurred only when agonist was 
bound to the receptor and that it paralleled the loss of agonist-stimulated adenylyl 
cyclase activity (Sibley etal., 1987).
Chick heart muscarinic and 0C2 *adrenergic receptors were also 
phosphorylated by pARK in an agonist-dependent manner, which coincided with 
desensitisation of agonist-stimulated responses (Kwatra et al., 1987; Kwatra et al., 
1989; Sibley et al., 1987). Other receptors including the muscarinic cholinergic 
receptors (Richardson and Hosey, 1990; Richardson et al., 1992) and the a l -  
adrenergic receptor in smooth muscle cells (Leeb-lundberg et al., 1987), were also 
reported to undergo agonist-dependent phosphorylation.
Hence the phosphorylation of either the bombesin or vasopressin receptor in 
Swiss 3T3 cells may play a key role in the initiation of desensitisation of receptor- 
linked responses to agonist. Although there is no direct evidence of bombesin 
receptor phosphorylation in Swiss 3T3 cells, C-terminal serine and threonine 
domains of the GRP receptor were found to regulate receptor internalisation when 
mutant receptors were transfected into Chinese hamster ovary fibroblasts expressing 
papovavirus large T antigen (CHOP fibroblasts) (Benya et al., 1993). As 
desensitisation of bombesin-stimulated PLD activity was PKC-independent, a 
kinase, perhaps that activated by PtdOH (Bocckino et al., 1991) (section 1.4.(ii)) 
may phosphorylate the agonist-occupied receptor. Alternatively activation of 
tyrosine kinases may stimulate a serine/threonine kinase such as MAP kinase as 
previously proposed (section 5.1.5). In this way feed back inhibition of agonist- 
stimulated PLD activity could be achieved. Phosphorylation of the receptor could be
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investigated in vitro using the purified receptor in a micellar system, or in vivo by 
incubating cells with bombesin in the presence of 32P, prior to immunoprecipitation 
with receptor antibody.
5.3.2 Receptor domains involved in sequestration.
Desensitisation of G-protein coupled receptors to agonist-stimulation is also 
regulated by sequestration (section 4.1). In support of this, the rapid desensitisation 
of agonist-stimulated [3H]PtdBut generation in Swiss 3T3 cells appeared to reflect to 
a significant extent the transient loss of receptor binding.
The control of receptor internalisation remains unclear despite numerous 
studies, but after shorter agonist exposure it appears to be a mechanism by which 
receptors are reactivated after their uncoupling from effector systems. The 
generation of mutant receptors has suggested that the C-terminal domain is essential 
for sequestration, though reports conflict as to the mode of regulation. Mutation of 
serine and threonine residues in the C-terminal tail of the p-AR prevented agonist- 
stimulated receptor sequestration (Hausdorff et al., 1991). C-terminal serine and 
threonine residues were also found to regulate the internalisation of the GRP receptor 
(Benya et al., 1993). However, removal of the C-terminal tail of p-AR resulted in 
internalisation that was similar (Strader et al., 1987) to or more rapid than the wild 
type receptor (Hertel et al., 1990). Similarly, results from other mutant receptors 
containing deleted C-terminal tails have led to confusion. Mutation of the 
thyrotropin-releasing hormone receptor (TRHR) resulted in a decreased 
internalisation rate Nussenzveiget al., 1993), whereas that in the luteinizing hormone 
chorionic gonadotropin receptor was increased (Rodririguez et al., 1992). The 
domains controlling internalisation may be receptor specific as serine and threonine 
rich domains in the third cytoplasmic loop have been proposed to regulate the 
sequestration of muscarinic cholinergic receptors (Moro et al., 1993; Lameh et al.,
1992).
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In addition to the requirement for serine and threonine residues, other amino 
acids have been found to regulate the transient decrease in cell surface receptors. 
Nussenveig et al. (1993) reported that cysteine residues in the C-terminal domain of 
the thyrotropin-releasing hormone receptor were important for receptor trafficking. 
Cysteine residues located in a similar postion near the seventh transmembrane 
domain are conserved in many G-protein coupled receptors including those of 
rhodopsin (Ovchinokov et al., 1988) and p-adrenergic agonists (O'dowd et al.,
1989). These cysteine residues constitute a possible palmitoylation site, a 
modification which may be important for internalisation. However, transfection of 
the GRP receptor containing mutated cysteine residues, into CHOP fibroblasts, 
resulted in receptor internalisation comparable to that attained with the wild type 
receptor suggesting that the putative palmitoylation site was not necessary for 
internalisation (Benya et al., 1993).
The regulation of receptor -mediated desensitisation by receptor C-terminal 
tyrosine residues has also been suggested. The essential tyrosine residues in 
lysosomal acid phosphatase and the low density lipoprotein receptor (LDL receptor) 
were found to adopt a tight turn. This conformation was proposed to be a signal for 
rapid internalisation (Eberle et al., 1991; Bansal and Gierasch, 1991). However, 
mutation of tyrosine residues in the P2 -AR was found to affect receptor down- 
regulation but not sequestration (Valiquette et al., 1990). Whether such a turn is 
possible in bombesin-receptors, in which the sequence contains a single tyrosine 
residue one amino acid from the end of the receptor seems unlikely (Battey et al.,
1990).
Thus it is possible that certain serine and threonine residues and/or other 
residues which may be phosphorylated or post-translationally modified, form a 
specific secondary structure essential for the regulation of receptor internalisation. A 
critical length of the C-terminal tail may be crucial for formation of the secondary 
structure, disruption of which may lead to loss of or uncontrolled receptor 
sequestration. Confirmation of the roles of domains of the bombesin and vasopressin
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receptor could be achieved by similar site directed mutagenesis experiments to those 
described above.
5.3.3 The interaction between receptor/G-protein uncoupling, sequestration 
and down-regulation.
Receptor sequestration appears to be functionally uncoupled from down- 
regulation in the P2 -AR. Down-regulation of the receptor is characteristically 
observed after prolonged exposure to agonist and is modulated by phosphorylation 
and decreased by mutations impairing receptor/Gs coupling (Bouvier et al., 1989, 
Campbell, 1991). However mutations that impaired receptor/Gs coupling did not 
affect sequestration. Conversely, mutations of the P2 -AR C-terminal tail that 
inhibited receptor phosphorylation and sequestration did not affect down regulation 
or stimulation of adenylyl cyclase activity (Hausdorff et al., 1991; Strader et al., 
1987)). Similarly, truncation of the C-terminal tail in the GRP receptor and TRHR 
receptors, which attenuated receptor sequestration as previously described , did not 
affect the hydrolysis of inositol phosphates (Nussenveig et al., 1993; Benya et al.,
1993).
5.3.4 Recycling of the receptor.
The proposals that the resensitisation in bombesin-stimulated PLD activity 
may have been due to recycling of the receptor is supported by studies in CHO cells 
transfected with the P2 -AR. Blockage of P2 -AR sequestration by mutagenesis or 
sucrose pretreatment was found to markedly reduce the rate of resensitisation upon 
removal of the agonist, which would normally have occurred with t i / 2  of 
approximately 3 minutes (Yu et al., 1993). The authors proposed that sequestration 
of P2 -AR was involved in reactivation and recycling of receptors . The recovery of 
agonist-stimulated adenylyl-cyclase activity therefore occurred with a similar time 
scale to that observed for the recovery of bombesin-stimulated PLD activation in 
Swiss 3T3 cells (section 4.2.1).
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Sequestered vesicles containing the P2 -AR have been found to be enriched 
in phosphatases and the internalised receptors were found to be less phosphorylated 
than the membrane associated ones (Sibley et al., 1986). The function of receptor 
internalisation was therefore proposed to be to dephosphorylate and hence reactivate 
the P2 -AR receptor. Similarly, internalisation of a phosphorylated bombesin or 
vasopressin receptor could result in their dephosphorylation.
Further comparisons with the P2 -AR can be drawn in terms of the finding 
that the recovery of bombesin-stimulated PLD activity, proposed to be partially due 
to receptor recycling, occurred even in the continual presence of bombesin. 
Similarly, recycling of the P2 -adrenergic receptor (Kurz and Perkins, 1992) and 
guanylate cyclase/atrial natriuretic factor receptors (Pandey, 1993) was reported to 
occur in the presence of agonist.
5.3.6 Characteristics of agonist-stimulated desensitisation in other systems.
The PKC-independency of the homologous desensitisation of bombesin- 
stimulated PLD activity is supported by findings in many other systems. For 
example, the waning of muscarinic-mediated [^HJcyclic GMP responses in 
neuroblastoma cells (Lai et al., 1990) and the attenuation over time of Ptdlns-PLC 
activity in thrombin-stimulated fibroblasts (Paris et al., 1988) and in histamine and 
thrombin-stimulated endothelial cells (Halldorssen and Thorgeirsson, 1989) were 
reported to be independent of PKC activity.
In many systems short-term desensitisation was found to involve both 
receptor and post receptor events as proposed in Chapter 4 for the desensitisation of 
vasopressin- and bombesin-stimulated PLD activity. For example, the time course 
for the desensitisadon of intracellular Ca2+ mobilisation differed from the loss and 
recovery of cell surface receptors in neurotensin-stimulated HT29 cells (Turner et 
al., 1990) and the extent of angiotensin II-stimulated desensitisation of Ins(l,4,5)P3 
production in vascular smooth muscle cells was greater than the loss of angiotensin 
II receptors (Ullian and Linas, 1990).
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A short bombesin pretreatment was found to reduce the GTPyS-stimulated 
PLD activity, however reports on the G-protein-stimulated effector signalling 
pathways vary in other systems. A1F- -and thrombin-stimulated phosphoinositide 
hydrolysis was unaltered by a thrombin pretreatment which attenuated subsequent 
thrombin-stimulated Ptdlns breakdown (Paris et al., 1988). However, in histamine- 
desensitised Hela cells both the NaF and bradykinin-mediated inositol phosphate 
production was attenuated suggesting that the site of desensitisation was at, or distal 
to the G-proteins (Bristow and Zamani, 1993).
5.3.6 Chronic and acute desensitisation are distinct.
In addition to the difference in initiating signals needed for chronic and 
acute desensitisation, studies on second-messenger generation following prolonged 
exposure to agonist has also shown differentiation between the two processes. 
Chronic agonist exposure generally results in receptor down regulation which 
depending on the system studied may or may not correlate with the extent of 
desensitisation. The relationship between sequestration and downregulation after 
longer exposure to agonist has been suggested to be an agonist-controlled change in 
equilibrium between the recycling of the internalised receptor and its degradation 
(von Zastrow and Kobilka, 1992).
Down-regulation of the P2 - adrenergic receptor after chronic agonist 
exposure is thought to be due to an instability in receptor mRNA (Hadcock et al.,
1989). Experiments in Chinese hamster ovary cells investigating the hydrolysis of 
phosphoinositides stimulated through muscarinic receptors, have suggested that the 
relative contribution of receptor/effector uncoupling and receptor loss to 
desensitisation depends on the efficacy of the agonists used in the desensitisation and 
activation stages (Hu et al., 1991).
Resensitisation of cells exposed for long times to agonist is also reversible. 
However, in contrast to the recovery after short agonist exposure, the process
178
requires long incubations in the absence of the desensitising stimulant and is 
dependent on protein synthesis.
Chronic desensitisation to bombesin in Swiss 3T3 fibroblasts resulted in a 
loss of binding sites without a change in their affinity, caused by receptor down- 
regulation. Pretreated cells were also unable to mobilise Ca2+ and stimulate DNA 
synthesis upon readdition of bombesin (Millar and Rozengurt, 1990). In contrast to 
the heterologous desensitisation observed after a short pretreatment with bombesin, a 
prolonged exposure did not affect Ca2+ mobilisation in response to other agonists. 
Prolonged pretreatment of Swiss 3T3 cells with vasopressin for at least 12 hours was 
found to desensitise cells to subsequent vasopressin-stimulated mitogenesis. 
Desensitisation was proposed to occur partly through post-receptor events as 60% of 
the vasopressin binding sites were retained (Collins and Rozengurt, 1983). 
Prolonged vasopressin stimulation was also reported to reduce the mitogenicity of 
bombesin, although there was no effect on the bombesin receptor (Millar and 
Rozengurt, 1989). This suggested that heterologous desensitisation after chronic 
agonist exposure primarily involved post-receptor events as for the heterologous 
desensitisation observed after short agonist stimulation (section 4.2.4).
A similar dissociation of early and late events during exposure to 
vasopressin was reported in WRK cells with the time course of VP-sensitive Ptdlns- 
PLC desensitisation occurring more rapidly than the downregulation of receptors 
(Cantau et al., 1988). However in these cells the reduction in binding sites correlated 
with the extent of inhibition of vasopressin-stimulated production of inositol 
phosphates.
Other mechanisms of adaptation can also exist. In cells such as muscarinic- 
stimulated SH-SY5Y neuroblastoma cells Ins( 1,4,5)P3 remains elevated above basal 
for prolonged periods of time. An adaptive mechanism causes a reduction in the 
concentration of Ins(l,4,5)P3 receptor such that Ins(l,4,5)P3 -induced Ca2+ release is 
attenuated (Wojcikiewicz and Nahorski, 1991; Wojcikiewicz et al., 1992). This 
process was found to be PKC- independent and was absolutely dependent on
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Ins(l,4,5)P3. Whether the mechanism involved receptor degradation or a reduction 
in the rate of receptor synthesis was unclear.
5.4. The relationship between continual receptor occupancy and mitogenic 
signalling pathways.
The continual production of PtdOH that would be produced on resensitisation of 
PLD activity in the continual presence of agonist, suggest that the activation of 
downstream effectors of PtdOH (or lysoPtdOH) may also be maintained in a similar 
manner. Multiple phases of second-messenger production may play a critical role in the 
control of cellular responses. Three phases of PKC activity were detected in IFNy- 
stimulated endothelial cells subsequent to increases of choline, PtdOH and DAG within 
the first 60 minutes (Mattila and Renkonen, 1992). The authors suggested that in each 
phase, PtdOH was metabolised to DAG which could then activate PKC. The multiphasic 
generation of DAG observed in a-thrombin stimulated human platelets in response to sub­
threshold levels of agonist, was proposed to be a controlling mechanism for the optimal 
activation of PKC during secondary aggregation (Werner et al., 1992). Furthermore, the 
second sustained phase of MAP kinase activation reported in a-thrombin fibroblasts was 
proposed to account for a-thrombin stimulated cell proliferation (Kahan et al., 1992). 
The function of the resensitised rate of bombesin-stimulated PLD activity may be to 
accumulate PtdOH, at least in the first few hours of agonist stimulation. This may act as a 
control mechanism for mitogenesis, perhaps a critical threshold of PtdOH must be reached 
for a certain length of time allowing prolonged activation of downstream effectors.
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5.5 Proposed models for the regulation of agonist-stimulated PLD activity
A model proposed for bombesin-stimulated regulation of phospholipase D 
activity is presented in figure 5.1. The bombesin receptor couples to Gq> hence 
activating Ptdlns-PLC. Stimulation of tyrosine kinases, of which an essential one is 
thought to be c-src, may occur directly through a G-protein Gq or Gd, or indirectly 
through the rise in [Ca2+]i. Gd is thought to be cytoskeletal associated and may 
belong to the small molecular weight class of G-proteins. Bombesin-stimulated 
protein tyrosine phosphorylation may be initiated through cytoskeletal changes 
controlled by rho , a possible candidate for Gd- Activation of c-src is also proposed 
to activate PLCy, contributing to the production of DAG and Ins(l,4,5)P3. The rise 
in [Ca2+]i and DAG activates PKC which stimulates PLD activity. Tyrosine kinases 
are proposed to activate PLD independently of PKC, possibly acting through an 
intermediate protein, for example MAP kinase. However, the mechanism of kinase 
regulation of PLD activity remains to be investigated. Stimulation of PLD activity 
may also occur by fatty acids such as oleate, produced as a result of bombesin- 
stimulated PLA2  activation.
The PtdOH produced from PLD-catalysed PtdCho hydrolysis is proposed to 
contribute to only a minor extent to DAG generation, which may activate certain 
PKC isoforms. The main function of PtdOH is to act as a second-messenger, 
eliciting various effects as previously described either in its own right or by 
conversion to lysoPtdOH (section 1.4.3(ii)). Some of the effects of PtdOH or 
lysoPtdOH may necessitate extrusion of the phospholipid from the cell.
A hypothetical scheme for the desensitisation of vasopressin and bombesin 
receptors is shown in figure 5.2 and is based upon models proposed for the p2-AR. 
Stimulation of the receptor leads to its uncoupling from the effector systems 
regulating PLD activity. This may occur through conformational changes, perhaps 
initiated by receptor phosphorylation on C-terminal serine and threonine residues 
and release of the G a subunit or a small molecular weight G-protein from the 
membrane. Reactivation of the receptor is proposed to occur by sequestration of the
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Figure 5.1 A proposed model for regulation of bombesin-stimulated PLD 
activity in Swiss 3T3 fibroblasts.
Interaction of bombesin (B • )  with the receptor activates PLCJ3 via the G- I 
protein Gq. The hydrolysis of PtdIns(4,5)P2 generates DAG and Ins( 1,4,5)P3. The 
concentration of [Ca2+]i is elevated through Ins(l,4,5)P3-induced Ca2+ release from 
the endoplasmic reticulum and entry of Ga2+ from the extracellular medium, through 
channels in the plasma membrane. PKC isoforms are activated by DAG from 
PtdIns(4,5)P2 hydrolysis and for PKC a , P and y, [Ca2+]i is also required. PKC 
activates PLD by an undefined mechanism which may involve direct 
phosphorylation of the enzyme or an intermediate regulatory protein. Bombesin 
receptors may regulate PLD activity through a pertussis-toxin insensitive G-protein 
other than Gq. The hypothetical G-protein, Gd, may belong to the heterotrimeric or 
low molecular weight classes of G-proteins and could activate PLD activity through 
a tyrosine kinase proposed to be c-src. Such an interaction could occur through 
bombesin-stimulated cytoskeletal changes mediated by the small molecular weight 
G-protein rho, a possible candidate for Gd. However, Gd may also activate PLD 
through an unidentified serine/threonine kinase. Stimulation of a tyrosine kinase 
may activate PLD directly or indirectly, possibly via activation of MAP kinase. 
Receptor activation of a tyrosine kinase may also lead to PtdIns(4,5)P2 hydrolysis | 
catalysed by PLCy. [Ca2+]j may activate PLD indirectly through PKC, or as a j 
cofactor in the activation of c-src. Unsaturated fatty acids from PLA2 -catalysed j| 
PtdCho hydrolysis may also contribute to bombesin-stimulated PLD activity. *
PLD-catalysed PtdCho hydrolysis generates PtdOH and choline which is 
not only accumulated inside the cell but is also extruded. For clarity choline is only 
shown leaving the cell. The PtdOH may act as a second-messenger itself eliciting a 
range of effects such as activation of kinases or its second-messenger effects may be 
mediated by conversion to lysoPtdOH. Possible extrusion of PtdOH or lysoPtdOH 
from the cell is not shown, again for clarity. Alternatively PtdOH may be converted 
by PAP-2 to DAG which could activate PKC. A line with a question mark above, 
denotes activation of the enzyme by an undefined mechanism. A dashed line ; 
indicates a possible but unproven route of activation. |
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Figure 5.2 Hypothetical scheme of bombesin and vasopressin receptor
i
i
desensitisation and resensitisation in Swiss 3T3 cells after short exposure to ]
agonist. ]
]
Schematic diagram is adapted from the model proposed for desensitisation j 
of p2  - AR (Yu et al.y 1993; von Zastrow and Kobilka, 1992). Dashed lines indicate 
hypothetical pathways of receptor desensitisation and resensitisation. After a short 
agonist ( • )  stimulation the receptor is uncoupled from the effector systems 
regulating PLD activity (see Fig. 5.1). This may occur via phosphorylation of the j 
receptor as proposed for the p2 - AR and deacylation of the G-protein regulating I 
PLD activity which may involve Gq and/or another undefined G-protein (G d )- The j 
phosphorylated receptors possibly in conjunction with the Gctq or Gd are J
I
sequestered into intracellular vesicles. Reactivation of the receptors may occur after i 
dephosphorylation of the internalised receptors by phosphatases present in the 
vesicles. A conformational change may also initiate reactivation of the receptor 
possibly elicited by dissociation and lysosomal degradation of the receptor bound 
agonist. The GTP-binding protein may be returned to the membrane after hydrolysis 
of bound GTP, reacylation or reassociation with py subunits. The receptor and G- ; 
protein may be recycled to the plasma membrane separately or together.
bombesin/vasopressin
receptor bombesin/vasopressin
receptor
PLDq/D q/D
q/D
dephosphorylation
lysosomal degradation
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receptor and G-proteins into vesicles, perhaps in a complex. Reactivation of the 
receptor occurs by degradation of the bound agonist and dephosphorylation which 
would result in conformational changes, dissociating the receptor from any 
receptor/G-protein complex. Similarly, the internalised G a subunit or GTP-binding 
protein could be reactivated by GTP hydrolysis or dissociation from the receptor and 
may reassociate with the membrane by interaction with Py subunits and/or 
reacylation. More prolonged exposure to the agonist promotes degradation of the 
sequestered receptor and G-protein sub-units, rather than their recycling to the 
plasma membrane.
5.6 Concluding rem arks
Further characterisation of the modulatory pathways of PLD activity 
through enzyme purification and molecular biology techniques will extend the 
current knowledgeof the linkage between initial events induced by receptor 
occupancy and mitogenesis. Loss of control of the desensitisation process may result 
in deregulation of agonist-stimulated second-messenger signalling pathways leading 
to unrestrained proliferation in response to mitogens.
Recent reports have described constitutively activated receptors which are 
associated with disease. A mutation in the luteinising hormone receptor resulting in 
agonist-independent elevation of cyclic AMP was associated with familial male 
precocious puberty (Shenker et al., 1993). Similarly, an alteration in the thyrotropin 
receptor leading to deregulation of adenyl cyclase was reported to cause 
hyperfunctioning thyroid adenomas (Parma et al., 1993). Discovery of the 
mechanisms involved in inactivation of agonist-stimulated receptors will therefore 
promote the development of novel therapeutic targets.
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Appendix
The following is a list of publications arising from the work presented in 
this thesis.
1. " The regulation of phospholipase D activity and its role in sn -1 ,2-  
diradylglycerol formation in bombesin- and phorbol 12-myristate 13-acetate- 
stimulated Swiss 3T3 cells."
Cook, S.J., Briscoe, C.P. and Wakelam, M.J.O. (1991) Biochem. J. 280,431-438.
2. " Phosphatidylcholine hydrolysis - a multiple messenger generating system." 
Wakelam, M.J.O., Pettitt, T.R., Kaur, P., Briscoe, C.P., Stewart, A., Paul, A., 
Paterson, A., Cross, M.J., Gardner, S.D., Currie, S., MacNulty, E.E., Plevin, R. and 
Cook, S.J. (1992) Adv. Sec. Mess. Res. 28,73-80.
3. "Rapid desensitisation and resensitisation of bombesin-stimulated phospholipase 
D activity in Swiss 3T3 cells."
Briscoe, C.P., Plevin, R. and Wakelam, M.J.O. (1993) Biochem. J. in press .
4. " The regulation of agonist-stimulated phospholipase D activity in Swiss 3T3 
fibroblasts".
Briscoe, C.P. and Wakelam,M.J.O. (1993) Biochemsoc. Trans. 492S.
5. "Phosphatidylcholine hydrolysis: A source of multiple lipid messenger 
molecules"
Wakelam, M.J.O., Briscoe, C.P., Stewart, A., Pettit, T., Cross, M.J., Paul, A., Yule, 
J.M., Gardner, S.D. and Hodgkin, M. (1993) Biochem. Soc. Trans. 21, in press.
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